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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

This issue of the Journal (pages 165 to
175) includes what I believe is a landmark
initiative regarding access to surgical care
in communities away from large centres.
The report by Inglis (pages 166 to 168)
gives important background information
and highlights the attitudes of surgeons
practising in communities with fewer than
40 000 people. Such communities gener
ally cannot attract or support the full
spectrum of subspecialty surgeons and yet
their hospitals serve populations some
times exceeding 100 000. Most of the 92
surgeons who responded to the survey
expressed positive attitudes towards the
professional rewards of their surgical
practice. This is an important observa
tion. It would be interesting to compare
their responses with those of general sur
geons in large centres.
Another interesting observation is that
the spectrum of surgical procedures, as
reflected in the 10 most commonly per

formed operations, depended upon the
size of the centre. In the smaller centres
the scope of surgical procedures was
broader than in the larger centres.
Regardless of the reasons for these vari
ations, it is evident that the information
from this kind of review should provide
guidance for those who wish to train sur
geons to meet the needs of smaller com
munities. A true population-based study
of surgical problems in various regions
w ould be invaluable b u t, to my
knowledge, this has not yet been done in
Canada. None the less, the survey by
Inglis provides us with information essen
tial to planning for training and
management.
O ’Brien (pages 171 and 172) has
reviewed his own experience in a smallcommunity surgical practice. Twenty-five
percent of his procedures were for frac
tures, other limb trauma and elective limb
surgery other than varicose veins, and
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15% were gynecologic surgery or oper
ative obstetrics, especially cesarean sec
tions. He also points out the importance
of being able to deal with urologic emer
gencies and acute head injuries. It is clear
that the kind of training provided in
Canadian general surgical residency pro
grams does not cover the spectrum of sur
gical cases being treated by Dr. O ’Brien
and surgeons like him in smaller centres.
Cutler (pages 172 and 173) has offered
several challenging and creative sugges
tions, perhaps the most controversial
being that small-community surgeons
should be affiliated with a tertiary care
hospital with privileges to admit and treat
patients in that hospital. He also points
out that competent anesthesia is part of
the whole issue relating to surgery in
smaller communities.
The issues raised by the papers from
this symposium on surgical manpower in
smaller communities are not confined to

l+l
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Canada. I took part in a survey of sur
gery performed in district hospitals of
Pakistan during 1984. It revealed that
only 38% of operations were “ general”
surgery, 30% were gynecologic proce
dures or operative obstetrics, 19% were
urologic procedures and 13% orthopedic
procedures. Surgeons trained in current
general surgical programs, sent to district
hospitals, found themselves ill equipped
to deal with the problems confronting
them. We proposed that the training of
a surgeon for district hospital service in
Pakistan should be broader than the cur
rent general surgical programs and should
include procedures identified by our sur
vey. Such trainees could be designated
“ comprehensive surgeons” .
There appears to be good reason to
consider such an approach in Canada.
The problem will be to negotiate with our
subspecialty colleagues to have such a
“ comprehensive-surgeon” training pro
gram include appropriate hands-on
experience. It appears that major rota
tions should be urology, obstetrics, gyne
cology and orthopedics. Trauma care
should also be a component of such train
ing; in fact, many smaller communities
with surgical specialists could be desig
nated regional trauma centres. I suggest
that university surgical departments
should “ adopt” many of the smaller
regional centres within their referral area
and provide back-up consultation, con
tinuing education and referral services.
The University of Manitoba has, in addi
tion to this approach, appointed surgeons
from smaller communities to the univer
sity teaching staff. Communications such
as library services, continuing education
programs and assignment of residents for
periods in surgical units of the small com
munities could be mutually beneficial to
programs in the tertiary centres and the
smaller community hospitals.
Canada is a vast country with widely
separated smaller communities. I agree
with Dr. Cutler that the best option for
providing surgical care to such commu
nities is an on-site surgical unit with an
appropriately trained comprehensive sur
geon. We should expand our knowledge
of surgical requirements, identify trainees
who wish to practise in smaller commu
nities and tailor their training to meet the
surgical problems that will face them.
R.J.
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CORRESPONDENCE
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Trauma Care
To the editors.—The symposium on the
organization of trauma care in the
November 1985 issue (pages 477 to 489)
prompted me to file the following account
of a local accident, which contained some
features of interest.
On Oct. 1, 1985, a small plane took off
from Lake Temagami on a sight-seeing
flight. Aboard were an experienced pilot
and three passengers. A fog closed in and
the pilot was unable to return to the lake.
In his search for an alternative landing
site he hit the top of some trees and
crashed.
Oddly, the signal of the downed air
craft was detected by an orbiting Russian
satellite. The information was relayed to
the Canadian Forces and a search aircraft
dispatched to the site. Rescue was not
possible until the following morning.
The casualties were lifted out by an
armed forces helicopter and brought one
by one to the Temiskaming Hospital,
about 45 km away. The first to arrive, a
woman in her 60s, had a pneumothorax
and a fractured tibia. She was treated by
closed chest drainage, and a plaster cast
was applied to her lower limb. Next was a
75-year-old woman who had a fractured
radius and ulna and was experiencing
considerable respiratory difficulty. Roent
genography suggested a ru p tu red
diaphragm and this was confirmed at
laparotomy when a large tear was
repaired from below. The third arrival,
a 55-year-old woman, had abdominal
pain. Laparotomy disclosed a rupture of
the middle portion of the ileum that was
repaired after peritoneal toilet.
The pilot, a 45-year-old man, had
severe facial lacerations and a fracture of
the upper end of the femur. After a
Thomas splint had been applied and his
lacerations sutured, he was transferred
elsewhere for treatment by an orthopedic
surgeon. Within a couple of days the
other two patients with fractures were
also transferred for more specialized
treatment.
In this instance some confusion was
engendered by three of the victims hav

ing the same surname and three having
the same Christian name! Extreme care
must be taken by the staff in such circum
stances to keep the charts accurate.

The Temiskaming Hospital has 137
beds and is served by one general surgeon
and 15 general practitioners. Although it
is unlikely that it would ever be designated
a regional trauma centre, the vagaries of
chance and weather have, over the years,
brought us many trauma cases so that the
hospital staff have special interest in
trauma. Indeed, in 1983, two instructors
from the advance trauma life support
course were persuaded to teach the course
in our institution and each year since then
a 10-week course has been provided for
all nursing staff working in the emergency
department and has been attended by
several members of the medical staff.
The following points emerged from the
accident described:
• Rescue and management of these
accident victims were accomplished with
no deaths and minimal morbidity. This
was partly due to the high level of interest
our hospital staff has in trauma.
• Three of the four casualties sus
tained bursting-type injuries—pneumo
thorax, ruptured diaphragm and ruptured
intestine—a combination of high impact
and use of seat belts.
• Airplane crashes do not invariably
bring the swift and certain death that the
aviation history of 1985 might suggest.
H.F. Jeffery, md , frcs,
A. H urtubise , md , ccfp
J.T. Ross, MD

frcsc

prostheses (scaphoid and trapezium)
made of silicone elastomer.
The title of their paper reminds us of
a hitherto undescribed complication of
silicone prostheses o f the m etacar
pophalangeal joints, namely, erosion
through soft tissue.
This was an incidental finding at
autopsy in a 73-year-old woman with
long-standing rheumatoid arthritis, who
died in a nursing home reportedly of “ old
age” . The same patient was previously
reported as an example of silicone lymphadenopathy resulting from finger-joint
prostheses.1 A Silastic implant of the
metacarpophalangeal joint of the right
index finger had eroded through the skin.
A drian J. C hristie ,
FRC PATH, FRCPC

Department of Pathology,
South Macomb Hospital,
Warren, MI 48093,
USA
M arven Oxley ,

To the editors.—In the January 1986
issue (pages 45 to 47) Wright and Wilgis
reported on erosive silicone synovitis
affecting the distal radius or carpal bones
(or both) adjacent to w rist-bone

m d , frcpc

Department of Pathology,
The Grace Hospital,
Windsor, Ont.,
N9A 5C6

Reference
1. C hristie AJ, We in berg er KA, D ie tr ic h M: Compli
cations of silicone elastomer prostheses (C). J A M A 1977;
238: 939

Temiskaming Hospital,
New Liskeard, Ont.,
POJ IPO

Silicone Synovitis

m d,

Pilonidal Disease
To the editors.—I feel obligated to reply
to Dr. Salvati’s response to my letter (Can
JSurg 1985; 28: 466) regarding the treat
ment of pilonidal disease.
During service with the RCAMC from
1944 to 1946, I had an opportunity to see
many cases of pilonidal disease. Since
then my interest has continued, and I
have found that certain basic principles
of treatment should always be considered.
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As the name indicates, it is the “ hair” ,
acting as a foreign body, that causes the
problem. I agree that in some instances
there are no “ pits” and therefore treat
ment should be designed to remove the
internal hairs and the inflammatory reac
tion that is created.
Dr. Salvati asks how I would treat a
“ large, dirty, recurrent pilonidal cyst with
a 2-cm ‘midline pit’ ” . This is certainly not
a “ pit” and represents a chronic inflam
matory reaction, possibly due to several
factors. The likeliest cause is retained hair
deep within the wound plus irritation
from adjacent hairs and lack of cleanli
ness on the part of the patient. In this case
the etiology of the draining area should
be explained to the patient and a plan
made for the area to be shaved and
cleansed and the patient to take soapy
baths once or twice a day. Treatment can
be facilitated by use of a Water-Pik with
which another member of the family can
irrigate the area. I believe that a 2-cm
opening would quickly close once this
regimen had been adhered to.
I have found that a Guthrie hook is a
wonderful instrument to remove the deep
pockets of hair. This small, sharp instru
ment with double-pronged hooks, which
is used primarily for delicate eye surgery
or in plastic surgery, works best if one
hook is removed. On numerous occasions

I have seen patients who have had drain
ing, necrotic wounds for months or even
years, but with removal of the hair and
the regimen I have described the disease
is manageable.
I reiterate that extensive major proce
dures are rarely indicated in the treatment
of pilonidal disease, and midline incisions
should be avoided.
M .J.

Furman,

m d , f r c s c , facs

960 East Green St.,
Pasadena,
CA 91106,
USA

O c c u lt B reast C an cer
To the editors.—Further to the paper
“ Intraoperative localization of occult
breast tum ours” (Can J Surg 1985; 28;
329-330) by L.J. Mahoney and his letter
on page 300 of the same issue, the
problem concerns marking of nonpalpable breast lesions seen mammographically by inserting a needle (additional
injection of blue dye or insertion of a
hooked wire are variations of the same
method). The emphasis is on nonpalpa
bility of the lesion; that is the reason for

the procedure, and to prove the accuracy
of localization the position of the needle
has to be demonstrated radiologically. If
this is not done the exercise is futile and
essentially blind. The added benefit of the
procedure is that it enables the surgeon
to remove the smallest amount of tissue
adjacent to the lesion to achieve removal
of a potentially malignant tumour; that
is, lumpectomy with the best possible cos
metic result.
Whether the incision will be areolar or
a more peripheral one depends on the
location of the abnormality in the breast
and on the surgeon’s preference. The
point is that the location of the lesion is
identified by the needle and this relation
ship is proven radiologically. This way
even small deep lesions are rarely missed
and the cosmetic result is excellent. The
pathologic nature of the tissue thus
removed may necessitate additional axil
lary node dissection later.
With cooperation between surgeon and
radiologist this accurate procedure is suc
cessful in a high percentage of cases.
I . S . SlMOR, MD, FRCPC

Department of Radiological Sciences,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont.,
M5G 1X5
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THE 12TH INTERNATIONAL CONFERENCE ON

HOFFMANN® EXTERNAL FIXATION
WILL BE HELD IN
GARMISCH PARTENKIRCHEN,
WEST GERMANY
FROM OCTOBER 9 -1 1 , 1 9 8 6
Top ics Will In clude:
Basic B io m e c h a n ics of External Fixation.
E x p e rim e n ta l, C lin ic a l and Theoretical
Research.
Ela stic E x tern al Fixation .
''Biocom p ressio n'.'
A p p lic a tio n of E x te rn a l Fixation in case of:
In tra -a rtic u la r fractures
Lower a nd up p e r e xtrem ity
fractures
Pelvic fra cture s
Spine
War in ju rie s
C h ild re n 's fractures
M axillo facial fractures
Infected fractures
Tu m o rs
M icro su rg e ry
M in ifix a tio n.
E x p a n d e d In d ic a tio n s for External
Fix atio n .
E x tern al Fix ation w ith Associated
In te rn a l Fix atio n .
C h a n g e of Tre a tm e n t Following External
Fix atio n .
Risks and C o m p lic a tio n s of External
Fixation ,
n u rs in g .
Prese n ta tion of U n u su a l Cases.
W orkshops.
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sk e l e t a l f ix atio n tech n o lo g y . As always, t h e m o s t e m i n e n t i n t e r n a t io n a l s p e a k e r s will be
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v aried e x p e r i e n c e s .
The official l a n g u a g e s will be G erm an , English a n d F re n ch with s i m u l t a n e o u s t r a n s l a t i o n .
The C o n g r e s s will tak e place in o n e of E uro pe's f o r e m o s t b e a u t y s p o ts , a t a p articu larly
p l e a s a n t s e a s o n o f t h e year.
For f u r t h e r i n f o r m a t i o n a n d re g i s t r a t i o n forms, p l e a s e a p p ly to t h e C o n g r e s s Secretary.
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F RG
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USA
USA
USA
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FRG
FKG

Dr. J . Ju p it e r
Dr. K a ra h a rju
Dr. J . K e llam
Dr. M. M e in e rt
Dr. K. K le m m
Dr. L. L a tta
Dr. J . l.azo Zbikow ski
Dr. L. Lu b b e rs
Prof. B. M cK ib b in
Dr. D. M ears
Dr. C. M ialhe
Prof. G . M o n tice lli
C o l. M o u lay

USA
F in la n d
C anada
USA
FRG
USA
S p a in
USA
U K
USA
F ra n c e
Ita ly
M o ro cco

Dr. K .h . M uller
FRG
Prof. S. Perren
S w itz e rla n d
Dr. 1. Pin d e r
U K
Dr. M. Pope
USA
Prof. L. R ic c ia r d i
Italy
Dr. R o ra b e c k
Canada
Dr. D. S e lig s o n
USA
Prof. T. S h a fi
Eg yp t
Prof. R. S p in e lli
Italy
P ro l. R. S zyszko w itz A u s tria
Prof. J . V id al
Fran ce
Dr. Z. Zab orszki
H u n g ary

O rg an ized By: B e r u f s g e n o s s e n s c h a f t l i c h e Unfallklinik, D-8110
Murnau , Bavaria. West G erm an y
(C o n g ress P re sid en t: Prof. J. Probst; C o n g r e s s S ecretary: Dr. G. Hofmann)
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.

General Surgery Places First-Year Training
Positions in Canada-Wide Match

Next month, departments of general sur
gery will officially register their first-year
training positions with the Canadian
Intern Matching Service (CIMS), leading
the way among specialties toward central
processing of residents’ training—a route
some consider the only way to a rational
system of physician manpower planning.
June 1 is the deadline for registering
positions, according to C.A. Casterton,
retiring executive director of CIMS. Of
the 16 medical schools, 12 to 14 are
expected to participate, with about 80
spots in all. The match will be done in
much the same way as for medical school
graduates seeking internships. The timing
will be different, however, since the selec
tion of candidates for training has tradi
tionally been in November.
A directory of the programs in the
match will be circulated. Candidates
searching for a position in general surgery
will be invited to register (the proposed
deadline is Aug. 30) and to rank their
choices (by Sept. 15). The program direc
tors then have an opportunity to consider
the candidates and submit their choices.
The match, complete with contracts
signed by the institution and student,
would be finalized by Nov. 1, without the
telephoning and sometimes the pressure
associated with the confirmation of can
didacies in the past.
Last year, Canadian medical schools
produced 1773 graduates, many of whom
sought postgraduate training to fulfil
requirements for licensure or to pursue a
Contributions to this column are welcome.
Please send your material to: Mrs. Amy
Chouinard, Canadian Journal o f Surgery, PO
Box 8650, Ottawa, Ont. K1G 0G8.

specialty. The numbers of positions
(straight and rotating internships, firstyear residencies) are just under 3000,
according to figures from the Association
of Canadian Medical Colleges, but the
prerequisites for entry vary widely by
province and program.
According to Casterton, differences in
selection criteria are a stumbling block for
specialties that have considered using the
services offered by CIMS. Some specialty
programs accept students directly from
medical school, although all surgical resi
dents must have completed a rotating
internship. He believes that a successful
result in general surgery will encourage
other specialties to join the match.
He also notes that the intern match has
become increasingly effective, as the num
ber of participating programs has grown
over the years. In 1986, for example, the
University of Alberta re-entered the
match, bringing 57 new positions and
boosting the total within CIMS to 1330.
The result was that almost 99% of the
graduates from Canadian medical schools
who entered the mate! found positions
of their choice immediately.
The picture for graduates of foreign
medical schools is less pleasant, with only
22 of 481 finding spots through CIMS this
year. Casterton is troubled by the grow
ing numbers of foreign-trained physicians
searching for positions, especially as the
federal government is moving to relax res
trictions on immigration. “ If we admit
people on humanitarian grounds, we can
not continue to exclude them from posi
tions in their profession” , says Casterton,
noting that Quebec is the only province
that earmarks some of its positions for
foreign graduates.

Charles Drake, FRCSC

Drake to Receive F.N.G.
Starr Award
Charles G. Drake of London, Ont.,
this year will receive the highest award
bestowed by the Canadian Medical
Association, adding the F.N .G . Starr
award to his long list of honours.
Drake was chosen for the award at the
CMA board meeting held at the end of
March, in recognition of his contributions
to neurosurgery and particularly the treat
ment of cerebral aneurysms.
The native of Windsor, O nt., formerly
chaired the Department of Surgery at the
University of Western Ontario, where he
received his first medical degree in 1944,
and still is professor.
He also has had an active career in
organized medicine, serving, for example,
as the president of the American College
of Surgeons last year.
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Beware When Inserting Cathe
ters in Central Venous System
The Health Protection Branch (HPB)
recently alerted surgical and other hospi
tal staff about deaths caused by catheters
inserted in the central venous system to
monitor pressure and to deliver parenteral
fluids. The message was a reminder of
basic rules, such as confirming radiologically the position of the catheter and
ensuring that for parenteral therapy the
tip of the catheter is inserted not much
beyond the subclavian or jugular vein and
for pressure monitoring not beyond the
entrance to the right atrium.
The HPB reported that the rigidity of
the materials currently used in the
catheters has increased the need for cau
tion, particularly with mobile patients

J. Edward Mullens, FRCSC, assistant
secretary-treasurer for the Canadian Med
ical Protective Association, has been named
1986 Janes Surgical Visiting Professor. The
award from the Royal College of Physi
cians and Surgeons of Canada gave Mullens
the opportunity to visit medical faculties in
Hamilton, Winnipeg and St. John’s in
March.

Healthy
Aging?

who may dislodge the catheters by bend
ing or rolling.

U.S. Surgical Club to
Visit Canadian West

have since died out” , probably because
of improved electronic means to share
information.

Foothills Surgeons to be
Featured in CBC Eye-Opener

The Wisconsin Surgical Club will be
touring medical centres in Winnipeg, Cal
gary and Edmonton next month in their
biennial trip to search for innovative tech
niques in the surgical world.
Peter J. Cruse, FRCSC, head of the
Department of Surgery, University of
Calgary, says his group will feature 12
research projects in 15-minute presenta
tions.
“ Travelling clubs, like this one from
Wisconsin, were very popular in the late
40s, early 50s,” commented Cruse, “ but

As part of its 20-year celebrations next
month, Foothills Hospital in Calgary has
struck an agreement with the Canadian
Broadcasting Corporation to interview
members of the staff each morning
between June 9 and 13 on its eye-opener
program.
D. Birdsell, FRCSC, who is chief of
plastic surgery and the burn unit at the
hospital, is one of the planned speakers.
A my C h o u in a r d

Low-voltage machines for continuous passive motion are being developed in conjunction
with the Hospital for Sick Children in Toronto; these two contraptions are for passive move
ment of hand (left) and leg (right).

A sound m ind and a
s o u n d body a re th e
keys to independence.
Learn to adapt to your
ch a n g in g life s ty le as
you reach retirem ent.
Take H e a lth y A g in g ,
your key to an indepen
dent futu re !

St. John Ambulance
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IN METASTATIC BREAST CANCER

THERAPEUTK
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In spite of the use of
aggressive chem otherapy
regim ens incorporating such
, agents as doxorubicin, the
survival rate in m etastatic
L t breast cancer has plateaued in
the last decade.’
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clindamycin concentrating in PMN lysosomes

clindamycin-laden PMN moving
toward the site of infection

Phosphate S.S.
enhances
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2’3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144( 5)
2) Johnson JD, et al (March 1980) J l_ab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
(eds. J Nelson, C Grass!) Am Soc Microbiol Vol 2
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REVIEW ARTICLE
C. T id ia n e T o u r e , m d ;* G illes B e a u c h a m p , m d , f r c s c ;! M a r y a m A r o ic h a n e i :

Physiopathologie et correction chirurgicale
du reflux gastro-oesophagien: revue de la question

Les auteurs font un rappel de la phys
iopathologie du reflux gastrooesophagien en soulignant le role
preponderant du sphincter inferieur de
I'oesophage au sein des mecanismes
antirefiux. Le diagnostic de reflux gastrooesophagien doit se baser sur un
faisceau d'arguments issus d'un ques
tionnaire minutieux et d'une batterie de
tests dont les plus importants sont I'endoscopie et la pH-metrie. Des recommandations sont faites quant aux gestes
chirurgicaux afin de prevenir les compli
cations. Les operations de Hill, de Belsey
et de Nissen, designees sous le terme
generique de valvuloplastie, ont fait la
preuve de leur plus grande efficacite
dans la correction du reflux gastrooesophagien. Une revue de la litterature
confirme les meilleurs resultats obtenus
avec la fundoplicature totale de Nissen.

The authors review the pathophysiology
of gastroesophageal reflux, pointing out
the predominant role of the lower
esophageal sphincter in antireflux
mechanisms. The diagnosis of gas
troesophageal reflux must be based on

Du departement de chirurgie, Hopital
Maisonneuve-Rosemont, Montreal, PQ
*Assistant chef de dinique chirurgicale,
University de Dakar. Stagiaire, Hopital
Maisonneuve-Rosemont, Universite de
Montreal, Montreal, PQ
t Professeur agrdge de clinique, departement
de chirurgie, section de chirurgie thoracique, Hopital Maisonneuve-Rosemont

the results of detailed examination and
other tests of which endoscopy and
esophageal pH monitoring are the most
important. The authors describe how to
manage operation for gastroesophageal
reflux so as to prevent complications.
Although the Hill, Belsey and Nissen
operations, referred to as valvuloplasties,
have proved their effectiveness in curing
gastroesophageal reflux, a review of the
literature shows that better results are
achieved by Nissen total fundoplication.

L ’essor des nouvelles methodes d ’investigation a permis une connaissance plus
approfondie de la physiopathologie du
reflux gastro-oesophagien, un diagnostic
plus precis et une meilleure comprehen
sion des mecanismes d ’action des
differentes methodes therapeutiques tant
medicales que chirurgicales. II en a
decoule une amelioration de ces traitements et des indications plus pertinentes
grace notamment a une definition plus
precise des objectifs therapeutiques et a
un meilleur choix des candidats chirur
gicaux. Actuellement, les techniques
chirurgicales qui ont fait la preuve de leur
efficacite sont celles qui component une
valvuloplastie, c’est-a-dire les techniques
de Hill, de Belsey et de Nissen, precedes
dont nous parlerons ici. La technique de
Nissen est la plus performante quant a la
correction du reflux. Toutefois, la chirur
gie de cette affection, benigne initialement, comporte une certaine morbidity
qu’une rigueur dans l’execution et les
indications peut amoindrir.

XEtudiante en medecine, Universite de
Montreal

Physiopathologie

Accepts pour publication le 22 octobre
1985

Le reflux gastro-oesophagien cor
respond a un renvoi de liquide gastrique
dans la lumiere oesophagienne. Le reflux
survient chez les individus normaux.1'2
Le reflux physiologique est transitoire et
n ’occasionne pas de degdts sur
I’oesophage. Toutefois, le reflux peut

Les demandes de tires-a-part doivent etre
adressees au: Dr Gilles Beauchamp,
Departement de chirurgie, Hopital
Maisonneuve-Rosemont, Montreal, PQ
H IT 2M4
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evoluer vers un desordre clinique si les
mecanismes de defense sont debordes.
Ces mecanismes en question sont anatomiques et physiologiques.
Les facteurs anatomiques
de continence cardiale
Au nombre de ces facteurs ont ete cites:
la fronde du pilier droit du diaphragme,
Tangle de His, Timplantation particuliere
de I’oesophage sur Testomac, la mem
brane phreno-oesophagienne, la rosette
muqueuse oesophagienne au niveau du
sphincter inferieur de I’oesophage et Texistence d’un segment abdominal suffisamment long pour subir la pression intraabdominale. Ces facteurs anatomiques ne
sont pas toujours les plus importants. Par
example, il existe des hernies hiatales
(anomalie d ’un ou plusieurs facteurs
anatom iques) sans reflux gastrooesophagien et vice versa. II y a souvent
une absence de correlation entre les fre
quences respectives de ces deux affec
tions; la hernie hiatale etant plus souvent
rencontree.3'4 Le facteur anatomique le
plus important semble etre la longueur
d’oesophage abdominale. Bonavida et
collaborateurs5 ont demontre experimentalement qu’une longueur d ’oesophage
abdominal inferieure a 2 cm constituait
une predisposition anatomique au reflux
et ne permettait pas de contrecarrer la
pression intra-gastrique. Au cours des
dernieres annees, on s’est surtout interesse
au sphincter inferieur de I’oesophage mais
on s’est apergu de la necessite de la coex
istence d ’une longueur suffisante
d’oesophage abdominal et d’un tonus
adequat du sphincter inferieur de
I’oesophage pour controler le reflux
gastro-oesophagien.
Les facteurs physiologiques s ’opposant au
reflux et a ses effets
Le sphincter inferieur de I’oeso
phage.—Ce sphincter est un element
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essentiel de la continence cardiale. Les
travaux d’Atkinson et collaborateurs,6
de Botha et collaborateurs,7 et de Fyke
et collaborateurs8 ont montre que le
sphincter inferieur de l’oesophage maintient un tonus basal plus eleve que la pression intra-gastrique. Le sphincter se
relache avec la survenue d ’une onde
peristaltique et se referme apres cette
relaxation. II subit deux types de controle,
l’un intrinseque, l’autre extrinseque;9' 11
celui-ci se faisant par le biais du vague.
Le tonus du sphincter inferieur de
1’oesophage est en outre influence par
differentes hormones, dont la gastrine, la
motiline et la bombesine qui l’elevent; la
secretine, la cholecystokinine, le peptide
intestinal vasomoteur, le “ gastric inhibi
tory peptide” et le glucagon qui
l’abaissent.12
Dans le reflux gastro-oesophagien, le
plus souvent, le tonus du sphincter gastrooesophagien est bas, et l’absence de gra
dient de pression oesophago-gastrique
permet la survenue du reflux.13
Les autres facteurs physiologiques. —
Chez un sujet normal, lorsqu’un reflux
survient, la vidange oesophagienne se fait
grace aux contractions primaires ou
secondaires ou par gravite s’il est en
orthostatisme. Chez l’individu presentant
un reflux gastro-oesophagien, il existe
souvent une vidange oesophagienne
defectueuse14,15 et cette anomalie s’aggrave lo rsq u ’il s’y associe une
oesophagite.16-18
La salive joue un role de lavage et de
neutralisation du sue gastrique reflue.19
Une fonction antro-duodenale normale
est necessaire. Le passage normal des ali
ments vers le duodenum permet 1’inhibition de la secretion acide, empeche le
reflux duodeno-gastrique et le passage des
secretions biliaires et pancreatiques dans
le liquide gastrique reflue. Un transit
gastro-duodenal normal autorise une ele
vation du tonus du sphincter.20 Un pas
sage antro-duodenal defectueux provoque
une distension gastrique, une baisse du
gradient oesophago-gastrique et augmente la quantite de liquide gastrique disponible pour le reflux.21
Les consequences locales du reflux
L ’intensite des desordres cliniques et
anatomiques, e’est-a-dire la production
d ’oesophagite occasionnee par le reflux
gastro-oesophagien, depend de la quan
tite de liquide reflue, de la nature des
substances qu’il renferme et du temps de
contact de ces substances avec la
muqueuse oesophagienne. L ’association
de sels biliaires, d’enzymes pancreatiques
et d’acide chlorhydrique est particulierement nocive.22,23
Consequences sur la parol oesopha
gienne.—Le contact prolonge des subs
tances, telles que l’acide chlorhydrique,
la pepsine et les sels biliaires, avec la

muqueuse oesophagienne altere celle-ci
aux niveaux macroscopique et microscopique.16 II se produit alors des ulcera
tions qui vont se creuser davantage pour
interesser finalement toute la paroi
oesophagienne et le tissu perioesophagien.24-26 Lorsque 1’irritation disparait, le processus de guerison se fait par
le developpement de Pepithelium voisin.
Un autre processus de cicatrisation, survenant apres une irritation de duree plus
prolongee, est la constitution d ’un tissu
de granulation qui conduit a la sclerose
et a la stenose. Une autre eventualite,
enfin, est le remplacement de la perte de
substance parietale oesophagienne par de
Pepithelium cylindrique gastrique: e’est
l’endobrachy-oesophage (oesophagite de
Barrett).12
Les troubles moteurs oesophagiens. —
L’oesophagite creee par le reflux gastrooesophagien finit par alterer la muscula
ture oesophagienne. II s’ensuit une baisse
du tonus du sphincter inferieur de l’oesophage27 et Papparition d’ondes secondai
res au niveau du corps de l’oesophage.28
On a pu montrer experimentalement que
Poesophagite provoque une baisse de
P amplitude des contractions et une moins
bonne vidange oesophagienne.16,18 Tous
ces facteurs vont majorer le reflux et il se
cree ainsi un cercle vicieux.
Diagnostic

Il repose sur un interrogatoire et un
examen minutieux, et sur une batterie de
tests. Cooper et Jeejeebhoy29 ont judicieusement affirme que ce qu’il faut, e’est
avoir une vision equilibree se fiant a un
bon jugement clinique, sans ecarter les
tests de la fonction oesophagienne, mais
tout en ne les considerant pas comme
infaillibles. En effet, le diagnostic doit
decouler d’un faisceau d ’arguments.
Parmi les tests, certains sont d’une grande
sensibilite et d ’une grande precision,
d ’autres le sont moins. Ils evaluent soit
le reflux, soit Poesophagite.
• L ’endoscopie permet d ’apprecier et
de classer une oesophagite et de pratiquer
des biopsies. Elle explore egalement
l’estomac et le duodenum a la recherche
d’une pathologie associee.30
• La pH-metrie oesophagienne de 24
heures, decrite initialement par Johnson
et DeMeester,1 a une sensibilite et une
specificite de 90%.31 C’est actuellement
le maitre-test pour evaluer le reflux.
• La m anom etrie oesophagienne
donne des informations sur la longueur,
le tonus et le fonctionnement du sphinc
ter inferieur de l’oesophage: on peut ainsi
affirmer l’incompetence du sphincter.
Elle permet egalement de qualifier et de
quantifier les contractions oesophagiennes. Cependant, ce test seul (comme
d’ailleurs tous les autres) n ’est pas suffisant pour poser une indication.29

• La scin tig ra p h ie oesophagogastrique peut etre utile dans la recher
che d ’anomalies morphologiques et fonctionnelles associees au reflux gastrooesophagien. Elle peut eventuellement
reveler un reflux actif. Ce test permet ega
lement de la vidange gastrique. En defi
nitive, Pindication premiere de la scinti
graphie oesophagienne au cours du reflux
gastro-oesophagien est la recherche des
desordres moteurs associes.32
• Le transit baryte oesophago-gastroduodenal fournit des details d ’ordre anatomique et fonctionnel sur l’oesophage,
renseigne sur l’estomac et le duodenum.
Ce n ’est toutefois pas un bon test de
reflux.
Traitement medical

Le traitement poursuit trois objectifs:
la d im in u tio n du reflu x gastro oesophagien en quantite, frequence et
duree; la baisse du potentiel agressif du
liquide reflue: acide chlorhydrique, pep
sine, bile et enzymes pancreatiques; et la
restauration des mecanismes antireflux:
sphincter inferieur de l’oesophage et fac
teurs anatomiques.
Dans un premier temps, on soumet le
patient essentiellement a des mesures
hygieno-dietetiques: cure d ’amaigrissement; elevation de la tete du lit pendant
le sommeil; eviter le port d ’habits trop
serres; modifier le regime alimentaire: evi
ter les exces a table, les aliments gras, le
chocolat, le cafe, le the, la menthe et les
aliments connus du patient lui-meme
comme causes du reflu x gastro oesophagien; eviter Palcool et le tabac;
proscrire les medicaments provoquant ou
majorant le reflux gastro-oesophagien:
progesterone, theophylline, anticholinergique, diazepam, morphine;21 corriger
les situations de stress et d’instabilite emotionnelle si possible, ou tout au moins les
reconnaltre.9
On associe a ces mesures, l’administration d ’anti-acides et de P acide alginique
avant et apres les repas et avant le coucher. Ce traitement sera poursuivi de 3 a
6 mois avant de poser une indication operatoire. Chez les patients obeses, il faudra etre patient et poursuivre le traitement
medical pendant au moins 1 an .33
Neanmoins, malgre cette approche therapeutique, environ 25% des patients presenteront quand meme une persistance ou
une aggravation des symptomes. Il faut
alors poursuivre les investigations tout en
administrant certains medicaments aux
indications bien particulieres. Ainsi, pour
ameliorer la vidange oesophagienne, on
utilisera volontiers le betanechol;20 le
metoclopramide ou bien le domperidone.34-37 Les antagonistes des recepteurs
H2 (cimetidine et ranitidine) seront utili
ses pour combattre une hypersecretion
gastrique acide. De plus, le reflux gastro-
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oesophagien pourra etre ameliore par le
metoclopramide et le domperidone qui
accelerent la vidange gastrique.17,38,39
Toutefois, 10% a 20% des patients ne
repondront pas au traitement medical. II
est alors legitime de proposer au patient
un traitement chirurgical dont il faudra
discuter les avantages et les inconvenients.
Le but du chirurgien sera de choisir les
bons candidats chirurgicaux capables de
subir sans risques de mortalite Tintervention. De plus, il devra s’assurer du choix
judicieux de la technique chirurgicale,
compte tenu des donnees sur la compe
tence du sphincter inferieur, la vidange de
l’oesophage et de l’estomac, de la pre
sence ou non d’une stenose peptique ou
d’un oesophage court.
Traitement chirurgical

Principes d ’une reparation ideate du
reflux gastro-oesophagien
Objectifs therapeutiques.—Il s’agit
d ’obtenir une continence cardiale ade
quate en restaurant la competence du
sphincter inferieur de l’oesophage et une
longueur suffisante d’oesophage abdomi
nal. Ainsi, on laissera un segment oeso
phagien sous-diaphragmatique suffisamment long pour subir les pressions
intra-abdominales positives.5,29,40 Il fau
dra, de plus, proceder a un rapproche
ment des piliers du diaphragme.
Les facteurs impliques dans la realisa
tion d ’une valvuloplastie (Fig. 1).—
Toutes les valvuloplasties realisent une
reconstruction de Tangle de His (Fig. 1:
1). Selon le cas, on procedera a une libe
ration des vaisseaux courts de l’estomac
afin de permettre la rotation du fundus
(Fig. 1: 2). L’etendue de fundus mobilise
depend, d ’une part, du type de fundoplicature (totale ou partielle) et, d’autre part,
de la longueur d ’oesophage entoure de
fundus (Fig. 1: 3, 4 et 5). Selon le cas, le
nerf vague est inclus ou exclus de la fundoplicature. On doit menager entre le
fundus et Testomac un espace suffisamment lache pour ne pas provoquer de
dysphagie. Le fundus plicature doit etre
fixe a 1’oesophage meme afin d ’eviter un
glissement vers l’estomac (Fig. 1: 6).
Meme si initialement on a utilise les deux
parois anterieure et posterieure du fun
dus et que Tutilisation de la face poste
rieure seule est aussi possible, les techni
ques actuelles de fundoplicature utilisent
essentiellement la paroi anterieure (Fig.
1: 7).
Prevention des complications chirurgicales.—Lorsqu’on effectue une fundopli
cature, la reparation ne doit etre ni trop
serree, ni trop lache. Trop serree, elle peut
etre la source de dysphagie, d ’impossibilite de vomir ou d ’eructer; trop lache, elle
laisse un sphincter inferieur de l’oesophage incompetent. Il faut eviter de pro
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ceder a une reparation trop longue, car
la encore, on peut voir apparaitre une
impossibility d ’eructer ou de vomir, et
done un syndrome de “ gas bloating” .
Une fundoplicature doit etre stable, e’esta-dire qu’elle doit pouvoir se maintenir
sans tension sous le diaphragme, sinon on
risque d’observer une protrusion dans le
thorax. La fermeture des piliers du diaph
ragme ne doit pas etre trop serree afin
d ’eviter la dysphagie, une obstruction a
la vidange de Toesophage et une dilata
tion de celui-ci. La reussite du traitement
chirurgical du reflux gastro-oesophagien
exige un estomac qui se vide normalement. Il faudra done controler medicalement ou chirurgicalement toute maladie
ulcereuse contemporaine. Il faut preser
ver Tintegrity des nerfs vagues afin de ne
pas compromettre la vidange gastrique.
Tout reflux biliaire doit etre corrige afin
notamment de prevenir une gastrite
biliaire. On doit mobiliser suffisamment
Toesophage abdominal afin que la fun
doplicature se fasse autour de Toesophage
distal et non autour de Testomac proxi
mal. Dans ce dernier cas, on risque de
voir apparaitre le phenomene dit du
“ telescopage” .41 On evitera d’abandonner la fundoplicature dans le thorax.
Cette attitude expose au developpement
d ’ulcere gastrique et de gastrite dans la
poche intra-thoracique avec les risques de
perforation et d ’hemorragie.42 Afin de
permettre une meilleure mobilisation du
fundus et de rendre la fundoplicature plus
lache, on pensera a lier quelques vaisseaux
courts, entre autres quand on effectue une
fundoplicature de Nissen.
Dans tous les cas, il s’agit, la, d’une
pathologie initialement benigne dont la
correction peut se faire avec un minimum
de morbidity et ne doit entrainer aucune
mortalite.
Mode de fonctionnement
des valvuloplasties
Des hypotheses explicatives et des travaux experimentaux on ete consacres a ce
sujet. Dans les valvuloplasties, le cardia
est replace dans Tabdomen et sera plus
ou moins entoure du fundus (selon le type
d’intervention), ce qui restaure la compe
tence du sphincter inferieur de Toeso
phage. Dans Tabdomen, les fibres musculaires oesophagiennes longitudinales
sont stimulees et accroissent leur tension
sous l’effet de la pression abdominale
positive.40,41 L ’enveloppe fundique
autour de Toesophage se comporte
comme un ballonnet qui se gonflerait sous
l’effet de la pression intra-gastrique et
viendrait comprimer Toesophage. Ce der
nier mecanisme serait comparable a celui
d ’un clapet.43 Dans la fundoplicature
totale de Nissen et Toperation de Belsey,
le tonus musculaire de Tenveloppe fun
dique vient augmenter celui de Toeso

phage.44 La fundoplicature ameliore le
rapport tension appliquee-force de ferme
ture du sphincter inferieur de Toesophage
en agissant au niveau des fibres musculaires de la couche circulaire.45 Ces deux
derniers mecanismes sont d ’autant plus
accentues que la circonference oesophagienne entouree du fundus est plus importante. Ceci explique que la competence du
sphincter inferieur de Toesophage est
mieux restauree apres une fundoplicature
totale de Nissen.44
Les techniques de correction chirurgicale
Nous allons decrire les techniques de
Belsey, de Hill et de Nissen. Ces trois pre
cedes possedent en commun les modalites techniques suivantes: mobilisation
adequate de Toesophage, restauration
d ’un segment intra-abdominal de Toeso
phage, fundoplicature totale ou partielle
afin d’augmenter la competence du
sphincter inferieur de Toesophage, rap
prochement posterieur des piliers du
diaphragme afin de corriger ou de preve
nir une hernie.
La voie d ’abord.—L’abord abdominal
est obligatoire pour Toperation de Hill.
Cette voie abdominale peut egalement
etre utilisee pour effectuer une fundopli
cature de Nissen. On doit pratiquer une
thoracotomie pour realiser Toperation de
Belsey-Mark IV. On peut tout aussi bien
pratiquer une fundoplicature de Nissen
lors d’une thoracotomie et cette voie est
privilegiee par certains. Toutefois, la voie
thoracique sera voluntiers utilisee pour
pratiquer une fundoplicature sur un oeso
phage “ difficile” : oesophagite marquee
(raccourcissement), recidive, autres
lesions oesophagiennes ou alors en cas
d’obesite du patient ou de pathologie tho
racique associee et a traiter dans le meme
temps. Cette voie thoracique permet
d ’apprecier de visu les lesions oesopha
giennes et, en outre, de proceder a une
meilleure mobilisation de Toesophage et
d’effectuer une reparation sans tension.
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FIG. 1—Facteurs impliques dans la con
struction d’une valvuloplastie: 1 = reconstruc
tion de Tangle de His, 2 = liberation ou non
des vaisseaux courts, 3 = quantile de fundus
disponible pour la fundoplicature, 4 = lon
gueur d'oesophage entoure par le fundus, 5 =
degre d’enroulement de Testomac autour de
Toesophage: fundoplicature totale et fun
doplicature partielle, 6 = fixation de Ten
veloppe fundique a Toesophage, 7 = utilisa
tion de la paroi anterieure du fundus pour
confectionner la valve fundique.
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Les techniques
• L ’operation de Belsey-Mark IV .46
La voie d’abord est une thoracotomie
gauche, habituellement a travers le 6e
espace intercostal. L’oesophage est mobi
lise jusqu’au niveau de la crosse aortique.
La partie superieure du petit epiploon est
incisee. On procede a l’ablation de la
graisse recouvrant le cardia afin de favoriser ulterieurement l’apparition d’adherences avec le fundus plicature. Les nerfs
vagues sont liberes de l’oesophage abdo
minal afin de leur faire adopter une posi
tion posterieure et d ’etre a l’abri des
points de suture de la fundoplicature. Une
plicature utilisant le fundus gastrique est
executee autour de l’oesophage sur une
circonference de 270° et sur une hauteur
d ’environ 4 a 5 cm,29 mais laissant le
cote postero-droit de I’oesophage libre.
Le nerf vague droit se trouve ainsi en
dehors de la plicature. On fixe le fundus
a 1’oesophage abdominal a l’aide de
points en U horizontaux disposes en deux
rangees de trois points chacune. Les
points de la rangee superieure chargent le
bord de la partie tendineuse du diaphragme. Les sutures doivent charger la
musculeuse oesophagienne sans pour
autant interesser la muqueuse.42 Les
piliers sont rapproches en arriere de
l’oesophage de fason a admettre un
index. L’oesophage est reintegre en posi
tion abdominale, sans tension, avant le
serrage des noeuds.
• L ’operation de Hill.47,48 L’abord
sera abdominal. L’oesophage abdominal
est mobilise apres division du petit epi
ploon et section de la membrane phrenooesophagienne. On mobilise la grande
courbure et cela peut necessiter eventuellement la ligature d’un ou deux vaisseaux
courts. S’il y a une hernie hiatale, elle est
reduite. Le ligament arque median est
repere: c’est la partie antero-inferieure de
l’orifice aortique du diaphragme. On disseque aussi le fascia pre-aortique et
l’arcade fibreuse. Le bord inferieur du
ligament arque est libere par dissection.
II est situe juste au-dessus du tronc coeliaque. On placera une lame en-dessous
du ligament arque afin de proteger le
tronc coeliaque et l’aorte. Un tube de
Levin no 18 est introduit dans l’oesophage
qui permettra d’apprecier la fermeture du
hiatus et d’eviter une plicature du cardia.
Les piliers du diaphragme sont alors fixes

FIG. 2—Fundoplicature totale de Nissen.

entre eux, en arriere de l’oesophage, par
deux ou trois points en X au fil non resor
bable. Cette fermeture des piliers doit
autoriser le passage de l’oesophage contenant le tube de Levin et de l’index. On
suture la berge interne du petit epiploon
incise, les bords anterieur et posterieur de
la petite courbure de l’estomac au liga
ment arque (quatre points suffisent en
general). On suture egalement la partie
posterieure du ligam ent phrenooesophagien (que l’on fait passer a gau
che de l’oesophage) au fascia preaortique. La tension ainsi appliquee sur
le cardia s’exerce sur le sphincter inferieur
de l’oesophage, accentue Tangle de His
et cree un effet de valve. Hill recommande
de “ calibrer” le cardia en plaqant des
points de suture entre, d ’une part, la partie du cardia maintenant situee en avant
de Toesophage et la jonction gastrooesophagienne et, d ’autre part, entre la
partie du cardia maintenant a droite de
la petite courbure et le ligament arque.
Cette “ calibration” doit permettre a
l’index du chirurgien d’invaginer la paroi
gastrique a cote du tube de Levin.47
• La fundoplicature totale de Nissen
(Fig. 2). Decrite en 1956 par Nissen,49
elle a ete modifiee en 1971 par Rossetti
et Allgower.50 Nous decrirons la techni
que modifiee de Rossetti. La voie d ’abord
est thoracique ou abdominale. On pro
cede a une section du ligament triangulaire gauche du foie qui est recline. Deux
ou trois vaisseaux courts peuvent etre lies
au niveau de la grande courbure. L ’esto
mac est attire vers le bas et le peritoine
parietal est incise au niveau de sa reflexion
pres du hiatus. La membrane phrenooesophagienne est sectionnee. Le peri
toine pre-oesophagien est ouvert et la
graisse peri-cardiale est enlevee, permettant de decouvrir les fibres musculaires
longitudinales de Toesophage. On pro
cede a une liberation aux doigts des atta
ches posterieures de Toesophage jusqu’a
permettre le passage de deux a trois doigts
derriere Torgane. On fait passer un lacs
en caoutchouc autour du cardia afin d’en
faciliter la traction en bas et en avant. Le
vague posterieur est habituellement bien
en arriere de Toesophage et reste en
dehors de la fundoplicature.
Le vague anterieur est a droite, sur la
face anterieure de Toesophage, et on doit
en reperer egalement le rameau hepatique.
Ces derniers elements seront inclus dans
la fundoplicature et devront continuer
leur trajet et apparattre a la partie inferieure du repli fundique. L’operateur
demande a Tanesthesiste d’introduire
dans Toesophage une bougie de Hurst no
50 ou 52 Fr. Les piliers du diaphragme
sont rapproches en arriere de Toesophage,
mais les fils ne sont pas noues. Ensuite,
coiffee de la paroi anterieure du fundus,
un doigt de 1’operateur la fait passer en
arriere de Toesophage et ressortir sur le

bord droit de celui-ci ou elle sera saisie
a l’aide de deux pinces d ’Allis. On fait
passer un autre pli de la paroi anterieure
du fundus en avant de Toesophage. On
fixe entre eux les deux plis anterieur et
posterieur avec cinq ou six points extramuqueux au fil non resorbable chargeant
egalement la musculeuse de la face ante
rieure de Toesophage. On cree ainsi un
manchon d’une hauteur de 3 cm environ
autour de Toesophage abdominal, assez
lache cependant pour permettre le passage
d ’un doigt. On procede au serrage des
noeuds assurant la fermeture des piliers
du diaphragme. Cette fermeture doit per
mettre le passage de deux doigts. La bou
gie est retiree et remplacee par une sonde
de Levin no 18.
Les complications
Les complications peroperatoires.—
Ces complications ne sont pas frequentes. Les perforations peuvent etre obser
v e s sur Toesophage ou sur le manchon
gastrique.41,51 Lorsqu’on les decouvre
pendant Tintervention, on peut les fermer
par apposition de la paroi gastrique.
Neanmoins, elles peuvent etre gravissimes. L ’hemorragie n ’est pas exceptionnelle et est en rapport avec la richesse vasculaire de la jo n ctio n
gastro-oesophagienne.42 L ’incidence des
lacerations de la rate est de 5% a
7% .41,52 Ces blessures peuvent survenir
lors de la mobilisation du fundus ou de
Toesophage, elles peuvent etre dues aux
ecarteurs. La fundoplicature de Nissen
(qui utilise davantage de fundus) semble
exposer plus que les autres procedes a ces
blessures de la rate. L ’instrumentation
moderne utilisant les retracteurs du
sternum et de la region sousdiaphragmatique, la lumiere frontale a
fibre optique et les instruments longs permettent de realiser avec confort ce type
de chirurgie.
Complications postoperatoires.—La
dysphagie demeure la plus frequente de
ces complications. Sa frequence, de
l’ordre de 50%, diminue a mesure qu’on
s’eloigne de la date de Tintervention.44,51,52 Cette dysphagie retient plusieurs etiologies. Elle peut relever d ’une
imperfection technique (rapprochement
excessif des piliers du diaphragme, man
chon fundique trop serre ou trop long),
d ’un oedeme52 ou de la meconnaissance
d ’un etat dyskinetique oesophagien preexistant.51 De toute fapon, on observe
une impossibility de la relaxation com
plete apres reparation.41 La dysphagie
est plus frequente apres une fundoplica
ture totale de Nissen.42
Le “gas bloat s y n d r o m e ’’ (ou
syndrome post-fundoplicature), decrit initialement par Woodward,43 correspond a
une satiete precoce; a une sensation de
plenitude au niveau de Tepigastre et de
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Fhypochondre gauche; a une difficulty,
voire une impossibility d’eructer, accompagnee d ’une accentuation des borborygmes intestinaux et d’une flatulence. II se
voit essentiellement apres une fundoplicature de Nissen. Woodward43 a d’abord
estime sa frequence a 20%, puis finalement a 11 % ;53 Rossetti et Allgower50
trouvent ce syndrome chez 10% de leurs
590 patients; d’autres auteurs (Beau
champ G: Etude retrospective comparent
le Nissen et le Collis-Nissen. Non publie),42 enfin, le rencontrent encore
autour de ce dernier chiffre. L’explication
de cette anomalie n ’est pas univoque.
Toutefois, on constate que la confection
d ’une valve trop serree ou trop longue
peut en etre la cause. La valve formerait
un clapet qui empecherait F evacuation de
Fair vers l’oesophage. L ’amputation
fonctionnelle du fundus dans la fundoplicature pourrait etre a l’origine d’anomalies de vidange gastrique qui provoqueraient le “ gas bloat syndrome” . Une
autre cause a ete decouverte par DeMeester et collaborateurs31 qui ont identifie
des sujets “ avaleurs d’air” et presentant
un reflux en orthostatisme lors de la pHmetrie prolongee. L ’air avale permettrait
de lutter contre les effets du reflux. Ces
patients seraient predisposes a presenter
un “ gas bloat syndrome” du fait de la
moins bonne evacuation de Fair, notamment apres fundoplicature totale.31’44'54
Une vagotomie accidentelle peut survenir lors de la dissection de Foesophage
distal. La cause peut en etre une section,
une elongation ou une prise d’un nerf
dans un noeud. Chez certains patients,
cela provoque une stase et une distension
gastrique;42 chez d ’autres, on peut obser
ver une diarrhee.41 Siewert et Blum41
l’observent chez 3% de leurs patients. II
semble que la frequence des vagotomies
accidentelles soit plus grande avec l’abord
abdominal.44
Enfin, on peut observer une persistance
ou une recidive du reflux. Orringer, et
collaborateurs55 trouvent pour [’opera
tion de Belsey, sur 892 patients, un taux
de recidive de 12% a plus de 3 ans et de
15% a 10 ans et plus. Avec la fundopli
cature de Nissen, Polk52 trouve un taux
de 4.5% de recidive symptomatique ou
anatomique avec un suivi postoperatoire
de 5 ans. En 1977, Hill47 donnait un taux
de recidive de 0.89% pour sa technique.
II faut remarquer que, en general, les recidives anatomiques sont moins frequentes
que les recidives symptomatiques.
Resultats
Evaluation endoscopique.—La guerison endoscopique d ’une oesophagite est
obtenue au bout de 10 a 12 semaines.41
Le premier controle endoscopique sera
effectue au bout de 3 mois. Un autre con
trole le sera demande 1 an plus tard. La
recidive du reflux gastro-oesophagien
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serait rare lorsque le resultat a 1 an est
bon.56
Evaluation fonctionnelle. —L’evalua
tion par le pH-metrie de 24 heures montre une superiority de la fundoplicature
de Nissen sur les autres techniques. Une
etude de DeMeester et collaborateurs44
revele une correction du reflux a 100%
avec la fundoplicature de Nissen, 73%
avec celle de Hill et 46% pour celle de Bel
sey. L’operation de Nissen est la plus performante aussi quant a l’augmentation de
la pression du sphincter inferieur de
Foesophage.44 La fundoplicature restaure la pression du sphincter a des
valeurs egales ou superieures aux valeurs
preoperatoires. Sur le plan clinique, on
recherche la disparition du reflux. Les
bons resultats sont de l’ordre de 90% avec
la fundoplicature de Nissen (Beauchamp
G: Etude retrospective comparent le Nis
sen et le Collis-Nissen. Non pu
blic).41'50'52 Hill et collaborateurs48 ont
rapport 97% de bons resultats avec leur
technique. Skinner et Belsey46 font etat
de 85% de bons resultats avec la fundo
plicature partielle de Belsey.
De nouvelles attitudes se degagent
maintenant dans le suivi des patients ope
ras pour reflux gastro-oesophagien. Tous
les patients devraient etre suivis methodiquement pour une periode d’au moins
5 ans pour s’assurer des resultats a long
terme. Tous ces patients devraient etre
soumis a des examens objectifs de con
trole comme la cineradiologie de Foeso
phage, Fendoscopie, la manometrie. La
pH-metrie prolongee serait le test de plus
fiable; cependant, compte tenu des difficultes de la technique et des couts, il ne
faudrait pas en faire une evaluation de
routine chez les patients qui vont bien.
L ’etude de Negre et collaborateurs57
montre bien que les resultats postoperatoires a long terme ne sont pas toujours
aussi parfaits que semblent le repeter cer
tains auteurs qui proposent leur propre
technique de reparation.
Conclusions
L’affinement des methodes d’investigation a permis une meilleure connaissance de la physiopathologie du reflux
gastro-oesophagien, un diagnostic plus
precis et des indications plus pertinentes.
Le traitement du reflux non complique est
d ’abord medical. L’echec du traitement
medical legitime le recours a la chirurgie.
En matiere de traitement chirurgical, les
valvuloplasties, qui regroupent les opera
tions de Belsey, de Hill et de Nissen, ont
fait la preuve de leur efficacite quant a
la correction du reflux. La technique de
Nissen s’est averee la plus performante.
Toutefois, une certaine morbidity accompagne cette chirurgie, morbidity que
davantage de rigueur dans le geste et les
indications pourrait amoindrir.
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If fibroids require treatment, hysterec
tomy is usually the therapy of choice.
Myomectomy is best reserved for
women who wish to preserve their
uterus and have a single large fibroid
tumour; it is not normally recommended
for either abnormal uterine bleeding or
infertility. The blood supply of leiomyomas
is from the periphery and is such that
degeneration frequently ensues.
Degeneration, in particular the acute
degeneration that may occur in pregnancy,
is rarely an indication for operation.
Myomectomy has been associated
with considerable blood loss intraoperatively and prolonged morbidity postoperatively. The former can be avoided by
limiting the uterine circulation during
surgery with a uterine tourniquet
and vascular clamps. Atraumatic intracapsular removal of the tumour and
perfect hemostasis will minimize the latter.
On consictere gen6ralement I'hysterectomie comme le traitement approprie pour
soigner les personnes atteintes de
fibromyomes. On a principalement
recours a la myomectomie pour les fem
mes qui d^sirent garder leur uterus et qui
sont atteintes d’une seule grosse tumeur
fibreuse; il n'est generalement pas
recommande d'utiliser la myomectomie pour
des saignements ut6rins anormaux ou pour
les cas de sterilite. L'apport sanguin du
leiomyome s'effectue au niveau de leur
Peripherie, et cela peut frGquemment
entrainer leur deg£nerescence. Celle-ci,
et particuliferement la d£gen£rescence
aigue qui peut se manifester chez une
femme enceinte, ne constitue pas un
signe que la femme doit etre operee.
On associe souvent la myomectomie d
une perte de sang considerable lors de
l’op6ration, et £ une morbidity postoperatoire prolongee. Cette perte de sang
excessive lors de I'op6ration peut etre
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evitee en limitant la circulation uterine
pendant la chirurgie en utilisant un tour
niquet et des pinces vasculaires. Afin de
prevoir une morbidity postoperatoire
excessive, on doit s'assurer d'enlever
avec soin la tumeur capsulde atraumatique et s'assurer d'une parfaite hemostase en utilisant des techniques
chirurgicales soignees.

Uterine fibroids are the most common
tumours found in women. It is important
that general surgeons be aware of the
nature of these tumours and of the
symptoms they may produce and are cog
nizant of recommended therapy. This
appreciation will affect therapeutic
recommendations, particularly those for
hysterectomy. A myomectomy may be
indicated not only per se but also to gain
access to the pelvis during difficult
abdominal or pelvic operations, such as
abdominoperineal operation in the
presence of a large fibroid.

are in the capsule, thus it is nourished
from the periphery, and as the centre of
the tumour is approached the blood sup
ply is diminished. Degeneration is recog
nized as a normal phenomenon, chang
ing only in degree and not in itself an
indication for operative intervention. It
becomes especially marked as the fibroids
enlarge, the most dramatic example being
the red degeneration of pregnancy. A
minority of fibroids increase rapidly in
size during pregnancy,4 thus outgrowing
the already marginal blood supply and so
acute degeneration occurs.
Malignant Change

Fibrosarcoma may be the malignant
transformation of a benign fibroid or a
new growth in the uterine wall; opinion
favours the latter.5 Malignant change in
fibroids is rare. Buttram and Reiter6
found three leiomyosarcomas amongst
1815 operative specimens. The incidence
is considerably less, however, as the
majority of fibroids are not removed.
Development
Should a fibrosarcoma develop, the prog
Fibroids are benign smooth-muscle-cell nosis is guarded, especially when the
tumours (leiomyomas). The individual tumour is discovered in a postmenopausal
uterine tumour develops from the woman.7 The most common presenting
proliferation of a single parent cell1 symptom of leiomyosarcoma is abnormal
whose growth is stimulated by estrogen. vaginal bleeding. A perceived enlarging
Some patients with fibroids have pelvic mass is an unusual presentation.
increased estrogen secretion, but most do
not, even though there may be increased Symptoms
estrogen activity in the tumour itself. This
There are few symptoms diagnostic of
heightened activity is apparently due to
fibroids,
the patient is usually unaware of
an increased number of estrogen recep
tors in the tumour2 and a change in local their presence and removal is generally
not necessary for continued well-being. If
enzymatic activity.3
As the fibroid enlarges it displaces the symptoms do develop they are due to one
adjacent musculature, compressing it into or more of the following: a pelvic mass,
a thick homogeneous layer called the menstrual disturbance or infertility.
pseudocapsule, which forms a dense wall
around the fibroid. Its presence on cut Pelvic Mass
It is not often that fibroids cause
section is pathognomonic. By dissection
women discomfort because of their size.
within this capsule the fibroid can be
The physician usually discovers the mass
removed with the certain knowledge that
on routine examination for an unrelated
adjacent structures are not injured.
complaint. The woman may, however,
Pathological Changes in Fibroids
palpate the mass herself and bring it to
her physician’s attention. How large
Degeneration
should an asymptomatic fibroid be before
The blood vessels supplying the fibroid
it should be removed? The traditional
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answer is equivalent to 14 weeks’ gesta
tion or larger (15 cm in greatest diameter).
The reason for removal in such instances
is the fear of malignant change and the
difficulty of palpating the uterine append
ages, thus making diagnosis of cancer of
the ovary difficult. When discovered at
laparotomy for an unrelated complaint,
removal is rarely prudent, and small
asymptomatic fibroids should not be
■removed.
Menstrual Disturbance
Although disturbance of menstrual
function is frequently associated with
uterine fibroids, cause and effect are
difficult to establish. Various explana
tions have been offered to explain the
heavy menstrual flow, including (a)
impeded uterine venous blood flow,8 (b)
interference with the contractility of the
uterine wall9 and (c) an increased
endometrial surface area.10 None is com
pletely convincing, and it may be that the
menorrhagia is caused by a hormonal dis
turbance resulting in dysfunctional uter
ine bleeding. This same hormonal distur
bance may be associated with fibroid
development. Menorrhagia is not always
relieved when fibroids are removed and
the results of myomectomy, for this rea
son, are unpredictable and often disap
pointing.11
What of other menstrual dysfunction?
Bleeding between periods may be due to
submucous fibroid, but a pregnancy
threatening to abort or endometrial
cancer (particularly in older patients)
should be considered. Secondary dys
menorrhea is uncommon and thought to
be caused by excess production of
prostaglandins from the large endometrial
surface. Dysmenorrhea is an infrequent
indication for myomectomy.
Infertility
Infertility has become a questionable
indication for myomectomy.12 Although
patients with fibroids tend to be older and
less fertile, most patients with fibroids
conceive with ease.13 If they do not, an
infertility investigation will, in most
instances, reveal other causes. This is sub
stantiated by the indifferent results that
follow myomectomy done for infertility
alone (17%).12 The published results14 of
myomectomy for infertility do not differ
greatly from “ treatment independent
pregnancy rates” and may be lower.
A particularly difficult situation arises
when fibroids are discovered in patients
who have had pelvic inflammatory dis
ease. Myomectomy combined with tubal
surgery, in the hopes of enhancing fertil
ity, has not been successful. In a large ser
ies from Jamaica15 there were no intrau
terine pregnancies after this procedure,
162

and a report from Nigeria16 is equally
discouraging.
Treatment

Alternatives to Myomectomy
Except when fertility or the uterus must
be preserved, hysterectomy is most often
the treatment of choice. Menorrhagia will
certainly be cured; the fibroid mass will
not recur; hysterectomy is generally tech
nically easier than myomectomy and
postoperative complications are less fre
quent. Therefore, if the patient’s family
is complete and there is no cultural or
individual desire to preserve the uterus,
hysterectomy should be recommended.
In recent years there have been isolated
reports on hormone treatm ent for
fibroids.17 An analogue of gonado
tropin-releasing hormone will create a
medical menopause, reducing the size of
the myoma. Unfortunately, the side
effects are relatively severe and there are
no long-term studies of such therapy.
Contraindications
Myomectomy should not be done dur
ing pregnancy, either for treatment of
acute degeneration or incidentally at the
time of cesarean section. Red degenera
tion, which may be acute and associated
with severe abdominal pain and local
peritoneal signs, will almost always
resolve with conservative management.
Surgery may result in abortion or prema
ture delivery and frequently intraopera
tive or postoperative hemorrhage, which
may require hysterectomy to control the
situation.18 The case against myomec
tomy immediately after cesarean section
is equally strong. The age of the woman
and the number of fibroids influence the
choice of procedure. Myomectomy is
favoured in the young, but large numbers
of fibroids are a contraindication.
Malone19 reported that when multiple
myomectomies were done, 26% of the
women required hysterectomy later.
Surgical Technique

Hemostasis
It is generally accepted that the blood
supply to the uterus should be secured
before myomectomy.20-22 This is not
necessary with small subserosal fibroids,
but in these cases myomectomy is rarely
performed. Control of the blood supply
limits blood loss and also permits care
ful surgical technique in an effort to pre
vent adhesions postoperatively. A theo
retical objection is the possibility of
ensuing vascular damage,6 but this risk
has been discounted.23

If a tourniquet is to be used, the first
step is to dissect the bladder from the
lower segment of the uterus, which is
encircled by a red rubber catheter. The
catheter is pulled up tight and grasped
with a Kocher clamp, thus occluding the
uterine vessels. The remaining blood sup
ply to the uterus comes from the ovarian
vessels, which are controlled with
Satinsky vascular clamps placed over the
vessels (w ithout disturbing the
peritoneum).
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Incision
The uterine incision should be vertical
and placed as low as possible on the
anterior uterine surface. It is in the least
vascular portion of the uterus and from
it secondary tunnelling incisions can be
made to reach other fibroids. It is also an
incision that can be extraperitonealized
with the bladder flap. These advantages
limit blood loss and help prevent adhe
sions postoperatively.
Although subject to controversy, the
classic approach to fibroids on the
posterior wall of the uterus is from the
anterior surface, through the endometrial
cavity.22 This approach allows simul
taneous removal of submucous fibroids
and also avoids incising the posterior uter
ine wall where adhesions of the adnexa
and small intestine are most likely to
occur. On the other hand, adhesions may
form in the uterine cavity6 and there is
the fear of uterine rupture in a subsequent
pregnancy, a factor that is now largely
discounted.
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Myomectomy
First one must find the plane between
the fibroid and its capsule. This is most
readily achieved by cutting boldly into the
fibroid (nearly bisecting it) and then exert
ing traction on each half with a tenacu
lum. The plane is usually obvious, and
magnification techniques are not nor
mally required. Dissection of the fibroid
from its wall is now done atraumatically,
with ease. Nutrient arteries from the cap
sule are ligated separately. The wound is
closed with a single layer of interrupted
0 polyglycolic acid sutures, tied beneath
the serosa, which in turn is approximated
with a 5-0 polyglycolic acid Lembert
suture. Perfect hemostasis is ensured after
the tourniquet and the ovarian artery
clamps are released. The bladder is now
elevated and sutured in place to cover the
incision on the anterior uterine wall. It
has recently been suggested that the use
of the operating laser would reduce tis
sue trauma and blood loss during
myomectomy.24 Intraperitoneal adminis
tration of Dextran is thought to help pre
vent adhesions; therefore a final step is
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Summary

the instillation of 200 mL of 10% Dextran into the peritoneal cavity.

Myomectomy should be done only for
a tumour of considerable size in a patient
who desires to retain her uterus. It is
sometimes indicated for menstrual abnor
malities, but the success of the procedure
is unpredictable. Likewise, infertility is a
rare indication for myomectomy, for the
results are poor. The technique of myo
mectomy includes meticulous hemostasis.

Vaginal Myomectomy
No description of myomectomy is com
plete w ithout m ention o f vaginal
myomectomy. Even gynecologists who
believe that there are few indications for
abdominal myomectomy acknowledge
the place of its vaginal counterpart.25
The clinical situation in which this oper
ation is indicated is one in which a fibroid
has prolapsed through the cervical os. The
tumour, which can be large, is attached
to the endometrial surface by a pedicle.
The patient may have bled heavily from
the ulcerated, infected fibroid. Immedi
ate abdominal hysterectomy has been
traditionally discouraged for fear of
postoperative peritonitis and an increased
risk of injury to ureters and bladder.20
Vaginal myomectomy on the other hand
is straightforward. Before myomectomy,
an attempt is made to sound the uterine
cavity. This avoids mistaking a chronic
uterine inversion for a prolapsed fibroid.
The pedicle can be suture-ligated or sim
ply twisted and cut. Blood supply to the
fibroid is poor and hemorrhage postoperatively seldom a problem. The results of
vaginal myomectomy are excellent with
both febrile morbidity and hospital stay
being less than those after abdominal hys
terectomy, for a comparable case.26
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SESAP V Question
Items 195-197
The lettered headings below are followed by a list of numbered phrases or statements. For each number select one of
the following:
A
B
C
D
(A)
(B)
(C)
(D)

if
if
if
if

the numbered
the numbered
the numbered
the numbered

item
item
item
item

is
is
is
is

associated
associated
associated
associated

with (A) only,
with (B) only,
with both (A) and (B),
with neither (A)nor (B).

Staphylococcus epidermidis
Candida albicans
Both
Neither

195.

Common cause of nosocomial infections in intensive care units

196.

Important pathogen in long-term central venous catheterization for total parenteral nutrition (TPN)

197. Treated with vancomycin
For the critique of Items 195 to 197 see page 204.
(Reproduced by permission from SESAP V Syllabus; Surgical Education and Self-Assessment Program No. 5. For enrol
ment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American College of Surgeons,
55 East Erie St., Chicago, IL 60611.)
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1. Introduction
Since its foundation 9 years ago, the
Canadian Association of General Sur
geons (CAGS) has attempted to address
the problems of all general surgeons, not
simply those living in the larger conurba
tions. In trying to define future man
power and training requirements, the
question arose as to just what the general
surgeon in smaller communities was
expected to do. Numerous attempts have
been made to define the scope of general
surgery and it was considered important
Presented as part o f a symposium on surgi
cal manpower in the smaller community at
the 54th annual meeting o f the Royal Col
lege o f Physicians and Surgeons o f
Canada, by the Royal College in coopera
tion with the Canadian Association o f
General Surgeons, Vancouver, BC, Sept.
11, 1985
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to document the variety and number of
procedures actually carried out by sur
geons living in smaller communities, often
relatively remote from multispecialty
hospitals. The Committee on Manpower,
Practice and Economics of the associa
tion therefore designed a questionnaire to
be sent to such surgeons; in addition to
the basic questions regarding procedures
done, the questionnaire included queries
relating to hospital facilities, workload,
professional relations and educational
requirements. The task of putting this
information together was undertaken by
Dr. F.G. Inglis and his report forms the
basis of this symposium. Excerpts from
the report are contained in the paper
by Dr. Inglis beginning of page 166.
Following Dr. Inglis’s report, Dr.
Leonard Rivers compares the advantages
and disadvantages of practice in a smaller
and relatively remote community. Dr.
Rivers practised in a teaching hospital in

Edmonton before moving to Fort McMurray and is ideally suited to make this
comparison. Dr. Edward O ’Brien also
moved from an academic environment in
Montreal to Salmon Arm, BC, where he
has practised for many years; he discusses
the training and continuing medical edu
cation requirements of the surgeon in this
type of practice who frequently needs far
more expertise in orthopedics, gynecology
and urology than that offered in the usual
residency program.
The question is often raised as to the
future of the general surgeon in smaller
communities. Dr. Barry Cutler addresses
this subject on the basis of his experience
and with the knowledge that he has some
strongly held opinions on the matter.
Finally, Dr. Richard Railton, President
of the Canadian Association of General
Surgeons, comments on the relevance of
this organization to the community
surgeon.

BOOK REVIEWS
ADVANCES IN GASTROINTESTINAL
SURGERY. From the Forty-seventh
Annual Continuation Course in Surgery,
University of Minnesota Medical School,
Minneapolis. Edited by John S. Najarian
and John P. Delaney. 640 pp. Illust. Year
Book Medical Publishers, Inc., Chicago,
1984. Price not stated. ISBN 0-8151-6336-3.

There is a profusion of publications reporting
the proceedings of conferences, workshops and
courses. Although some are essential reading,
few are widely read. It seems logical to take
a successful postgraduate course and transpose
it into a book so that a much wider audience
might benefit. Unfortunately, this rarely
works. Advances in Gastrointestinal Surgery
is perhaps the ultimate example of this regret
table failure. It is a faithful reproduction of
part of the 47th Annual Continuation Course
in Surgery, conducted by the University of
Minnesota Medical School. This widely

acclaimed course enjoys a deservedly high repu
tation. It attracts a distinguished panel of lec
turers and a large audience that is enthusiastic
in its praise. Yet the book is disappointing. 1
believe this is mainly because the editors have
too faithfully reproduced the speakers’ texts
and discussions. Since the art of speaking is
entirely different from the art of writing, an
excellent lecture may make a poor book chap
ter. The variation in style and personalized
messages so necessary in a course make for dis
jointed, unconvincing and at times frustrating
reading.
The editors note in their preface that the dis
cussions were printed essentially as they were
given. It is perhaps because of this deliberate
lack of editing that these same sections of the
book fail to prove either controversial or enter
taining.
As the book covers only selected topics in
gastrointestinal surgery there are some glaring
omissions. All aspects of hepatobiliary and

pancreatic surgery are omitted and even gas
tric cancer has been excluded, yet the book
includes three chapters on the surgery of m or
bid obesity.
The true value of this excellent course does
not come through in the book. It is certainly
less expensive than a trip to Minneapolis and
so deserves a place in every medical library
where it can be consulted by residents looking
for material for rounds not readily found in
standard texts.

M.M. C ohen, md, frcsc
Member,
Editorial Board.
Professor of Surgery,
University of Toronto,
Ste. 440,
600 University Ave.,
Toronto, Ont.,
MSG 1X5
continued on page 173

VOLUME 29, NO. 3, M A Y 1986 / THE CANADIAN JOURNAL OF SURGERY

165

i

- *

4

«

F rederic G. Inglis ,

m d , m sc , frcsc , facs

2. The Canadian Association
of General Surgeons’ Questionnaire:
Results and Observations
The Canadian Association of General
Surgeons distributed a questionnaire to
members located in communities of
40 000 population or less. The objective
was to establish a minimal referral base
of general surgeons, to identify the scope
of procedures performed and the ade
quacy of training for serving smaller
communities and to gain knowledge of
the need for other specialists and the
activity of the general practitionersurgeons in smaller centres.
A review of 92 replies indicated that,
in general, these surgeons are very satis
fied with the hospital and laboratory
facilities, and perform a broad range of
operative procedures for which there is
abundant operating time. In communities
of 10 000 to 20 000 there appears to
be a need for extra training in obstetric,
gynecologic and orthopedic procedures.
Most of the larger communities have an
adequate number of ether surgical
specialists with the exception of neu
rosurgeons. Of the respondents, 8 0 %
practised on a referral basis only with an
average of 10 referring general practi
tioners; 2 4 % were in competition with
general practitioner-surgeons, but most
indicated that this is a diminishing
problem. It appears that practice in small
communities provides a very rewarding
and professionally challenging surgical
career.
L'Association canadienne des chirurgiens
generaux a distribue un questionnaire 6
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ses membres qui pratiquent dans des
agglomerations de 40 000 habitants ou
moins. L'objectif etait d'etablir une base
de reference des chirurgiens generaux,
d'identifier I'etendue des interventions
pratiquees et la pertinence de la forma
tion chirurgicale pour desservir les petites communautes, et d'acquerir des
connaissances sur les besoins en specialistes d'autres disciplines et sur les activites des chirurgiens-praticiens generaux
dans les petits centres.
L'etude des 92 reponses recues indique que, en general, ces chirurgiens sont
tres satisfaits des hopitaux et des servi
ces de laboratoire dont its disposent, et
qu'ils pratiquent un vaste eventail
d'interventions chirurgicales pour iesqueiles ils disposent d'amplement de temps.
Dans les communautes de 10 000 a
20 000 habitants, il semble exister un
besoin pour davantage de formation en
chirurgie obstetrique, gynecologique et
orthopedique. La plupart des villes plus
importantes possedent un nombre suffisant de chirurgiens specialistes, a
I'exception des neurochirurgiens. Parmi
ceux qui ont repondu, 8 0 % ont une pra
tique de consultation avec en moyenne
10 praticiens generaux comme source de
malades; 2 4 % sont en competition avec
des medecins-chirurgiens quoique la plu
part indiquent que ce probleme soit en
voie de disparition. II semble que la prati
que dans les petits centres procure une
carriere chirurgicale d la fois tres gratifiante et stimulante au plan professionnel.

more than 40 000 people. Thus, the final
sample is based on 92 replies. The follow
ing findings and observations are excerpts
from the committee’s report presented in
February 1985 to the executive of the
Canadian Association of General Sur
geons.
In general, the committee’s findings
reflect three problems:
1. The fear o f the general practitioner
that the presence of a surgeon undermines
his competence (“ didn’t you take the full
course in medical school?” was an
apocryphal question by Premier Tommy
Douglas to a physician in northern
Saskatchewan who stated he didn’t do
surgery).
2. The fear that a surgeon will engage
in family practice if he is not busy
enough. This is a real concern and, from
the comments o f the respondents, it takes
a fair bit of single-mindedness for the sur
geon to let the community know that sur
gery will only be done on a referral basis.
Once that has been established, the
problems usually resolve.
3. The problem o f communities with
two clinics, one o f which has a qualified
surgeon. This creates competition and
sometimes inconveniences patients requir
ing surgery. In this situation the surgeon
would be advised to establish a solo
practice.
The comments of respondents to the
questionnaire were important and gener
ally indicated a tendency towards the
acceptance of specialists in smaller com
munities. This trend will be further aug
mented by the infusion of graduates of
current family practice residency pro
grams, in which the physician receives lit
tle practical surgical training.

The Canadian Association of General
Surgeons instituted a study to identify the
scope of surgical practice in smaller Cana
dian communities. A questionnaire
designed by the Manpower Economics Workload
and Practice Committee was sent to mem
Not all respondents indicated whether
bers of the association who practise in
municipalities with a population of not their workload was optimal, adequate or
more than 40 000. Of the 300 question too heavy. Only 7 of the 92 indicated that
naires sent out, 104 were returned; 12 their workload was too heavy. A review
were eliminated because they came from of the annual operative load revealed
surgeons practising in communities with somewhat surprising figures. One surgeon
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stated that he did a total of 1700 opera
tions, which included 500 endoscopies.
Eleven respondents did more than 1000
operations. When these questionnaires
were reviewed in detail, they revealed
that, with one exception, each surgeon
was practising with others in the commu
nity and, in general, the communities,
although ranging in population from 10
000 and 20 000, had a drawing popula
tion of 30 000 up to more than 40 000
and, in one case in northern Quebec,
exceeded 100 000. Only 2 of the 11 sur
geons indicated that they were overly busy
(i.e., were doing more than they wanted
to do) and none of them did general prac
tice. Also, there was an abundance of
general practitioners in the area and either
the communities were in isolation or they
were in highly populated areas such as
southwestern Ontario. Taking the group
as a whole, the average number of oper
ations was 618/yr (range from 35 to
1700).
In response to the question on time
spent in nonoperative work, consultations
averaged 10 h/w k, scheduled office visits
14 h/wk, night calls (between 2000 hours
and 0800 hours) approximately 4 h/wk,
and night operations during the same
period approximately 2/wk. Other duties,
such as resuscitation of trauma patients
or work in the intensive care unit, took
up a maximum of 4 h/wk and a minimum
of 2 patients a year. Other nonoperative
duties included administration (8 h/wk),
endoscopy (10 h/wk) and meetings and
committee work (approximately 5 h/wk).
Operative Procedures

Operations were reviewed in commu
nities of 10 000 or less, 10 000 to 20 000,
20 000 to 30 000 and 30 000 to 40 000.
Some surgeons were asked to check off
the frequency of operations, others sim
ply noted that the operation was per
formed in their centre. Thus, in formulat
ing the summary of these answers, it was
possible only to show what procedures are
done, with some indication of the rela
tive frequency (Table I).

The range of surgery practised in the
smaller communities seems to be more
broadly based than in the communities of
30 000 and over. It should be remembered
that these findings represent relatively
small numbers. On reviewing the ques
tionnaires, one gains the impression of
general trends. It would appear that in
communities of 40 000, the surgeon con
fines himself more and more to gastroin
testinal surgery and surgery that is more
commonly part of the general surgery
program in the teaching centres through
out Canada. At the other end of the scale,
surgeons are expected to provide expert
services for which they were not originally
trained, but to which it appears they can
readily adapt (i.e., gynecologic and
obstetric surgery). This should be taken
into consideration by program directors.
It is anticipated that, as the general sur
geons in the larger centres retire, they will
be replaced by younger graduates but, as
general surgeons proliferate into the
smaller communities, it is expected that
fewer general practitioners will do intra
abdominal surgery, so the requirements
for this career choice should be modified
in training programs to meet the antici
pated demand.
Questions in the questionnaire regard
ing the management of specific injuries
were not well answered, but they gave the
impression that all patients with neurosur
gical complications were immediately
referred. Those with more serious multi
ple injuries were resuscitated and sent to
the nearest centre. It was encouraging to
note that several surgeons indicated that
they had applied the advanced trauma life
support (ATLS) protocol (American Col
lege of Surgeons) before referring patients
to central areas. A recurring comment
was that whenever head injuries were
involved, patients were referred because
of the lack of neurosurgical expertise in
the local situations. This was also the case
when qualified orthopedic consultation
was not available. Otherwise, plastic and
abdominal surgery was managed locally.
Burns were usually either handled
locally, if a plastic surgeon or a general

T a b le 1 - T e n M o s t C o m m o n ly P e r fo r m e d O p e r a t iv e P r o c e d u re s
P o p u la t io n in th o u s a n d s (n o . r e s p o n d e n t s )
<

1 0 (2 6 )

C h o le c y s te c to m y

1 0 - 2 0 (3 1 )

2 0 - 3 0 (2 1 )

3 0 - 4 0 (1 4 )

C h o le c y s t e c t o m y

C h o le c y s t e c t o m y

C h o le c y s te c to m y
H e rn io rrh a p h y

H e r n io r r h a p h y

H e r n io r r h a p h y

H e r n io r r h a p h y

T u b a l lig a tio n

A p p e n d e c to m y

A p p e n d e c to m y

A p p e n d e c to m y

C e s a re a n s e c tio n

V a r ic o s e v e in

B r e a s t b io p s y

B r e a s t b io p sy

A n o re c ta l s u rg e ry

V a r ic o s e vein a n d

A p p e n d e c to m y

p ro c e d u re s

H y s t e r e c to m y

B r e a s t b io p s y

C o lo n r e s e c t io n

e m e rg e n c y v a s c u la r

B r e a s t b io p s y

F r a c t u r e re d u c t io n

D ia g n o s t ic la p a r o t o m y

s u rg e ry

F r a c tu r e r e d u c tio n

A n o re c ta l s u rg e ry

V a r ic o s e v e in

A n o r e c ta l s u r g e r y

S m a ll b o w e l s u rg e ry

V a r ic o s e v e in

C y s to s c o p y

S m a ll b o w e l s u r g e r y

G a s t r ic s u r g e r y

B ilia r y t r a c t ,

p ro c e d u re s

p ro c e d u re s

g a s t r ic s u r g e r y

T h y r o id s u rg e ry
A n o r e c t a l, b ilia ry
t r a c t s u rg e ry
C o lo n s u rg e ry
G a s t r ic s u rg e ry
S m a ll b o w e l s u rg e ry

surgeon with a special interest in the area
was available, or the patient was referred
after resuscitation. Some surgeons indi
cated an interest in treating burns. For
instance, one respondent in Alberta
stated, “ I treat burns up to 20% to 30%
in adults and up to 10% to 15% in chil
dren. There is a problem with nursing
care if I treat major burns.” From Brit
ish C o lu m b ia, another surgeon
responded, “ Resuscitate and transfer to
a Burn Unit if greater than 30% to 40%
total body surface or complicated by
respiratory or other problems.”
Cancer surgery is certainly carried out
in the smaller centres as indicated by the
response concerning the percentage of
surgical operations that dealt with cancer.
Twenty-eight respondents indicated that
less than 10% of their operations were
involved with cancer, 52 estimated that
10% to 20% of operations were per
formed for malignant disease and 10 esti
mated greater than 20%. Two did not
answer this question.
Endoscopy performed by surgeons has
been a controversial issue in terms of sur
gical training, and to establish the role of
this problem in smaller communities, we
asked surgeons to state whether they did
endoscopy: 83 did, 6 did not and 3
did not respond. Some performed up to
500 endoscopies annually. The average
was 75. Specifically, surgeons did 95
esophagogastroscopies, 60 colonoscopies
and 57 flexible sigmoidoscopies per year
on the average. Surgeons practising in the
communities of 40 000 people or less per
formed an average of 42 endoscopic
retrograde cholangiopancreatographies,
21 bronchoscopies and 48 cystoscopies
annually.
Summary

In general, the replies to the question
naire were very positive, indicating that
practice in the smaller communities was
rewarding from the surgical standpoint
and that facilities were adequate for the
surgeons to do things they were trained
to do. There were relatively few com
plaints concerning the lack of equipment.
Hospital facilities were generally consi
dered most satisfactory, but there was the
occasional complaint that frozen-section
facilities were not always available. A let
ter from a surgeon who practised in com
munities of 40 000 in both Alberta and
currently in British Columbia provided a
balanced perspective:
In the size of communities that I have prac
tised in, there is no doubt that the full spec
trum of...general surgical expertise is required.
Any general surgeon coming out into this size
of community would be expected to have con
fidence in endoscopy, both upper and lower,
but not in highly specialized endoscopy, such
as ERCP and endoscopic sphincterotomy...he
must be able to perform standard thyroid sur-
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gery, but salivary gland surgery would proba
bly be optional because the volume is
small. Major neck surgery...would be sent
away to head and neck specialists in a tertiary
referral centre.
One would be expected to perform all the
normal G.I. operations but not liver resections
and the degree of pancreatic surgery would
depend largely on experience, but...m ost peo
ple facing the prospect of a Whipple resection
would prefer to refer such a patient to a ter
tiary referral centre . . . Also I think that most
people in this size of community would tend
to refer adrenal tumors and generally complex
endocrine problems . . . There would, of
course, be the usual necessity to do varicose
veins, hernias and minor anorectal problems,
including much neglected hemorrhoidal band
ings and cryosurgery . . . Most general sur
geons in the smaller community will do limited
vascular surgery such as aortic resection,
femoropopliteal bypass and profundoplasty,
but would not get involved in mesenteric revas
cularization, renal artery stenosis and carotid
and cerebral problems and certainly no cardiac
or thoracic aortic problems . . .

In communities like . . . and . . . one has
enough orthopedic, plastic surgery and urolog
ical back-up that only a limited expertise in
these areas is necessary . . . I feel that the
general surgical training as learned within the
residency programs as they stand today is a
very satisfactory training for a surgeon work
ing in this size of community as he will get the
opportunity to practise his full spectrum of
skills but to be selective in sending away com
plex problems to the tertiary referral centre.

Perhaps the spirit of practice in a
smaller community is best reflected by the
comments o f an Ontario community
surgeon:
We do a wide range of procedures. We are not
confined like so many teaching hospital sur
geons. What we do is done competently and
safely. We feel we have excellent facilities for
the type of surgery we do. We could support
a full-time neurologist. However, a full-time
gynecologist would severely cut into our ‘bread
and butter’.

A respondent from British Columbia
reflected an expected change in the pat
tern of practice:
The scope of practice has been unlimited, but
in the recent 2 or 3 years, patients’ expecta
tions, ease of transportation and readily close
availability of orthopedists have continued to
change the pattern of practice substantially.

And, from Nova Scotia,
I am mostly concerned that new graduates keep
sending many patients to tertiary care hospi
tals when they could easily be looked after in
our hospital — don’t they realize that we
trained at the ‘Great Halls of Learning’ also?

Despite the occasional plaintive com
ment, it appears that general surgeons
practising in communities o f 40 000 or less
have very satisfying and professionally
challenging careers.

L e o n a r d F . R iv e r s , m d , f r c s c , fa c s

3. The Advantages and Disadvantages
of Practising Surgery in a Small Community
The advantages of practice in a commu
nity encompassing a population of about
35 000 include readily available beds
and operating rooms, a relative diversity
of surgical problems, increased job satis
faction and solid community support
through service clubs and other volun
teer organizations.
Disadvantages in some situations can
include lack of investigational facilities
and of internists for consultation. A lack
of surgical assistants, anesthetists and
intensive-care-unit support are other
potential negative factors. The quest for
continuing medical education requires
definite resolve, and practice finesse
must be well honed.
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Les avantages d'une pratique chirurgicale
dans une agglomeration d'environ
35 000 habitants incluent la facilite
d'acces aux lits d'hopitaux et aux salles
operatoires, une diversity relative des
problemes chirurgicaux, une grande
satisfaction au travail et un solide sou
tien communautaire de la part des clubs
sociaux et autres organismes de volontaires.
Les inconvenients dans certaines situa
tions peuvent inclure un manque d'equipements pour les examens et i'absence
d'internistes pour les consultations.
L'absence d'assistants de chirurgie,
d'anesthesistes et d'unite de soins intensifs sont d'autres facteurs negatifs possi
bles. La poursuite d'une formation
medicale continue exige de la determina
tion: la finesse dans la pratique doit etre
bien aiguisee.

In 1979 my family and I moved from
Edmonton, where I had practised in a
550-bed metropolitan hospital, to the
northern city of Fort McMurray, Alta. At
the time, the construction o f a new
regional hospital was almost complete.
My comments reflect the experiences we
have had as a result o f this move.

Fort McMurray, a city o f 35 000 with
an additional drawing population of
about 2000, is located 450 km northeast
of Edmonton.
With an average age o f less than 25
years, 50% o f the population in school
and 800 births per year, the inhabitants,
who work principally in the mining, sepa
ration and upgrading of tar sand into syn
thetic crude oil, can best be described as
enthusiastic and productive.
Fort McMurray Regional Hospital,
although built to accommodate 300
patients, has only 150 beds at present.
Departments were formed from the major
services of family practice, medicine,
obstetrics and gynecology, surgery and
anesthesia when the new facility was ini
tially occupied. The services of pediatrics,
radiology, pathology and psychiatry have
since been added as fellowship-qualified
physicians have been recruited to the area.
In 1979 there were 12 physicians on staff,
this number has increased to 40. The
department o f surgery comprises two
general surgeons, one orthopedic surgeon
and four general-practitioner surgeons.
Advantages of Practice in This Setting
The greatest advantage to such a prac-
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tice is the availability of beds and oper
ating rooms. Urgent cases can be admit
ted within 48 hours and waiting lists for
elective surgery are almost always less
than 4 weeks. U tilization rounds,
although they are required occasionally,
are pleasantly infrequent. This utopic sit
uation we all realize is temporary, and will
gradually be eroded as more surgical sub
specialists are recruited to the area.
The need to perform many different
types of surgery in a host of subspecialty
areas, I regard only partly as an advan
tage. It is not unusual for a general sur
geon in this environment to address,
according to his or her training, interest
and skill, problems relating to the special
ties of orthopedics, obstetrics and gyne
cology, plastic, thoracic and vascular sur
gery, and urology, in addition to the
traditional areas of abdominal, breast,
head and neck and, to a varying extent,
pediatric surgery. Obviously no one sur
geon could hope to provide in-depth
definitive coverage of the areas just men
tioned. Referral to a subspecialty surgeon
in a metropolitan centre must be consi
dered in every case. Critical assessment
of my capabilities, compared with those
of a subspecialist less than 2 hours away,
is mandatory in all circumstances. One
must be ruthlessly honest, for on the other
side of the coin looms the possibility of
providing your patient with less than
optimal care and the legal liability
associated therewith. You will recognize
that many of the subspecialty areas men
tioned have a substantial litigation
potential.
Job satisfaction, paramount to a happy
practice, is more readily achieved in the
setting of a small community. The general
surgeon is regarded as a cornerstone of
surgical and trauma care. The provision
of elective and, on many occasions, life
saving surgical skills to a peripheral popu
lation is indeed gratifying. These patients
would otherwise be inconvenienced and
financially imposed upon when required
to seek care in an often-impersonal,
m etropolitan environment. Another
advantage is the relief of many of the
daily frustrations associated with
metropolitan practice.
Surgical practice in the small commu
nity calls for close cooperation with our
administrative colleagues, which is
required for the management of our facil
ities. In my experience, because both
groups are fewer in number, the issues
seem to be addressed with more dispatch
than in larger hospitals.
Because there is usually only one hospi
tal in a small community, a near monop
oly exists for donated funds raised by
service clubs and others. These consider
able donations are responsible for the
acquisition of innumerable pieces of
equipment and even assist in the institu
tion of some new services. In a metropoli

tan environment such funds usually are
gobbled up by high-profile institutions
such as university hospitals and cancer
clinics that provide high-profile services
(e.g., coronary artery surgery, transplan
tation).
Teaching housestaff, although not a
regular activity in my present situation,
is sometimes required and I have found
the experience always stimulating and
rewarding, a statement I could not make
while involved in a metropolitan practice.
Candidates coming to this smaller centre
do so electively, are well motivated, ener
getic and have a desire to be close to the
action.
Disadvantages

Continuing medical education requires
definite resolve. In the past the arrange
ments for physician coverage, family and
pets presented particular difficulty in
small communities. Adequate coverage
by another surgeon may be impossible.
Now these problems have been partially
overcome by the introduction of telecon
ferencing and video cassette programming
for continuing medical education. Regu
lar clinical surgical rounds by a depart
ment small in numbers is difficult, and
peer fellowship and information transfer
were the most negative aspects associated
with our relocation to a small city prac
tice. Initially the telephone provided a
substitute but gradually our needs in this
area are being met as more surgical
specialists are being recruited.
Practice finesse, the art of relating to
your referring physicians, important in
any practice, must be handled with kid
gloves in a smaller centre. My experience
is that family practitioners respect and
readily accept specialists provided they
don’t infringe on family practice. That
means the surgeon must establish a prac
tice by referral only from the outset. If
such a stand cannot be supported, then
probably surgical specialists are not
required in the area. Surgeons who prac
tise family medicine must develop their
surgery from that practice. It is difficult
to maintain a practice by referral only.
Your secretary must be your closest ally
in dealing politely but firmly with the
myriad attempts to secure appointments.
Referring physicians will be reassured
when they receive a completion of care
letter that reads: ’’Dear Dr. Smith, I
return to your care Mrs. ...” . Equally
critical I believe are practice groups in
which specialists are associated with other
specialists and preferably surgeons with
surgeons. Multidisciplinary clinics involv
ing family practitioners and specialists
have many problems, not the least of
which is the alignment of the specialists
with one general practitioner. In such a
situation other family practitioners may
refer their patients out of the local

environment rather than risk losing cases
to the opposition!
Investigational facilities are certainly
limited in the small community. In
Alberta, regionalization of health care by
the provincial government has led to the
establishment of extensive investigational
facilities in regional hospitals. The lack
of computed tomography in investigating
acute head trauma and in other situations
is particularly noteworthy. This and other
investigational requirements necessitating
transfer to a large centre will be mostly
filled during the next decade.
The lack of internists in some smaller
communities occasionally poses problems
for surgeons who, with family practi
tioners, become responsible for total
m anagem ent
of
p atien ts
w ith
emphysema, asthma, angina pectoris,
hypertension and diabetes mellitus.
Although this may be gratifying, input by
an internist in such situations would be
desirable.
Sometimes surgical assistants are
difficult to find unless a reciprocal
arrangement can be made with another
surgeon. Even this is not ideal for it dou
bles the time spent by each surgeon in the
operating room. Family practitioners also
are often reluctant to be separated from
their busy offices. In our hospital, full
time emergency physicians regularly assist
during their off hours. I often think this
would be a useful activity for retired phy
sicians and surgeons living in a small com
munity. The problem doesn’t exist when
housestaff are available.
General surgical practice is eroded by
each new subspecialist arriving in the
community. Although this provides more
and varied services, it may lead to a ques
tion of the viability of a referred general
surgical practice. The training require
ments of general surgeons practising in
smaller communities must address this
problem.
Anesthetic capability and coverage,
intensive-care-unit support, operatingroom facilities and staffing — all poten
tial restrictive obstacles — have presented
no problem in our setting.
Comment

I have addressed many aspects of clin
ical practice in a small community, but
the most critical requirements dictating
success or failure of practice in this set
ting relate to factors that support the
spouse and family, such as the provision
of education, the availability of cultural
activities, shopping, religion, extended
family and social contacts and recreation.
Many variables apply to practice in a
smaller city, but so, too, do they apply
to practice in metropolitan areas. For me
the advantages of practice in a facility
such as Fort McMurray Regional Hos
pital far outweigh the disadvantages.
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4. Training and Continuing Medical Education
Requirements for Practice in the Small Community
The author considers the training require
ments of a general surgeon who will be
the only surgical specialist in a small
community. Apart from the usual heavy
gastrointestinal content, the surgeon's
training should include 1 year of fracture
and trauma training, the care of head in
juries and urologic injuries, and, the
management of abdominal gynecologic
problems and the technique of cesarean
section. Attendance at smaller regional
surgical meetings, participation in the
Surgical Education and Self-assessment
Program (SESAP) of the American Col
lege of Surgeons and other continuing
education programs are also essential in
maintaining standards.
L'auteur envisage les besoins de forma
tion medicate pour un chirurgien general
destine a devenir I'unique specialiste de
la chirurgie dans une petite communaute.
En plus de la forte concentration
habituelle en chirurgie gastrointestinale,
la formation du chirurgien devrait comprendre une annee dans les soins des
fractures et traumatismes, les lesions
craniennes et urologiques et le traitement
des probl&mes gynecologiques
abdominaux ainsi que le technique de
c£sarienne. La presence a de petites
reunions rggionales de chirurgie, la par
ticipation au programme d'autoevaluation et d'education chirurgicale
(Surgical Education and Self-Assessment
Program ou SESAP) de I'American Col
lege of Surgeons de meme que d'autres
programmes de formation mgdicale con
tinue sont aussi essentiels au maintien
de standards eleves.
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Although surgical manpower is not in
short supply, there is a problem of dis
tribution that is common to all of medi
cine. There are now 7558 funded post
graduate training positions in Canada,
mostly in specialty training programs
which turn out 2200 to 2300 new physi
cians a year. It is therefore unlikely that
there will be a shortage of general sur
geons in the forseeable future. The
problem of maldistribution must be
solved. Young surgeons should be
encouraged to practise in smaller commu
nities, where there is a clear need for them
and where general surgical practice can
be very satisfying.
I have been asked to consider and to
discuss the training of a community sur
geon. The Canadian Association of
General Surgeons’ study of 1985 looked
at towns with a population of 40 000 or
less. Most towns of this size in Canada
have an adequate supply of surgical
specialists. Such a town near my location
has three orthopedic surgeons, three
ophthalm ologists, two obstetriciangynecologists, one otolaryngologist, one
urologist and three general surgeons.
General surgeons here are primarily
abdominal surgeons.
I shall consider the training required by
the general surgeon in a community where
he or she is the only surgical specialist
available. The suggestions are my own,
supplemented by ideas solicited from my
general practitioner colleagues as they
apply to the current situation. I have sur
veyed my own practice since 1974 and
have found that 25% consisted of frac
tures and other limb trauma, and elective
limb surgery other than varicose veins.
Before 1974, when there were few ortho
pedic surgeons in the interior of British
Columbia, fractures and other limb
trauma constituted 35% to 40% of my
practice. Gynecologic problems and cesa
rean sections make up 15% of the
practice.
The training of the general surgeon
should be as broad as possible for as long
as possible. It should start with a rotat

ing internship. You learn a great deal
from your fellow trainees at this level, and
a broad base in all major medical dis
ciplines is important to the future sur
geon. The most serious gap in present
general surgical training is in the area of
fractures and limb trauma. Another lies
in the lack of exposure to gynecologic sur
gery and cesarean sections, all of which
are important in a small community prac
tice. Training in these areas should be at
a senior level, after 2 years o f surgical
training. Any trainee expressing an inten
tion of practising in a small or isolated
community would benefit from as much
as a year on a fracture service.
I am not familiar with every training
program in the country, but I would plead
that the care of fractures, gynecologic sur
gery and cesarean sections be included in
training programs. The care of urologic
emergencies and of acute head injuries
must also be taught. I would say that such
training is more important for a commu
nity surgeon than training in endoscopy.
Continuing medical education is a
major consideration, especially important
for the surgeon living away from a teach
ing centre. With the plethora of oppor
tunities, there is no excuse for not keep
ing up to date. Continuing education,
however, is an attitude of mind, not ease
of access. It begins at home. In our com
munity, we have a journal club that meets
monthly. It is amazing how much can be
learned from colleagues in this way. A
good hospital library also is important.
In British Columbia, we are fortunate in
having a provincial medical library serv
ice run by the College o f Physicians and
Surgeons of British Columbia. The librar
ian visits each hospital annually and sug
gests purchases to update the library.
They will search the literature for you and
provide reprints, up to 100 pages free each
year. Another home activity that I recom
mend is participation in the American
College of Surgeons’ Surgical Education
and Self-Assessment Program (SESAP).
It is most useful, shows you your weak
nesses and will keep you sharp for the
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inevitable future appearance of recertifi
cation examinations.
I like to get away to meetings and find
that I prefer smaller ones, like those of
the British Columbia Surgical Society.
The one big meeting I attend is the Ameri
can College of Surgeons Clinical Con
gress. Postgraduate courses at these meet
ings are usually excellent and have a
considerable basic science content, which
I find important. Three or 4-day surgical
review courses, such as those run by the
University of Toronto, are also excellent.

The new videotape clinics are often well
done and we place these in the hospital
library where they are available to all.
Continuing education is a personal
responsibility. As you know, the Ameri
can Board of Surgery now certifies suc
cessful candidates for only 10 years,
requiring re-examination at that time. The
Canadian Association of General Sur
geons should take the lead in this field and
urge the Royal College of Physicians and
Surgeons of Canada to introduce recer
tification. In the meantime we should

require our members to participate in the
SESAP program. We should be the sur
gical leaders in this country. If we aren’t,
governments or other agencies will be.
In summary, I make a plea for the
general training of general surgeons.
Community surgeons must be trained to
manage fractures and other limb trauma,
abdominal gynecology, cesarean sections,
emergency urologic problems and head
injuries. Continuing education begins at
home. Postgraduate courses and smaller
regional meetings are recommended.

B a r r y K. C u t l e r , m d , f r c s c , fa cs

5. Is There a Future
for the Community General Surgeon?
The author attempts to assess the fac
tors affecting the future of surgery in
Canadian communities with a population
of 10 000 to 30 000. Five problems are
identified: (a) unrealistic patient expecta
tions, (b) government cutbacks causing
reduced equipment budgets, (c) difficulty
in getting competent, modern
anesthesia from well-trained general
practitioners, (d) undergraduate and
postgraduate training focus and (e) politi
cal enlargement of medical schools and
reduced funding for health care.
The proposed solutions are as follows:
realistic patient expectations should be
possible through authoritarian advertising
compaigns; residency training should be
keyed to community surgery; community
health care standards can be promoted
and maintained by creating a link
between the community surgeon
(specialist) and the tertiary hospital of
his choice. This can be accomplished by
creating a new class of staff appoint
ment in the tertiary hospital, the "refer
ring consultant" (i.e., the community
surgeon).
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L'auteur a tente d'evaluer les facteurs
qui vont influencer le futur de la chirurgie
dans les agglomerations canadiennes de
10 000 6 30 000 habitants. Cinq problemes sont identifies: a) les attentes irrealistes des patients, b) les coupures
gouvernementales sur les budgets
d'equipements, c) les difficultes de recruter des praticiens generaux bien entraines capables d'assurer avec soin un
service d'anesthesie moderne et de
bonne qualite, d) la specialisation de la
formation au niveau universitaire et gradue, et e) la decision politique d'augmenter le nombre d'etudiants en medecine
tout en reduisant les fonds consacres
aux soins de sant£.
Les solutions proposees sont les suivantes: les attentes des patients pourront etre rendues realistes par la mise
sur pied par les organismes appropries,
de campagnes d'information; la resi
dence devrait etre orientee vers la chirur
gie communautaire; les standards de
soins de sante communautaires peuvent
etre am6liores et ensuite maintenus par
la creation de liens entre le chirurgien
communautaire (specialiste) et I'hopital
tertiaire de son choix. Ceci pourrait etre
realise en errant une nouvelle classe de
medecins affilies aux hopitaux tertiaires,
celle des "consultants exterieurs" (e'est
a dire les chirurgiens communautaires).

Is there a future for the community
general surgeon? I say no, not if present
trends are allowed to continue. By com
munity I mean a population centre of
10 000 to 30 000, more than 30 minutes
by road from a tertiary care centre. There
are fewer than 200 such communities in
this country and in many the shift of peo

ple toward the large cities is reducing their
population. In each of those 200 commu
nities reside between one and four gen
eral surgeons. When you remember that
the present membership of the Canadian
Association of General Surgeons is about
1000, it is obvious that these community
surgeons deserve the attention of our
organization.
The Problems

I have identified five specific problems
that must be resolved.
1. Patients have expectations that are
unrealistic. These are fed by the media
and reinforced by massive medicolegal
settlements. On television and in maga
zines they can see replacement of almost
every body part and they realize that they
can have input into the decisions as to
where and how they are treated. Their
attitude is that they pay for the service so
they should get the best of care. This atti
tude shouldn’t surprise us because it
parallels that of the National Health Serv
ice in Great Britain. Unfortunately, our
society has finite resources and we can’t
afford “ the best” care for everyone,
meaning that priorities must be set.
2. Government cutbacks have reduced
equipment budgets everywhere. Equip
ment for procedures such as image inten
sification computed tomography and
nuclear isotope scanning is not available
in every community hospital and unfor
tunately much publicity has been given to
the idea that such equipment is essential
for surgical practice in 1985.
3. In contrast, competent, careful and
up-to-date anesthesia is essential to
modern surgery and I rank it highly as a
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problem in the small community because
I believe there is a crisis in the making.
Unfortunately medicolegal settlements,
increased training requirements and
escalating insurance premiums are mak
ing this area increasingly unattractive to
family physicians who form the backbone
of anesthesia in the smaller community.
The protective, isolationist attitude of cer
tified anesthetists does not help this
problem.
4. Undergraduate training programs
are not directed toward community sur
gical practice, for which the training must
be broadly based and adaptable to the
locality where the surgeon is to practise.
Surveys such as Dr. Inglis has carried out
are needed to study accurately the work
load on the spot and to make appropri
ate adjustments to fit the needs.
With respect to postgraduate training
or continuing medical education, how
does the bewildered community surgeon
handle the three-ring circus that goes on
at most major surgical meetings? How
does he choose which sessions to attend?
For example, we are trained as general
surgeons, now mostly gastrointestinal;
when we attend a meeting we want to hear
the papers that will bring us up to date
in that area, but next week we might have
to perform a tendon repair, a breast
red u ctio n , an arthroscopy or an
obstructed obesity bypass, so that papers
on those subjects would also be valuable
to us. If the sessions overlap, how do we
decide which to attend? Effectively, we
set our own limits or out patients and
general practitioner colleagues set them
for us.
5. Governments are flooding the med
ical schools with students on the one hand
and cutting back funding on the other.
Recent graduates are frightened away
from practice in smaller communities
because they may never be able to get
back into the urban setting. Ideal general

surgeon-population ratios are now quoted
as 1:17 000 but such figures are totally
meaningless unless we have a better defi
nition of what that surgeon’s practice
encompasses — and I suspect that may
vary from community to community.

BOOK REVIEWS

Some of the authors have written similar, more
thorough chapters elsewhere. There are,
however, several things that can be learned,
especially in the chapter on hand infections.
This book, which makes relatively light read
ing, is not a must for your bookshelf.

continued from page 165

CURRENT CONCEPTS IN HAND SUR
GERY. Edited by John A. Boswick, Jr. 287
pp. lllust. Lea & Febiger, Philadelphia,
1983. $47. ISBN 0-8121-0881-7.

Is this book a useful addition to the library of
the experienced hand surgeon or of those train
ing for a career involving hand surgery? It is
essentially a compilation of papers presented
at the 9th annual Rocky Mountain Interna
tional Seminar on Hand Surgery. Twenty-three
of the 38 chapters are written by visiting
faculty, while the remaining 15 are authored
by Denver hand surgeons. Each chapter reflects
the experience and writing skills of its author,
thus quality is inconsistent. A broad range of
topics is covered, many in a very sketchy man
ner with inadequate figures and references.

The Solutions
Should we resist the trend by defining
our limits of practice in the smaller com
munity and sticking to them or should we
instead urge governments to purchase
more helicopters and abandon the field
to the general practitioner and the tertiary
care hospital?
1 suggest to you the former solution
rather than the latter but with perhaps a
different twist. I challenge you that there
will always be a need for certified sur
geons in small communities.
How then can we solve the problems
we have identified?
• Patients’ expectations could be made
more realistic by a judicious advertising
campaign, especially if it came from
provincial medical associations and from
the Royal College. There is ample evi
dence of the benefit of such campaigns
in the “ second-opinion” campaign of the
American College of Surgeons which
resulted in a reduction of unnecessary sur
gery in the United States.
• 1 have already alluded to ways of
making the training of community sur
geons more meaningful. It must be more
broadly based and yet it must not be per
ceived as being second-class qualification.
The easiest solution of all is that of con
tinuing medical education or postgradu
ate training. The organizers of meetings
must involve people who are working in
smaller centres and find out from them
what is relevant, and must keep asking
until they get meaningful answers.
• Governments must be convinced that
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better use o f health-care dollars can be
made to keep the community hospital
system (in which they already have a huge
investment) alive and healthy. There must
also be evidence that the standards of care
are maintained. How do we do this —
and solve the problem of anesthetists? I
propose that a new class of hospital staff
appointment be created — the “ referring
consultant” — and that the surgeons be
brought back into the tertiary care
centres. Every community surgeon would
choose the tertiary hospital he liked to
refer to, and would have privileges in that
institution, to admit and ideally to treat
his patients. Commensurate with these
privileges would be responsibilities —
attending rounds, making presentations,
serving on some hospital committees and
maintaining records, just like every other
staff appointment. Thus, if the commu
nity surgeon had a patient with a special
medical or anesthetic problem that had
a simple surgical solution, such as a her
nia with emphysema or a blood dyscrasia, the surgeon might choose to carry out
the operation in the tertiary centre where
the support facilities are available. Also,
a patient who had previously been oper
ated on in a community hospital and who
required a complex operation would be
better served by having his community
surgeon assisting (involved) in that proce
dure. How better to influence the stan
dards of care than to have the commu
nity surgeon involved and subtly soaking
up the methods as they are developed in
the training centres. The benefits to all
specialties would be far-reaching.
This solution would not be easy —
scheduling of operations and office hours
would be more complex, travel time and
costs would be greater, but the end result
I firmly believe is that the community
hospitals would be constantly rejuvenated
and that the patient would be the better
for it.

taining to systems in which the orthopedist is
only occasionally involved are practical and a
pleasure to read. Of particular interest are the
chapters on the adult respiratory distress syn
drome and on urologic assessment o f the mul
tiply injured patient.
The author provides enough guidelines to
manage adequately the patient in the acute
phase until the orthopedist can be called to take
care o f these systems and further complica
tions.
The chapters concerned with orthopedics
give enough detail to allow the resident and the
young orthopedist to make rational decisions
for the treatment of complex problems. The
more frequent problems are: open fractures
grades 1 to III, pelvic fractures, ipsilateral,
femoral and tibial fractures and segmental frac
tures of femur and tibia, ligament injuries with
lower extremity fractures, head injury and mul
tiple fractures.

This book is clear, concise and didactic in all
of the subjects it exposes. The chapters per
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6. The Canadian Association of General Surgeons
and the Community Surgeon
The relationship between the Canadian
Association of General Surgeons and the
community surgeon is a symbiotic one.
Despite the controversy about medical
costs and the oversupply of physicians,
there is and will continue to be an
increased need for general surgeons in
Canada. Highly trained general surgeons
are needed in medium-sized and smaller
communities where the bulk of general
surgery is done. The Canadian Associa
tion of General Surgeons sponsors
research in education that will affect sur
gical knowledge and the training and
future of community surgeons.

L'Association canadienne des chirurgiens
generaux et le chirurgien communautaire
ont I'un pour I'autre un rapport symbiotique. En depit du debat qui a cours concernant les couts des soins medicaux et
le surplus de medecins, il existe et il con
tinu es d'exister un besoin croissant de
chirurgiens generaux au Canada. Des
chirurgiens generaux possedant une
solide formation sont requis dans les
agglomeration de petite et moyenne
tailles ou la majeure partie de la chirurgie
generate est pratiquee. L'Association
canadienne des chirurgiens generaux
soutient la recherche dans le domaine de
I'education touchant les connaissances
chirurgicales, ainsi que la formation et le
futur des chirurugiens communautaires.

Does the community surgeon need the
Canadian Association of General Sur
geons?
The association’s board meeting
agenda this year shows that the creation
Presented as part o f a symposium on surgi
cal manpower in the smaller community at
the 54th annual meeting o f the Royal Col
lege o f Physicians and Surgeons o f
Canada, by the Royal College in coopera
tion with the Canadian Association o f
General Surgeons, Vancouver, BC, Sept.
11, 1985
Accepted fo r publication Nov. 1, 1985
Reprint requests to: Dr. R.H. Railton,
Medical Arts Building, 165 Plymouth Rd.,
Welland, Ont. L3B 3E1

174

of a general surgery task force has been
discussed especially to look into the
danger of fragmentation of general sur
gery by special-interest groups. A com
mittee on community surgery has been set
up. State-of-the-art advice has been
sought and is given, for example this year
on antibiotic prophylaxis in colorectal
surgery.
The Canadian Association of General
Surgeons has taken off like a house on
fire and now has over 1000 members,
making it the largest surgical association
in Canada. The first clinical meeting held
at the Royal York Hotel in Toronto
enjoyed a good turnout of community as
well as academic surgeons, with Profes
sor Goligher as the highlight speaker.
Program committees worked diligently,
with the consequence that general sur
geons are coming back to the Royal Col
lege meetings in increasing numbers. The
Canadian Association of General Sur
geons’s program is now regarded as an
important part of continuing medical
education, as well as a chance for mem
bers to see old friends and find out what
is really going on in the communities and
the medical schools. Increased commit
tee activity has increased expenses and
forced a re-examination of our involve
ment with the Royal College. The possi
bility of making use of the Royal College
of Surgeons’ expense allowances is being
considered. Better budgeting procedures
and increased use of teleconferencing
have all helped. This has allowed us to
keep our dues extremely low.
Our interest in continuing medical edu
cation for the community surgeon
encouraged us to become involved with
SurgSat (video taped continuing medical
education for surgeons). The spin off has
improved our membership and financial
situation and the programs have been of
value to residents as well as to the prac
tising surgeon.
The community surgeon has often felt
alienated from the Royal College of Phy
sicians and Surgeons, considering it to be
the forum of the academic surgeon. He
has fallen into the trap of the old “ towngown” antipathy. A membership poll,
however, clearly showed that the majority

of members wish to hold the annual meet
ing in conjunction with that of the Royal
College. This relationship is improving
steadily with effort and better communi
cation. It continues to be monitored and
may be changed.
Efforts to maintain a bilingual associ
ation have been made from the start and
have ensured enthusiastic support from
French-speaking surgeons, with input to
all committees. Community surgeons are
represented on the Advisory Council and
on the Executive.
The Canadian Association of General
Surgeons has been and is sponsoring
research in education that will affect sur
gical knowledge and training and the
future community surgeon. Accumulated
data on the surgical needs of the commu
nity are already influencing the training
of general surgeons that many felt was
becoming too restricted. The association
has vigorously promoted endoscopy as an
integral part of general surgery. It is now
mandatory in surgical training programs.
The annual course in endoscopy is
increasing in popularity and is dedicated
to making all interested community sur
geons proficient in endoscopy.
Our association has provided surgical
tariff committees with information use
ful to them in discussions with their
provincial organizations. Manpower
studies are ongoing and are typical of the
increased medical-political activity that
will be required in the future.
Gradually the Canadian Association of
General Surgeons is accumulating data on
surgical practice and should be a resource
for such information. We have heard
from Dr.Jnglis about the results of our
questionnaire sent to surgeons in smaller
communities. A previous study by Dr.
MacKenzie,1 a general practitioner and
economist from Kingston, showed that
the average general surgeon is much older
than the other surgical specialists. We are
joining the Royal College in the joint
Royal College/Canadian Medical Associ
ation (CMA) project on peer validation,
which is a cross-check on the CMA Phy
sician Resource Data Bank.
The CMA Special Committee on Med
ical Manpower reported to its General
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Council on Aug. 15, 1985 (unpublished
data). The report was referred back
without action, and opinions will be
sought from this association, as well as
others. The committee in its report
became involved with control on physi
cians entering general practice and was
opposed by the Canadian Association of
Internes and Residents and other groups.
One “ non-problem” identified was that
a general surgeon may not be competent
to deliver primary care, and the report
suggested changes in licensure to prevent
this.
The Federal/Provincial Advisory Com
mittee on Health Manpower was direct
ed by the Conference of Deputy Ministers
of Health to undertake a short-term study
on medical manpower in Canada in late
1982. Their report2 was released in midJuly 1985. It stated that physician man
power supply requirements, distribution
and costs are a concern. In the 20 years
from 1961 to 1980, the physician supply
more than doubled, while the population
increased by one third. The physician to
population ratio increased from 1:1004 to
1:643. The committee used the Southam
medical data base which has been criti
cized by the CMA committee and the
Canadian Association of Internes and
Residents, but it was the best medical
manpower data bank available at the
time. The Hall Report3 and other man
power studies4 have all suggested a phy
sician oversupply. Strategies to reduce this
oversupply are recommended, such as
cutting down medical school enrolment
and physician immigration, but the
recommendation is to increase surgical
training. Shortages in surgical and labora
tory specialties are predicted by the year
2000. Some of the recommendations are

impractical but in spite of all the rhetor
ic from ministries of health about the
oversupply of physicians and the stated
intent to reduce the number of specialists,
a shortage of surgeons is predicted. Some
of the numbers in the report are of in
terest (Table I).
What does all of this mean? Despite the
controversy about medical care costs and
the oversupply of physicians, there is and
will continue to be an increased need for
general surgeons in Canada. This is of
great importance to program directors.
Trunkey and Blaisdell5 in the July
1985 Bulletin o f the American College o f
Surgeons cried out against a return to the
“ barber surgeon” who cuts when and
where he is told. They promote the con
cept of the broadly trained general sur
geon who can provide global and com
prehensive surgical care. Surgeons should
be constantly reminded that they have
advanced from barber surgery to the
present state of excellence through the
introduction of scientific principles.
Canadian Association of General Sur
geons’ committees have struggled for
years over a good definition of general
surgery and have at last come up with
such a statement. With a background in
anatomy, physiology and pathology, such
highly trained general surgeons are
needed in medium-sized and smaller com
munities where the bulk of general sur
gery is done.
Frank Turner, who organized this sym
posium, has sometimes questioned the
relevance of the Canadian Association of
General Surgeons to the community sur
geon, citing the proliferation of societies
offering useful continuing medical edu
cation. He has been like the boy who
pointed out that the Emperor wasn’t

Table I—Features of Interest From the Report2 of the Federal/Provincial Advisory Committee on
Health Manpower

1. General surgeon supply - December 1980:
Canada
2106
New Brunswick
57
94
British Columbia
253
Nova Scotia
Alberta
154
Prince Edward Island
10
Saskatchewan
Newfoundland
29
70
4
Manitoba
94
Yukon Territories
741
Ontario
600
Quebec
2. Annual average inflow from 1979 to 1982 - 70 per year.
3. In 1980 the number of general surgeons who had graduated from Canadian medical schools between
1942 and 1961 was 1246 and it is assumed that these surgeons will retire or die by the year 2000.
4. Outflow annually
(1981-1990)
56.3
Retired or dead
Moved
20.8
11.0
Returned to training
(1991-2000)
68.3
Retired or dead
17.1
Moved
Returned to training
11.0
5. Target 1980 is 1971 general surgeons. This gave a surgeon to population ratio of 1:12 292.
6. The age-sex adjusted increase in requirements for 1981 to 2000 is 640.6.
7. The female productivity adjustment is 55.8 and by the year 2000 target is 2667.4.

wearing any clothes and has made all of
us consider our raison d ’etre. I think
today’s panel has helped answer the ques
tion, “ Do community surgeons need the
Canadian Association of General Sur
geons?” Of course they do. More impor
tantly, the association needs the commu
nity surgeon.
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PIPRACIL
Parental Antibiotic for Intravenous and Intramuscular Use
INDICATIONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the
designated organisms in the conditions listed below. Intra abdominal Infections including hepatobiliary and
surgical infections caused by Escherichia coli, Pseudomonas aeruginosa, enterococci. Clostridium sp., anaerobic
cocci, and Bacteroides sp., including B. fragilis. Urinary Tract Infections (complicated and uncomplicated)
caused by Escherichia coli, Klebsiella sp., Pseudomonas aeruginosa, Proteus mirabilis and enterococci. Also
uncomplicated urethritis caused by Neisseria gonorrhoeae. Gynecological Infections including endometritis and
pelvic inflammatory disease caused by Bacteroides sp., including B. fragilis, anaerobic cocci, Neisseria
gonorrhoeae, and enterococci (Streptococcus faecalisl. Septicemia caused by Escherichia coli, Klebsiella sp.,
Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci, Pseudomonas aeruginosa, Bacteroides sp., and
anaerobic cocci. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp.,
Pseudomonas aeruginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci.
Although improvement has been noted in patients w ith cystic fibrosis, lasting bacterial eradication may not be
achieved. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp.,
Acinetobacter sp., Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis,
Bacteroides sp., including B. fragilis, anaerobic cocci and enterococci. Bone and Joint Infections caused by
Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci. PIPRACIL* is useful for the
treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms;
infections produced by organisms resistant to other penicillins, some aminoglycosides and cephalosporins; and
infections at various sites caused by streptococcus species including Group A beta hemolytic Streptococcus and
Streptococcus pneumoniae.
PIPRACIL* may be administered as single drug therapy in some situations where normally two antibiotics might
be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
bacterial strains. PIPRACIL* has been used clinically w ith aminoglycosides, especially in patients w ith impaired
host defences. Both drugs were used in full therapeutic doses. PIPRACIL'can be used safely in combination with
a penicillinase-resistant penicillin, e.g. oxacillin, in mixed infections when beta-lactamase-positive Staphyloccus
aureus is isolated along w ith piperacillin-susceptible organisms. It may be administered concomitantly w ith a
cephalosporin, provided that an additive or synergistic antibacterial action of the tw o antibiotics is ascertained
through in vitro tests. Based on in vitro data, cefoxitin should not be given w ith piperacillin when Pseudomonas
infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients w ith
hepatobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic
reactions to other drugs, w ith appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if
appropriate, once the results are known.
CONTRAINDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
WARNINGS: Serious and occasionally fatal hypersensitivity (anaphylactic! reactions have been reported in
patients receiving therapy w ith penicillins. These reactions are more apt to occur in persons w ith a history of
sensitivity to multiple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy
w ith PIPRACIL* careful inquiry should be made concerning previous hypersensitivity reactions to penicillins,
cephalosporins and other allergens.
If an allergic reaction occurs, the antibiotic should be discontinued. SERIOUS ANAPHYLACTOID REACTIONS
REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS
AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS NECESSARY.
PRECAUTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics
including piperacillin. These reactions have sometimes been associated w ith abnormalities of coagulation tests
such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients with
renal failure.
If bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
therapy instituted.
The possibility of the emergence of resistant organisms and the development of superinfections should be kept in
mind, particularly during prolonged treatment. As w ith other penicillins, patients may experience neuromuscular
excitability or convulsions if higher than recommended doses are given intravenously.
Dosage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mgl of Na -+- per gram based on
vial content w hich includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
mEq/g (42.55 mg). Periodic electrolyte determinations should be made in patients w ith low potassium reserves
and the possibility of hypokalemia should be kept in mind w ith patients w ho have potentially low potassium
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
prolonged-treatment in patients w ith impaired cardiac function.
Prior to treatment, patients w ith gonorrhea should also be evaluated for syphilis. Specimens for darkfield
examination should be obtained from patients w ith any suspected primary lesions, and serologic tests should be
performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
minimum of 4 months.
The use of penicillins (ampicillin, amoxicillin) has been associated w ith morbilli form rashes in some cases of
infectious mononucleosis. PIPRACIL* should be used w ith caution in the treatment of patients w ith infectious
mononucleosis.
Drug Interactions: The mixing of PIPRACIL* w ith an aminoglycoside in vitro can result in substantial inactivation
of the aminoglycosides.
Usage During Pregnancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined.
Because animal reproduction studies are not always predictive of human response, this drug should be used
during pregnancy only if clearly needed. It has been found to cross the placenta in rats. Caution should be
exercised when PIPRACIL* is administered to nursing mothers. It is excreted in low concentrations in milk.
Pediatric Use: Dosages for children under the age of 12 have not been established.
ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been
local in nature, following intravenous or intramuscular injection. The following adverse reactions may occur:
Local R eactions-ln clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or
induration at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis
and hematomas. Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less
frequent findings: Pruritus, vesicular eruptions, positive Coombs tests. Gastrointestinal-Diarrhea and loose
stools were noted in 2.8% of patients. Less frequent reactions: vomiting, nausea, bloody diarrhea.
Hepatic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
Renal-Elevations of creatinine or BUN. Central Nervous System-Headache, dizziness, fatigue Hemic and
Lymphatic-Reversible leukopenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin
time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged
therapy at high dosages or in association w ith drugs known to cause this reaction. Serum Electrolytes-lndividualt
w ith liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a
decrease in serum potassium concentrations w ith high doses of PIPRACIL*. M usculo-Skeletal-Rarely, prolonged
muscle relaxation. Other-Superinfection, including candidiasis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular adminstration of 6 to 8 g
daily of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for
maintenance therapy after clinical and bacteriologic improvement has been obtained w ith intravenous piperacillin
sodium treatment. Administration should not exceed 2 g per injection at any one site. This route has been used
primarily in the treatment of patients w ith uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular
injection. The preferred site of injection is the upper outer quadrant of the buttock li.e. gluteus maximus). Also
may be given in the mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and
then only w ith caution to avoid radial nerve injury. Intramuscular injection should not be made into the lower or
mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted w ith 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein
irritation. The reconstituted and diluted solution may be administered by interm ittent or continuous drip.

Intermittent infusion should be administered over a period of about 30 minutes. During intermittent infusion it is
desirable to discontinue the primary intravenous solution. Any unused portion must be discarded. For continuous
infusion the solution may be administered over a longer period of time
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for injection, or if required Bacteriostatic
Water for Injection, Lidocaine HC1 0.5 or 1% (without epinephrmel-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required, Bacteriostatic Water
for Injection. Either parabens or benzyl alcohol. Lidocaine HC1 is contraindicated in patients w ith a known history
of hypersensitivity to local anesthetics of the amide type.
RECONSTITUTION TABLE
Product Size
Vials 2 g
3g

4g
Infusion Bottles
3g

4g

Volume of Diluent
to be added

Approximate Available
Volume

Approximate Average
Concentration

4.0 mL
6.0 mL
7.8 mL

5.0 mL
7.5 mL
10.0 mL

1 g/2.5 mL
1 g/2.5 mL
1 g/2.5 mL

15 mL
20 mL

17 mL
23 mL

The prepared solution may be further diluted to the desired volume w ith any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing any
of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
Intravenous Admixtures:
5% Dextrose in Water (DWV).
Normal Saline I + KCL 40 mEq.)
0.9% Sodium Chloride (Normal Saline) (NS).
5% Dextrose/Water |D,W) ( + KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride (D&NS)
5% Dextrose/Normal Saline (Dr.NS) ( + KCL 40 mEq).
Lactated Ringer's Injection, U.S.P.
Ringer's Injection, U.S.P. I + KCL 40 mEq).
Dextran 6% in 0.9% Sodium Chloride
Lactated Ringer's Injection, U.S.P. I + KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted w ith
recommended diluents and further diluted w ith the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarityl through 24 hours at room tern
perature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recommends
discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated If used as a
multi dose container, the vials must be reconstituted only w ith the bacteriostatic diluents noted above
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous
administration w ith solutions containing sodium bicarbonate.
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently w ith aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed w ith an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation to the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of
piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g/vial-3879 48 3 g/vial-3882 49 4 g/vial-3880 50
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium powder
equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles-3882 41 4 g/bottles-3880-42.
Pipercillin Sensitivity Discs impregnated w ith 100 j/g of piperacillin are also available.
Storage: PIPRACIL'vials and infusion bottles should be stored at controlled room temperatures of 15 30°C
(59-86°F).
Pipercillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously
by injection or infusion. Dosage and route of administration should be determined by the severity of the infection
and condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a
20 to 30 minute infusion administered intravenously. The maximum daily dose usually administered to adults is
24 g/day, although higher doses have been used.
__________
DOSAGE
Type of Infection

Usual Total Daily Dosage

Frequency of Administration

Serious infections such as septicemia, nosocomial
pneumonia, intra-abdominal infections, aerobic
and anaerobic gynecologic infections, and skin
soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most
community-acquired pneumonia.
Uncomplicated gonococcal urethritis.

12-18 gl.V.
(200-300 mg/kgl

Every 4 to 6 hours

8-16 g I.V. (125 200 mq/kql Every 6 to 8 hours
6-8 g I.M. or I.V.
Every 6 to 12 hours
1100-125 mg/kgl
2 g I.M .*
Single dose

*0ne gram of probenecid given orally 1/2 hour prior to injection.
Dosage in Renal Impairment
Creatinine Clearance
mL/min.

Urinary Tract Infection
(uncomplicated)

>40

No dosage adjustment necessary

Urinary Tract Infection
(complicated)

Serious Systemic
Infection

12 g/day 4 g every 8 hrs.

20-40

No dosage adjustment necessary

9 g/day 3 g every 8 hrs.

<20

6 g/day 3 g every 12 hrs.

6 g/day 3 g every 12 hrs. 8 g/day 4 g every 12 hrs.

Patients on
Hemodialysis*

'Hemodialysis removes 30-50% of piperacillin in 4 hours;
1 g additional dose should be administered following
each dialysis period.

6 g/day 2 g every 8 hrs.
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Reoperation After Failed Esophagomyotomy
for Achalasia
Of 4 9 patients w ith achalasia treated
surgically betw een 1 9 7 5 and 1 9 8 5 , 12
(8 w om en, 4 men) had undergone trans
thoracic e so p h a g o m y o to m y previously.
Four had had con com itant upper g a s 
trointestinal surgery. All 1 2 patients
com plained of d ysp ha gia ; other sy m p 
tom s included regurgitation, nocturnal
aspiration, heartburn, ch est pain, vomit
ing, upper gastrointestinal bleeding and
w eight loss. The average time from ini
tial operation to on se t of sym p to m s w a s
9 m onths. Preoperative investigations
and operative find in gs identified the
ca use of d ysp h a gia as inadequate or
healed e so p h a go m y o to m y with persis
tent or recurrent achalasia (eight
patients — tw o had partially disrupted fundoplications contributing to their d ysp ha 
gia), hiatus hernia w ith reflux esophagitis
ca u sin g esophageal s p a sm or peptic
esophageal stricture (tw o patients) and
incorrect initial d ia g n o sis and treatment
(tw o patients). Treatm ent, with the aid
of intraoperative m anom etry, included
repeat Heller m y o to m y (five patients),
Hill antireflux repair (four patients),
taked ow n of N isse n fundoplication and
extension of m y o to m y (tw o patients).
The average follow -up w a s 16 months.
Eight patients had g o o d results, tw o
required further operation and one under
w ent multiple dilatations postoperatively.
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The ca u se s of recurrent dyspha gia fol
low ing surgery for achalasia are diverse
and patients require individualized in v e s
tigation and treatment. Remedial su rge ry
for achalasia can correct postoperative
dyspha gia but results are le ss su c c e ssfu l
than those follow ing an adequate initial
operation.

D e 4 9 patients souffrant d'a ch alasie qui
ont ete operes entre 1 9 7 5 et 1 9 8 5 , 12
(8 fem m es et 4 hom m es) avaient precedem m ent subi une oesop h ago-m yo tom ie
transthoracique. Q uatre avaient eu une
chirurgie des vo ie s gastro-intestinales
superieures. Les 1 2 patients se plaignaient de d ysp h a gie et autres sym pto m es dont regurgitation, aspiration n o c 
turne, brulure d 'e sto m a c, douleur
thoracique, vom isse m en t, saignem ent
gastro-intestinal haut et perte de poids.
Les exam e ns preoperatoires et les o b se r
vations a I'operation ont identifie com m e
ca u se de d ysphagie, une o e so p h a g o m yo tomie inadequate ou cicatrisee avec achalasie persistante ou recidivante (huit
patients dont deux avaient com m e facteur contribuant & la dysphagie, un
derangem ent de fundoplicature), une hernie hiatale a vec reflux oesophagien causan t un sp a sm e o e so p h ag ie n ou un retrecissem e nt oesop h ag ie n (deux patients),
et un diagnostic initial et un traitement
errone (deux patients). Le traitement
a vec m anom etrie operatoire a com pris
une secon de m yotom ie de Heller (cinq
patients), une correction antireflux de Hill
(quatre patients), defaire une fundoplica
ture de N isse n et une extension de m y o 
tom ie (deux patients). La periode
d 'o b se rva tio n postoperatoire est de 16
m ois. Huit patients m ontrent de b o n s
resultats, deux ont ne ce ssity une nouvelle operation et un a sub i de multiples
dilatations postoperatoires. Les ca u se s
de dysp ha gie recidivante apres une o p e 
ration pour achalasie sont variees et elles
exigent des exa m e n s et un traitement

individualises. L e s operations d estin ee s a
corriger I'a c h a la sie so n t su sce p tib le s
d'am eliore r la d ysp h a gie postoperatoire
m ais elles y arrivent m o in s frequem m ent
que lors d 'u n e operation primaire reussie.

Controversy surrounds the current
management of patients with achalasia of
the esophagus. Pneumatic dilatation of
the lower esophageal sphincter or modi
fied Heller esophagomyotomy are the two
primary therapeutic modalities.1,2 Physi
cians who favour myotomy as the treat
ment of choice disagree on its extent3-5
and the need for a concomitant hiatal her
nia repair.5,6 Since there is no standard
operative technique, results of individual
series are difficult to compare. Most ser
ies report excellent or good results from
myotomy in 90% to 95% of cases.3,7
However, complications do occur, result
ing in persistent, recurrent or new sym
ptoms. Knowledge of the physiology of
normal esophageal function as well as the
pathophysiology of the disease process
are prerequisites for a proper operative
approach. When reoperation is necessary
this is even more important because the
cause of the patient’s symptoms may be
entirely different from that of the origi
nal motility disorder. We reviewed our
experience with reoperative surgery after
failed Heller esophagomyotomy at the
Virginia Mason Medical Center in Seattle.
Patients and Methods

Between 1975 and 1985, 49 patients
with achalasia were assessed and treated
surgically. Of these, 12 (8 women, 4 men)
had previously undergone a transthoracic
esophagomyotomy elsewhere. The mean
age was 38.6 years (ranging from 17 to
62 years). The mean time to recurrence
of symptoms postoperatively was 9
months (ranging from 3 to 24 months),
and the mean time to remedial surgery
was 24 months (ranging from 3 to 48
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months). Four patients had undergone
concomitant upper gastrointestinal proce
dures (two Nissen fundoplications and
two pyloroplasties). Before reoperation
all patients underwent upper gastrointes
tinal roentgenography, endoscopy,
esophageal manometry (also performed
intraoperatively), pH reflux testing and
esophageal radionuclide scintigraphy.
Preoperatively and intraoperatively every
effort was made to define the reason for
the failure of the previous operation. The
reoperative technique was tailored to cor
rect the specific cause of failure of the ini
tial procedure.
Results

All patients complained of recurrent or
persistent dysphagia to both solids and
liquids. Aspiration recurred as the main
symptom in three patients. Regurgitation
occurred in three others, two of whom
also had heartburn as a new symptom.
Chest pain, protracted vomiting, weight
loss and upper gastrointestinal hemor
rhage with hematemesis were present in
one patient each.
The causes for failed operation were
classified as unsuccessful myotomy (eight
patients), complication of myotomy (two
patients) and incorrect primary therapy
(two patients). Myotomy was unsuccess
ful in four patients because it was not
extended far enough distally to divide the
sphincter adequately. In two patients the
myotomy had healed completely with scar
tissue. In one patient intact muscle fibres
were identified at the base of the previ
ous myotomy. In one patient the
myotomy was not carried far enough
proximally (Fig. 1).
Complications of the myotomy took
the form of gastroesophageal reflux. In
one of the two patients the myotomy was
extended too far distally to the anterior
gastric wall, causing ulcerative esophagi
tis and a peptic esophageal stricture. The
other patient had a large hiatus hernia
postoperatively with secondary eso
phageal spasm (Fig. 2). This was not
present at the time of the original
esophagomyotomy.
Incorrect primary therapy resulted in
development of gastroesophageal reflux
in two patients. A patient with a
Schatzki’s ring misdiagnosed as achala
sia, had severe chronic ulcerative esopha
gitis with peptic esophageal stricture after
myotomy. The other patient underwent
myotomy for a short distal esophageal
stricture rather than achalasia. This
patient also suffered chronic gastro
esophageal reflux with a recurrent
stricture.
Remedial operations were individual
ized. Manometry was used intraopera
tively to determine the pressure and length
of the lower esophageal sphincter. Oper
178

ative procedures included repeat Heller
myotomy (four patients), antireflux
operation (posterior fixation sphincter
calibration—Hill procedure) with dilata
tion of a peptic stricture (four patients),
takedown Nissen fundoplication plus
repeat Heller myotomy (two patients),
repeat Heller myotomy plus reconstitu
tion of the gastroesophageal flap valve
(two patients). Following repeat myotomy
in two patients, the cardia was found to
be incompetent by palpation, and
manometry carried out intraoperatively
revealed that the sphincter muscle had
been completely divided. Therefore a flap
valveplasty was performed at the gas
troesophageal junction. Through a gastrotomy, musculomucosal sutures were
placed in the stomach so that a fold of
muscularis and mucosa overlapped the
gastroesophageal junction. The intraoper
ative measurements of lower esophageal
sphincter pressure before and after
remedial operation are shown in Fig. 3
and Table I. The length of the sphincter
in the first three groups was reduced from
2.5 cm to between 0.9 and 1.5 cm. The
length of the sphincter in the Hill
antireflux repair group was increased
from 2.0 cm to 4.0 cm (Fig. 4).
Good results were obtained in nine
patients (75%), who had only minimal
dysphagia and no gastroesophageal
reflux. The result was fair in one patient
(8%) who continued to have dysphagia
requiring intermittent dilatation. Two
patients (17%) had a poor result and
required a subsequent operation for relief
of dysphagia.
Discussion

Persistent or recurrent dysphagia fol
lowing a Heller esophagomyotomy for
achalasia is particularly distressing for
patients who have undergone surgery
expecting relief of this symptom. It is
equally disturbing for the surgeon who
has performed what he expects to be a
curative operation. Recurrent or persis
tent symptoms after a myotomy indicate
that the operation has been inadequate
whereas new symptoms (i.e. hemateme
sis) indicate complications of the
myotomy. In this series and others8-9
symptoms recurred within 9 months of a
failed operation. However, a remedial
operation is delayed an average of 2 years
and occasionally as long as 4 years
because the patient and physician are
reluctant to go ahead with further surgery
for what they believe is the same original
problem. Although dysphagia was
present in all of our patients, the reasons
for its recurrence were multiple and
included continued cardiospasm, peptic
esophageal stricture and secondary
esophageal spasm. Some patients com
plained of regurgitation, heartburn, chest

Fig. lb

Fig. lc
FIG. 1—(a) Preoperative esophagogram.
Inadequate length of myotomy proximally with
persistent achalasia and development of
megaesophagus, (b) Intraoperative manome
try identifies peak pressure in lower esophageal
sphincter of 100 mm Hg over 4 cm. (c) Post
operative esophagogram. Esophagus is less
dilated and there is no delay in transit of
barium.
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pain and hematemesis which were new
symptoms and were more troublesome
than their dysphagia.
These difficult problems require the full
armamentarium of modern diagnostic
tests to identify the type of motility dis
order as well as the reason for failure of
the previous operation. Remedial surgery
is then individualized to correct the
problem identified. This operation is tech
nically more demanding than the original
procedure because of intense scarring that
occurs both in the mediastinum and the
upper abdomen. The anatomy must be
redefined before undertaking repair, but
dissection of the scar tissue often results
in attenuation of the remaining normal
tissue, compounding the difficulty of the
operation.
Our classification of indications for
reoperation is similar to that of others.8’9
A clear distinction is made between

FIG. 2—Iatrogenic hiatal hernia after Heller
esophagomyotomy caused by overzealous hia
tal dissection. Hill antireflux repair was used.

FIG. 3—Intraoperative lower esophageal
sphincter pressures before (white bars) and
after (hatched bars) remedial operation.

patients having an unsuccessful myotomy
with continued achalasia and patients
having a complication of the myotomy
causing gastroesophageal reflux. The
third group — patients having incorrect
primary therapy — has not previously
been described.
Myotomy may be unsuccessful for var
ious reasons. Imperfect technique results
in an inadequate length of myotomy
either proximally or distally, or in in
adequate depth. Nonrelaxing lower
esophageal sphincter muscle remains and
symptoms persist or recur soon after
operation. This was the reason for
remedial surgery in five patients. If the
muscularis is not dissected away from the
submucosa for approximately 50% of the
esophageal circumference, the myotomy
may heal together rapidly, resulting in
early recurrence of symptoms.9'10 This
was the cause of failure in two patients
in this series. Patients presenting with a
megaesophagus have poorer results fol
lowing myotomy than if they had been
operated on earlier.11 Fekete and
associates8 reoperated on 10 patients
with megaesophagus who had unsuccess
ful Heller myotomies. Eight required
resection with colon interposition and two
had repeat myotomy. One of our patients
also had a megaesophagus (Fig. 1). Thick
ened circular muscle fibres were found
at the apex of the myotomy, indicating
inadequate proximal length of myotomy.
Following extension of the myotomy, the
patient was symptom-free and her upper
gastrointestinal roentgenogram showed
reduction in size of the esophagus. Inter
stitial or periesophageal fibrosis and
esophageal cancer have been d e
scribed8,10 as causes of unsuccessful
myotomy. We did not encounter these
problems in our series.
Complications of Heller myotomy
occur when it is carried too far distally.
The gastroesophageal junction becomes
incompetent and reflux occurs. Due to
disordered or absent motility in the body
of the esophagus in achalasia, prolonged
contact of acid with the esophageal
mucosa causes severe esophagitis. Overzealous hiatal dissection, resulting in an
iatrogenic hiatus hernia may also cause
reflux esophagitis. The myotomy must be
performed without mobilizing the gas
troesophageal junction. If the phreno-

esophageal bundles are damaged during
operation, the gastroesophageal junction
is free to migrate into the mediastinum.
Each of these complications occurred in
our series. Inadequate hemostasis at the
myotomy site causing periesophageal
fibrosis has been described as a cause of
failure.12 This was not identified in our
series.
The primary therapy was incorrect in
two patients in this series. One had a
Schatzki’s ring and the other peptic
esophageal stricture at the time of
myotomy. The condition of each was mis
diagnosed as being achalasia, and
myotomy caused subsequent development
of severe reflux esophagitis. These dis
turbing complications developed because
the preoperative investigation was inade
quate or interpretation of the findings of
preoperative studies was incorrect.
The controversy continues with respect
to the length of the esophagomyotomy3-5
and the necessity for concom itant
antireflux surgery.5,6 We use manometric
pressure measurements intraoperatively
as an adjuvant to surgery in patients with
esophageal motility disorders.13 The
technique allows us the luxury of an
objective intraoperative assessment of the
length of the myotomy necessary and
eliminates the need for concomitant hia
tal hernia repair. In repeat operations
when there may be uncertainty about the
extent of the previous myotomy, this
measurement is invaluable. We, and
others, believe that the addition of a rou
tine antireflux repair is not only unneces
sary but inadvisable because it replaces
the physiologic obstruction of the lower
esophageal sphincter with an anatomic
obstruction composed of an antireflux
repair.9 In two patients we found that a
fundoplication augmented lower eso
phageal sphincter pressure to the point at
which the dysmotile esophagus could not
propel swallowed bolus through the
sphincter. Ellis and Gibb9 reported simi
lar cases in which myotomy plus fun
doplication resulted in com plete
esophageal
o b stru c tio n
because
esophageal peristalsis was inadequate to
overcome the obstruction caused by the
fundoplication.
Recently we reoperated on two patients
in whom the gastroesophageal junction
was palpably incompetent following

T a b l e 1- M e a n M e a s u r e m e n t s ( ± S E M ) o f L o w e r E s o p h a g e a l S p h in c t e r
P r e s s u r e B e f o r e a n d A f t e r R e m e d ia l O p e r a t io n
L o w e r e s o p h a g e a l s p h in c te r p r e s s u r e , m m H g
R e m e d ia l p r o c e d u r e
H e lle r m y o t o m y
H e lle r m y o t o m y

A f t e r o p e ra t io n

3 6 .0 ± 4 . 0

1 2 .5 ± 3 . 0

4 0 . 0 ± 3 .0

8 .5 ± 1 .8

+

f la p v a l v e p l a s t y
Taked ow n

B e fo re o p e ra tio n

N is s e n

f u n d o p li c a t i o n

+

H e ll e r m y o t o m y
H ill a n t i r e f l u x r e p a ir

2 7 .5 ± 2 .7

9 .0 ± 1 .2

6 .5 ± 1 .8

3 6 .0 ± 3 . 2

FTG. 4—Length of lower esophageal sphinc
ter before (white bars) and after (hatched bars)
remedial operation.

VOLUME 29, NO. 3, M A Y 1986 / THE CANADIAN JOURNAL OF SURGERY

179

repeat myotomy. A gastroesophageal flap
valveplasty was performed to prevent
reflux. Both patients had no dysphagia
and no clinical or radiologic evidence of
reflux postoperatively. This technique
was devised with cadaver dissections. The
valve prevents reflux of gastric acid but
does not increase lower esophageal
sphincter pressure and is therefore ideal
in achalasia. This technique is now being
evaluated at a number of institutions.
Our results (75% good, 8% fair, 17%
poor) are similar to those in other series
of remedial surgery for achalasia.8,9’12 It
is apparent that reoperation does not
achieve as good results as after effect
ive primary therapy.3'7 Therefore it is
important to perform an adequate
myotomy initially and yet not be so
aggressive as to cause gastroesophageal
reflux.
We conclude that the best treatment for

patients with achalasia should be to pre
vent symptom recurrence by adequate
primary therapy. In our hands, intraoper
ative manometry has been invaluable in
this respect. When symptoms do recur,
intensive investigations are necessary to
determine the cause of the failure.
Individualized remedial surgery is
required to correct the problem. In these
difficult cases intraoperative manometry
to determine both the sphincter pressure
and length is critical in obtaining a good
postoperative result.
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Endobronchial Carbon-Dioxide Laser Therapy
<V 4

Twenty-four patients underwent single
and multiple carbon-dioxide laser treat
ments for endobronchial lesions at the
Mount Sinai Hospital in Toronto. Fifteen
had malignant disease, 2 had benign
tumours and 7 had benign strictures.
Rigid bronchoscopy with Venturi ventila
tion was used in all. with the C 02 laser
therapy directed down the open end of
the bronchoscope. In the majority of
cases laser therapy was combined with
mechanical debridement, consisting of
removal with biopsy forceps and use of
the end of the rigid bronchoscope to
"core out" the tumour mass. Assess
ments were made subjectively by the
patient and objectively by bronchoscopic
examination and post-treatment roent
genography. Worthwhile improvement
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was noted in patients who had proximal
malignant lesions and those with benign
lesions at all levels. Overall there was an
effective improvement in 18 of the 24
patients.

Au Mount-Sinai Hospital de Toronto, 24
patients souffrant de lesions endobronchiques ont subi un ou plusieurs traitements au laser de bioxyde de carbone.
Quinze etaient atteints de cancer, 2 de
tumeurs benignes et 7 de retrecissement
benins. Dans tous les cas, on a utilise un
bronchoscope rigide avec ventilation de
Venturi; le rayon laser au C 0 2 a ete
dirige a travers I'orifice du bronchos
cope. Dans la majorite des cas le traitement laser a ete associe a un debride
ment mecanique a I'aide de forceps de
biopsie et a I'utilisation de I'extremite du
bronchoscope rigide pour enlever le
coeur de la masse tumorale. Des appre
ciations subjectives ont ete faites par le
patient, et des evaluations objectives ont
ete realisees par bronchoscopie et radiographie post therapeutiques. Une amelio
ration notable a ete observee chez des
patients porteurs de lesions malignes
proximales et ceux qui avaient des
lesions benignes a tous les niveaux.
Dans I'ensemble, on a enregistre une
bonne amelioration chez 18 des 24
patients.

The application of laser technology to the
tracheobronchial tree has continued to
expand and has added an exciting new
dimension to bronchology and thoracic
surgery. Endoscopic application began in
1973 with the use of carbon-dioxide
(C02) laser therapy to ablate benign
neoplasms such as tracheobronchial
papillomas and, later, to palliate malig
nant obstruction of the major airways.1’2
Today, relief of airway obstruction from
tracheobronchial tumours has become a
common indication for laser bron
choscopy. Our initial experience was with
the C 0 2 laser; our more recent
experience with the neodymium-yttrium
aluminum garnet (NdiYAG) laser will be
presented at a future date.
The primary indication for laser ther
apy is to alleviate symptoms of malignant
disease; to relieve obstruction and control
hemoptysis. The laser removes endoscopically visible tumour from airways by
directing energy at the tumour mass,
causing vaporization. Therapy is deli
vered under the direct vision of the
endoscopist.
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Patients and Methods

Over the last 18 months, 24 patients
have undergone 50 C02 laser therapies at
the Mount Sinai Hospital in Toronto; 13
patients received a single treatment, 6
underwent two treatments and 1 patient
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Malignant Lesions (Table I)

Sex

no.

R

Age,

S ite o f

V

o b s tr u c tio n

Benign Stricture (Table II)

Fifteen patients underwent therapy for
malignant lesions. The average age of the
group was 62 years. Before the laser ther
apy, several patients had received various
other treatments such as surgery, exter
nal radiotherapy, chemotherapy and
endoscopy with the mechanical re
moval of obstructing tumour. Single
laser treatments were given in nine
patients, and in the remaining patients the
number of treatments varied from two to
seven. With multiple treatments, the
intervals between treatments varied
between 1 week and 5 months.
One patient underwent tracheal resec
tion after airway palliation by laser ther
apy preoperatively, and another has been

T a b le 1— E n d o b ro n c h ia l C a rb o n - D io xid e L a s e r T h e ra p y
P a tie n t

maintained with repeated laser therapies
for invasive and occlusive disease in his
proximal trachea, secondary to a medul
lary carcinoma of the thyroid. The others
died, at intervals ranging from 1 week to
4 months after therapy, o f either
metastatic disease or extension of local
disease.

sodium pentobarbital. Air oximetry was
routine. The concentration of oxygen
at the delivery point, at the end of
the bronchoscope, was kept at or below
35% to prevent laser-induced com
bustion.

each received three, four, five, six and
seven treatments. For those receiving
more than one treatment, the frequency
ranged from 2 days to 6 months (mean
8 weeks). The patients ranged in age from
31 to 84 years (mean 58 years).
The majority of the lesions were
malignant—primary bronchogenic carci
noma (nine patients), secondary carci
noma of the bronchus (two), primary car
cinoma of the trachea (three) and
secondary carcinoma of the trachea (one
patient) (Table I). Of nine benign lesions,
seven were strictures: secondary to pos
tresection granulation tissue (two),
tracheal scarring after tracheal resection
(three), lye burn (one) and tuberculous
bronchostenosis (one) (Table II). The two
remaining patients had obstructing lesions
of a major airway due to a benign
fibropapilloma and a carcinoid (Table
III).
In all instances ventilation was given by
rigid bronchoscope, using the Venturi
ventilation technique and intravenous
anesthesia with muscle relaxants and

D ia g n o s is

Of seven patients having benign stric
tures, five had airway resections and
postoperative stenoses or occlusive granu
lomas. The number of laser treatments
varied between one and four, with inter
vals of 2 days to 2.5 months. Laser ther
apy was ineffective in treating a lye stric
ture in the distal pharnyx, which was
eventually surgically bypassed. The
chronic stenoses produced by the tuber
culous stricture and the stitch granulomas
after resection did well after the laser
treatments. In the three with acute
stenoses after tracheobronchial resection
with circumferential narrowing, the laser
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therapy was effective in the short term,
but eventually these patients required per
manent endobronchial or endotracheal
prostheses.

of our 45 recorded assessments. In 7 the
response was minimal (Table IV).
Complications

Benign Tumours (Table III)

The major reported complication of
laser therapy is hemorrhage due to local
erosion into an adjacent segmental or
subsegmental artery. Other reported com
plications include tracheosophageal
fistula, endobronchial flash fires, post
treatment pneumonia and complications
secondary to the anesthesia. In this ser
ies, there was only one instance of
minimal bleeding postoperatively that
required reintubation for control of the
airway and tracheal toilet. The bleeding
resolved spontaneously and required no
further therapy. In one of our early cases,
one suction catheter vaporized, but this
did not happen again once we gained
more experience. On three occasions
patients had to be reintubated because of
bronchospasm, pulmonary edema and
tracheal stridor in one case each. They
were all promptly extubated in the recov
ery room and returned to the ward
without incident.

Two patients, aged 39 and 60 years,
constituted this group. A carcinoid of the
left main bronchus produced an obstruc
tion, that was effectively relieved by one
laser treatment; subsequently, this patient
had surgical resection. The other patient
had a fibropapilloma at the origin of the
left lower lobe, producing left-lower-lobe
atelectasis, which was effectively treated
with one laser treatment. This was help
ful in the short term, but YAG laser ther
apy was required distally for eventual
total ablation.
Results
The results of laser therapy were
assessed by a combination of pre
treatment and post-treatment roentgeno
grams, bronchoscopic assessment of the
diameter of the airway after therapy, and
by physical examination and discussion
with the patient after therapy.
Improvement was marked after 24 laser
therapies, moderate after 11 and minimal
after 9. On bronchoscopic assessment,
laser therapy brought about marked
improvement in 21 instances, moderate in
15 and minimal in 4. Objective radiologic
assessment was difficult unless distal
atelectasis was present. In the 14 patients
who were followed up by postoperative
chest roentgenography because of pre
treatment atelectasis, the roentgenogram
suggested a marked improvement in 3
instances, moderate in 1 and minimal
in 10.
We found that laser therapy was most
effective in patients who had chronic
benign strictures and benign tumours at
all levels. It had less effect in correcting
airway obstruction in patients with malig
nant disease, particularly if the obstruc
tion was distal to the main-stem bronchi
or there was significant extrinsic compres
sion. It was effective in 5 and effective to
some degree in 10. Overall, we noted a
moderate to marked improvement in 38

Discussion
The use of laser therapy for a variety
of endobronchial lesions has met with
general enthusiasm.3'5 From published
series it is difficult to determine specific
indications for it, based upon patients’
complaints, the location of tumour and
any concomitant therapy. Most reports
do not provide sufficient information to
permit adequate comparisons regarding
improvement in symptoms and long-term
efficacy. Our aim was to assess our
method of delivery for C 0 2 laser therapy
in patients compromised by airway occlu
sion, with both benign and malignant
disease.
Exophytic lesions of the trachea and
main-stem bronchi are most amenable to
therapy by laser, and improvement in
symptoms correlates best with improved
patency of larger airways. In most
patients the major portion of the
endobronchial debulking procedure can
be performed quickly by physically cor
ing out the exophytic tumour mass with

T a b le IV — O ve ra ll V a lu e o f E ndobron chial
C a rb o n D io x id e L a s er T h e ra p y

References
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M in im a l

—

the rigid end of the bronchoscope. A large
biopsy forceps can help accomplish this
with very little bleeding. The laser can
then remove any remaining tumour and
produce hemostasis of the tumour bed.
The major indication for laser therapy in
malignant lesions is to lessen or com
pletely relieve symptoms of obstruction.
Laser therapy to obstructed lobar or seg
mental bronchi rarely relieves or reduces
symptoms unless they are associated with
a post-obstructive pneumonia. When the
obstruction is long-standing, laser abla
tion may fail to establish airway patency.
Hemoptysis from exophytic lesions can
usually be well controlled. Laser therapy
to extrinsic compressive tracheal or bron
chial lesions is usually of little value. We
have found this type of therapy most suc
cessful in patients with proximal malig
nant lesions, benign lesions of the major
airways, and benign strictures. The
benign lesions may require repeat therapy
so that epithelialization of the laser cut
can occur between treatments. A severe
hemorrhage may occur, even in carefully
selected patients, and is the most serious
complication of this type of therapy.
When compared to diathermy coagu
lation, mechanical removal, cryotherapy
and radioactive seed application, the
advantages of C 0 2 laser bronchoscopy
are that it produces moderately good
hemostasis, it is rapid and it provides a
precise “ no touch” application with
minimal tumour manipulation.
The C 0 2 delivery system has certain
disadvantages that have more recently
been eliminated with the use of the
Nd:YAG laser. The C 0 2 laser cannot be
projected through fiberoptic material,
and relies on an articulated arm with deli
cate reflective surfaces. Delivery, through
a rigid bronchoscope, limits therapy to
the more proximal lesions, because dis
tal and upper-lobe lesions cannot be
reached. Because of low penetration,
effective hemostasis is limited to vessels
the size of terminal arterioles and capil
laries. Despite these disadvantages, the
C 0 2 laser is a precise cutting instrument
with limited penetration into underlying
tissue, moderately good hemostasis and
a great degree of safety when compared
with the coagulating and penetrating
effects of the Nd:YAG laser.
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W hen you want an effective antibiotic at all costs.
But not at any price.
During the critical 24 to 48
hour wait for susceptibility tests,
you need an antibiotic with a clini
cally proven spectrum of activity.
An antibiotic with an excellent rec
ord of safety. An antibiotic such
as Cefobid*.
When cost must also be
considered, Cefobid* remains an
antibiotic of choice. Its realistic

pricing structure and economical
twice-a-day dosage make
Cefobid* cost-effective therapy.12
Cefobid* is an advanced
cephalosporin proven effective
against a wide range of infections.
It is very well tolerated. With a
unique dual pathway of excretion,
Cefobid* at usual dosage requires
no modification of dosage in
patients with renal impairment.
Cefobid* Effective antibiotic
therapy you can well afford to use.

Kirkland, Quebec
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cefoperazone sodium/pfizer

IV/IM

First-line parenteral antibiotic therapy
Prescribing Information
Antibiotic
For Intravenous or Intramuscular Injection
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium)
results from the inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following
infections when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, Kleb
siella species (including Klebsiella pneumoniae), Pseudomonas aeruginosa, Escheri
chia coli, Proteus mirabilis, indole-positive Proteus species and Enterobacterspecies.
URINARY TRACT INFECTIONS caused by Escherichia coli, Pseudomonas aeruginosa,
Enterobacter species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylo
coccus aureus, Staphylococcus epidermidis and indole-positive Proteus species.
Due to the nature of the underlying conditions which usually predispose patients
to Pseudomonas infections of the lowe r respiratory and urinary tracts, a good clini
cal response accompanied by bacterial eradication may not be achieved despite
evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHO
LANGITIS caused by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Strep
tococcus agalactiae, Escherichia coli and Klebsiella species.
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus
aureus, Streptococcus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND
ENDOMETRITIS) caused by Streptococcus agalactiae, Neisseria gonorrhoeae,
Escherichia coli, Bacteroides species (including Bacteroides fragilis), Peptococcus
species and Peptostreptococcus species.
Specimens for bacteriologic culture should be obtained prior to therapy in order to iden
tify the causative organism and to determine its susceptibility to CEFOBID (cefoperazone
sodium). Therapy may be instituted before results of susceptibility testing are known;
however, modification of the treatment may be required once these results become
available.
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients
with known allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hypersensi
tivity reactions to cephalosporins, penicillins or other drugs. CEFOBID (cefoperazone
sodium) should be administered with caution to penicillin-sensitive patients or to any
patient who has demonstrated some form of allergy, particularly to drugs. If an allergic
reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of
the drug and treat the patient with the usual agents (e.g. epinephrine, antihistamines,
pressor amines or corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of
CEFOBID (cefoperazone sodium). Therefore, in those patients administered CEFOBID
(cefoperazone sodium) who develop diarrhea, it is important to consider such a
diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone
sodium) alters the normal flora of the colon and may permit overgrowth of Clostridia.
Studies indicate that a toxin produced by Clostridium difficile is one primary cause of
antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte, and protein supplementation as indica
ted. When the colitis is not relieved by the discontinuance of CEFOBID (cefoperazone
sodium) or when it is severe, consideration should be given to the administration of oral
vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins
has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine
have been observed, there is no evidence that CEFOBID (cefoperazone sodium) when
administered alone causes significant nephrotoxicity. However, the effect of ad
ministering CEFOBID (cefoperazone sodium) concomitantly with aminoglycosides is not
known.
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal
volunteers, 19 to 41% of the dose is excreted in the urine, the remainder being excreted
by the hepato-biliary system. The serum half-life of CEFOBID (cefoperazone sodium) is
usually prolonged and urinary excretion of the drug increased in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in these patients treated with doses in excess of 2 grams daily and dosage
should be adjusted as necessary.
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2 to 4 grams (1 to 2 grams every 12 hours) are administered. If higher doses of CEFOBID
(cefoperazone sodium) are used, serum concentrations of cefoperazone should
be monitored. If there is evidence of accumulation, dosage should be decreased
accordingly.

In one study in patients with chronic renal failure, the half-life of CEFOBID (cefopera
zone sodium) was reduced from 4.17 to 1.67 hours during hemodialysis. Thus, dosing
should be scheduled to follow a dialysis period.
In patients with both hepatic dysfunction and renal impairment, the initial dosage of
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum con
centrations of cefoperazone should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID
(cefoperazone sodium). The mechanism is most probably related to the suppression of
gut flora which normally synthesizes this vitamin. Those at risk include patients with
poor diet or malabsorption states (e.g. cystic fibrosis) and patients on prolonged intrave
nous alimentation regimens. Prothrombin time should be monitored in these patients
and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been
reported when alcohol is ingested during and as late as the fifth day after CEFOBID
(cefoperazone sodium) administration. Patients should be cautioned concerning inges
tion of alcoholic beverages in conjunction with administration of CEFOBID (cefoperazone
sodium). For patients requiring artificial feeding orally or parenterally, solutions con
taining ethanol should be avoided.
CEFOBID (cefoperazone sodium) should be administered with caution to individuals
with a history of gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of
CEFOBID (cefoperazone sodium). Patients should be observed carefully during treat
ment. If superinfection occurs, appropriate measures should be taken.
Drug Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's
solution.
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been
established. The use of CEFOBID (cefoperazone sodium) in pregnant women requires
that the likely benefit from the drug be weighed against the possible risk to the mother
and fetus.
Reproduction studies have been performed in mice, rats and monkeys at doses up to
10 times the human dose and have revealed no evidence of impaired fertility or teratoge
nic effects due to cefoperazone sodium. Animal reproduction studies, however, are not
always predictive of human response.
Nursing Mothers: Cefoperazone is excreted in low concentration (0.4 to 0.9 ^g/m L) in
human milk. Caution should be exercised when CEFOBID (cefoperazone sodium) is
administered to a nursing mother.
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not
been established.
ADVERSE REACTIONS
Hypersensitivity: Maculopapular rash, urticaria, pruritis, eosinophilia, drug fever.
Hematology — Decreases in hemoglobin and/or hematocrit have occurred. Slight
decreases in neutrophil count have been reported, and reversible neutropenia may occur
with prolonged administration. Transient eosinophilia has occurred. Hypoprothrombinemia has been observed. Some individuals have developed positive direct Coombs’ test
during treatment.
Liver — Transient elevations in SGOT, SGFT and alkaline phosphatase levels have been
noted. One patient with a history of liver disease developed significantly elevated liver
function enzymes during therapy with CEFOBID (cefoperazone sodium). Clinical signs
and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID
(cefoperazone sodium) therapy was discontinued, the patient’s enzymes returned to pre
treatment levels and the symptomatology resolved.
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been
noted.
Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported.
Most of these events have been mild or moderate, but some have been severe. In all
cases, these symptoms responded to symptomatic therapy or ceased when
cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Pseudomembranous colitis has been reported rarely in patients administered
CEFOBID (cefoperazone sodium). Symptoms of pseudomembranous colitis can appear
during or for several weeks subsequent to antibiotic therapy.
Disulfiram-like Reaction
Disulfiram-like reactions have been reported when alcohol was ingested during and as
late as the fifth day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intra
muscular administration. Occasionally, transient pain may follow administration by this
route. When CEFOBID (cefoperazone sodium) is administered by the intravenous route,
some patients develop phlebitis at the site of administration.
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone
sodium), no specific information on symptoms or treatment of overdosage is available.
Treatment should be symptomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
Dosage
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
Dosage and route of administration should be determined by severity of infection,
susceptibility of the causative organism, and condition of the patient.
Adult
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams ad
ministered in equally divided doses every 8 to 12 hours (See table below). The usual
duration of treatment is 7 to 14 days.
Adult Dosage
Type of infection
Daily Dose
Frequency and Route
Mild to moderately severe
2 to 4 grams
1 to 2 grams
infections such as pneumonia,
every 12 hours
acute urinary tract infection,
|. m . or I.V.
wound infection

Severe infections or infections
caused by less sensitive
organisms

4 to 8 grams

2 to 4 grams
every 12 hours
I.V.

Infections commonly requiring
9 grams
3 grams every
antibiotics in higher dosage
8 hours I.V.
(e.g. septicemia and life threatening
infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should he continued for
at least 10 days.
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2 to 4 grams (1 to 2 grams every 12 hours) of CEFOBID (cefoperazone sodium) are admin
istered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra
tions of cefoperazone should be monitored. If there is evidence of accumulation, dosage
should be decreased accordingly. For patients whose glomerular filtration rate is less
than 18 mL/min orwhose serum creatinine level is greaterthan 3.5 mg/dL, the maximum
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day.
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis
period.
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in patients treated with doses in excess of 2 grams daily and dosage should
be adjusted as necessary.
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial
dosage of CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and
serum concentrations of cefoperazone should be closely monitored.
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been
established.
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular
injection into a large muscle mass such as the gluteus maximus or anterior thigh. The
maximum dose of CEFOBID (cefoperazone sodium) should be two (2) grams.
Intravenous:
Direct Intravenous (bolus) injection: The reconstituted solution should be injected
slowly over a period of no less than three (3) minutes. The maximum dose of
CEFOBID (cefoperazone sodium) should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a
period of 15 minutes to 1 hour through the tubing of an administration set while any
of the intravenous solutions (See Solutions for I.V. Infusion) are being infused. During
infusion of the solution containing CEFOBID (cefoperazone sodium), it is desirable to
temporarily discontinue administration of the other solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be
administered over a longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination
with an aminoglycoside antibiotic, each should be administered at different sites
because of a physical incompatibility. An aminoglycoside should not be mixed with
CEFOBID (cefoperazone sodium) in the same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7- [ (R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2(p-hydroxyphenyl) acetamido] -3[ [ (1-methyl-1H-tetrazol-5-yl)thio ] methyl]-8-oxo5-thia-1- azabicyclo[4.2.0] oct-2-ene-2-carboxylate
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-CONHCHCONH

Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________ (ndL)__________ Volume (mL)___________ (mg/mL)________
1.0
3.5
4.0
250
2.0 __________ 7 0 ________________ SO__________________250__________
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to
allow any foaming to dissipate in order to permit visual inspection for complete solubili
zation. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID
(cefoperazone sodium).
For Intravenous Use:
Solutions for Reconstitution and Dilution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________ (mL|___________ Volume (mL)___________ (mg/mL)_______
1
9.5
10.0
100
2____________ 19T)_______________ 2 0 0 _________________ 100__________
Shake well until dissolved. The prepared solution may be further diluted to the desired
volume with any of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above
For intermittent intravenous infusion: Reconstitute as directed above
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The
reconstituted solution may be added to an appropriate intravenous bottle/bag containing
any of the solutions for I.V. infusion listed below:
Solution for I.V. Infusion
5% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection
5% Dextrose and 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.2% Sodium Chloride Injection (USP)
10% Dextrose Injection (USP)
Lactated Ringer's Injection (USP)
0.9% Sodium Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection
Normosol® R
Stability of Solutions
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if
kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours
if kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein
hydrolyzates, or amino acids. CEFOBID (cefoperazone sodium) should not be mixed
together with an aminoglycoside.
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1.0 g vial — cefoperazone 1.0 g as sodium salt
2.0 g vial — cefoperazone 2.0 g as sodium salt
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and
refrigerated (2 to 8° C).
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1. Carlin, H.S., M.Sc and Romankiewicz, J.A., Pharm. D., The New York Hospital
- Cornell Medical Center, New York, N.Y.: 'The impact of dosage regimen on
intravenous drug costs", presented as a scientific exhibit at the Mid-year Clinical
Meeting of the American Society of Hospital Pharmacists, New Orleans, Louisiana,
December 6-10,1981.
2. Based on costs compiled at a large Canadian hospital in Montreal, 4th Qtr 1983.
* Prepared by Pfizer Canada Inc. (R.U.)
Pfizer Inc. TM Owner.
© Pfizer Canada Inc. 1986

Molecular Formula: C2sHx N,0,S;,Na Molecular Weight: 667.65
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol,
poorly soluble in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane.
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The
sodium content of each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion).
The pH of a 25% (w/v) solution is 4.5 to 6.5 and the solution is colorless to straw yellow
depending on the concentration.
RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
0.5% Lidocaine Hydrochloride Injection
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Pros and Cons of Urgent Exploratory Sternotom y
A fter Open Cardiac Surgery
To determine whether it is appropriate to
perform urgent exploratory sternotomy
for potentially life-threatening complica
tions of open-heart procedures, the
authors reviewed the charts of 100 such
patients managed by exploratory ster
notomy between December 1982 and
December 1984. Group 1 comprised 32
patients who suffered cardiac arrest (8)
or had acute profound hypotension
(24). Group 2 included 68 patients
w ith persistent excessive bleeding. Of
group 1 patients operated because of
acute profound hypotension, 50% had
definite evidence of cardiac tamponade.
In the remainder the cause was severe
myocardial ischemia and left ventricular
failure. In group 2 an identifiable correc
table site of bleeding was found in 78%.
Four of the 8 patients with cardiac
arrest and 20 (83%) of the 24 patients
w ith acute profound hypotension sur
vived and left the hospital, in group 2,
58 (85%) of the 68 survived.
The mean postoperative stay was
higher in group 1 than group 2 — 20.3
± 3.08 days versus 14.2 ± 1.23 days
(p < 0.1). The duration of ventilatory sup
port in group 1 was also higher — 6.18
± 1.32 days versus 2.12 ± 0.38 days.
Postoperativeiy, sputum cultures gave
positive results in 19% of the patients,
all of whom had required prolonged ven
tilatory support. Minor sternal wound
infections were present in tw o and major
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in four. There was no sigificant differ
ence in morbidity of the survivors
between those who underwent ster
notomy in the recovery room or in the
operating room. In the authors' opinion
patients who undergo exploratory ster
notomy after cardiac surgery have a
higher morbidity in terms of infection
and prolonged hospital stay, but con
sidering the life-threatening nature of the
condition requiring the reopening, the
overall survival rate of 83% justifies its
use, so consideration should be given to
this procedure early even if it must be
performed at the bedside.

Les auteurs ont etudie de facon retro
spective 100 patients consecutifs qui
ont subi d'urgence une sternotomie
exploratrice a la suite de chirurgie cardiaque entre decembre 1982 et decembre
1984. Le groupe 1 comprenait des 32
patients qui ont ete explores a la suite
d'un arret cardiaque (8) ou hypotension
profonde (24). Le groupe 2 com
prenait 68 patients qui ont ete reouverts a cause de saignement excessif.
Des patients operas pour hypotension
profonde, 50% presentaient une tam
ponade cardiaque. Dans les autres cas il
s’agissait d'ischemie myocardique severe
avec defaillance du ventricule gauche.
Dans le deuxieme groupe nous avons
identifie une source de saignement chez
78% des patients.
Quatre des 8 patients qui ont eu un
arret cardiaque et 20 (83%) des 24
patients avec hypotension severe ont
surv6cus et ont pu quitter I'hopital. Dans
le groupe 2, 58 (85%) des 68 des
patients ont quitte I’hopital en vie.
L'hospitalisation a 6te plus longue
dans le groupe 2 que dans le groupe
1—20.3 ± 3.08 jours versus 14.2 ±
1.23 jours (p < 0.1). La duree de la venti
lation mgcanique dans le groupe 1 etait
aussi plus elev6e a savoir 6.18 ± 1.23
jours compare au groupe 2 —2.12 ±
0.38 jours. Les cultures de s6cr6tions

bronchiques dans les suites postoperatoires etaient positives chez 19% des
patients, toutes etant associees a une
ventilation mecanique prolongee. Les
auteurs ont note une infection sternale
mineure chez deux patients et majeure
chez quatre patients. Cependant, il n'y
avait aucune difference significative dans
la morbidite des survivants dont la poitrine avait et6 reouverte dans la salle de
reveil versus dans la salle d'operation.
Les auteurs croient que les patients
subissant une sternotomie exploratrice h
la suite de chirurgie cardiaque ont une
morbidity plus elevee en terme d'infection et de duree d'hospitalisation. Cepen
dant ils croient que la survie de 83%
justifie I'emploie de la sternotomie
exploratrice d'urgence qui devrait etre
meme employee dans la salle de reveil si
necessaire.

Cardiac arrest, excessive postoperative
bleeding or acute profound hypotension
after open-heart surgery may necessitate
an urgent exploratory sternotomy. Some
times this must be performed in the recov
ery room or intensive care unit. In an
effort to assess its efficacy we reviewed
the charts of 100 consecutive patients who
had required an urgent exploratory ster
notomy after open cardiac surgical proce
dures performed at the University of
Ottawa Heart Institute, Ottawa Civic
Hospital.
Table I—Initial Procedure Performed
on 100 Patients Who Required Urgent
Exploratory Sternotomy
Operation
CABG*
Valve replacement
CABG + valve replacement
CABG + left ventricular
aneurysmectomy
Miscellaneous

No. of
patients
74
12
7
3
4

'Aortocoronary bypass grafting.
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Patients and Methods
From December 1982 to December
1984, 82 men and 18 women ranging in
age from 38 to 92 years (mean 58 years)
underwent urgent exploratory ster
notomy. They represented 5.4% of adults
who had undergone open-heart opera
tions during this time.
The primary operative procedure is
demonstrated in Table I. There were three
indications for urgent sternotomy:
cardiac arrest unresponsive to initial mas
sage or defibrillation, or both (8 patients),
acute profound hypotension (24 patients)
and excessive bleeding—over 400 mL an
hour or 1200 mL in 3 hours (68 patients).
Eighty-one patients were explored in
the operating room. The condition of the
other 19 was considered too critical to
permit their transfer to the operating
room. Sterile reopening sets kept in the
recovery and intensive care rooms were
used. The chest was hastily prepared with
Proviodine and draped with sterile towels
and sheets. All except two patients were
already intubated at the time. These
two were rapidly intubated. Analgesia
was provided by intravenously adminis
tered morphine or fentanyl citrate.
In all patients the electrocardiogram
was monitored as was the arterial
blood, central venous or pulmonary
artery pressure. Temporary pacing wires
were used whenever needed. Arterial
blood gases were monitored for carbon
dioxide and oxygen pressures and pH,
and serum electrolyte values, hematocrit,

platelet count, prothrombin, activated
clotting and partial thromboplastin times
and fibrinogen levels were determined
when necessary. All drugs needed for
resuscitation as well as blood, colloids
and crystalloids were available in the
recovery room. Suction apparatus was
present at the bedside.
Findings
There were two groups of patients.
Group 1 comprised patients who were
explored after cardiac arrest and those
with acute profound hypotension. In the
eight patients with cardiac arrest no evi
dence of tamponade was found. Of the
24 who had acute profound hypotension,
12 had a pericardial collection causing
tamponade and opening of the sternal
incision was associated with a substantial
improvement in the hemodynamic state.
In the remainder, the cause of the pro
found hypotension was left ventricular
failure following severe myocardial ische
mia. An intra-aortic balloon was inserted
in six of the patients. Twenty patients in
the group had progressive circulatory
insufficiency and were already receiving
inotropic drugs. Two had an intra-aortic
balloon in place and exploratory ster
notomy was carried out as a last ditch
measure to exclude a correctable cause of
the low-output state.
Group 2 was made up of 68 patients
who had persistent excessive bleeding—
1276 ± 112mLover 189 ± 16.5 minutes.
Fifty of these patients had been given
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additional protam ine sulfate in tra 
venously after operation or had received
fresh-frozen plasma or cryoprecipitate or
platelets. Two patients were on cell-saver
equipment.
At surgery, 53 of these 68 patients had
an identifiable site of bleeding, which was
a vascular anastomosis in 18, the distal
marginal graft anastomosis being the
commonest site. Chest-wall bleeding was
seen in 13 patients. In each of the eight
patients who had previously undergone
bypass grafting of the internal mammary
artery, the source of bleeding was the bed
of the artery.
Survival Rate
In Group 1, of the eight patients who
had a cardiac arrest four survived.
Twenty (83%) of the 24 patients with
acute profound hypotension survived and
left the hospital. In group 2, 58 (85%) of
the 68 patients left the hospital alive.
Morbidity
The average postoperative hospital stay
was longer in group 1 than group 2—20.3
± 3.08 days versus 14.2 ± 1.23 days (p<
0.1, paired f-test). These figures compare
with an average postoperative hospital
stay for patients with a similar operative
profile at the University of Ottawa Heart
Institute of 10 days. Table II compares
the morbidity o f patients in the two
groups.
Forty-four patients were extubated on
schedule, that is within 24 hours after sur
gery. The length of ventilatory support in
group 1 patients was 6.18 ± 1.32 days
and was 2.12 ± 0.38 days in group 2. The
morbidity in patients who had extended
ventilatory support was higher than in the
others (Table III).
Table IV lists the bacteria identified
from various sites.
Sternotomy was carried out in the
recovery room in 13 of the 32 group 1
patients (group la) and in the operating
room in the others (group lb). Six
patients in group la died, five within 48
hours. In group lb one patient died
within 48 hours. The morbidity and the
mortality in the two groups are compared
in Table V.
The differences between the two groups
were not statistically significant.
Discussion
Exploratory sternotomy soon after
open-heart surgery is generally required
for sudden profound hypotension or
excessive p o sto p e ra tiv e bleeding.
Whenever possible the procedure is per
formed after transferring the patient to
an operating room. However, operating
rooms are not always readily available,
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and the patient must be disconnected
from the ventilator and monitoring equip
ment and transferred out of the recovery
room. Sometimes the sternotomy must be
done at the bedside in the recovery room.
Fairman and Edmunds1 reviewed emer
gency thoracotomies performed in the
recovery room after cardiac surgery and
found an incidence of 3Vo. The 19
patients in our series operated on in the
recovery room constitute 0.5 Vo of the
total number of open-heart procedures
performed at our institution. These
patients were too sick to tolerate the
delays in transporting them from the
recovery room to an operating room.
There is little published data on emer
gency sternotomy after open-heart proce
dures. The incidence would vary in differ
ent institutions depending on the attitudes
of the staff, fellows and residents and on
the accessibility of an operating room to
such patients. Our low incidence might
well reflect the immediate proximity of an
operating room to the cardiac recovery
room. This operating room is generally
used for pacemaker insertions and occa
sionally for open or closed cardiovascu
lar procedures.
The main concern for patients who
have to be re-explored is the possible mor
bidity that may result, especially if the
usual sterile precautionary measures of an
operating room are not possible. Our
study indicates an increase in morbidity
associated with exploratory sternotomy.
It is essential, therefore, that centres deal
ing with open cardiac surgery should take
extra care so that exploratory sternotomy
for an avoidable cause is not necessary.
Our incidence of 3.7Vo for reopenings
resulting from postoperative bleeding is
probably not high compared with rates
from other centres such as the 4.5Vo
reported by Zurick and associates.2 The
disturbing fact in our series was that of
the 68 patients who were opened for
bleeding, 78Vo had a localized correcta
ble source of bleeding. This could have
been avoided by careful attention to
hemostasis at the time the wound was
closed. Our study shows that the usual
sites that are overlooked are the bed of
the internal mammary artery pedicle after

dissection and the distal anastomotic site
on the marginal branch of the circumflex
artery. The latter is usually difficult to
evaluate as the graft lies posteriorly, and
assessment of hemostasis requires mobili
zation of the heart which often causes
hypotension and may not initially reveal
the site of bleeding. We have tried to
overcome this by injecting indocyanine
green through the graft before perform
ing the proximal anastomosis to identify
any sites of leakage from the distal
anastomosis or the vein.3 In our series
only a small percentage of patients had
serious bleeding postoperatively from
causes that were not surgically correc
table.
Infection associated with reopening
after open-heart procedures was more fre
quent than when reopening was not neces
sary. Culliford and colleagues4 and
Englem an’s group5 had the same
experience. They noticed an increased
incidence of mediastinitis and mediasti
nal wound infection in patients who had
excessive bleeding postoperatively. Cul
liford reported that 53Vo of the 39
patients with mediastinitis had blood loss
in excess of 1250 mL. This is surprising
because most patients who have bleeding
postoperatively can be transferred into
the sterile environment of an operating
room. Interestingly, when we compared
our patients who were reopened in the
recovery room with those who were reo
pened in the operating room, the differ
ence in morbidity between the two groups

was not significant. Our indication for
performing an emergency sternotomy in
the recovery room is sudden profound
hypotension that does not respond within
a few minutes to drugs or closed resusci
tation. We agree with Fairman and
Edmunds' that emergency thoracotomy
should be considered an important
adjunct of postoperative care after openheart surgery, and nurses and allied med
ical personnel should be trained in this
procedure. A ppropriate equipment
should be available and be readily
located. No patient should be allowed to
die in an intensive care unit from cardiac
tamponade, a correctable condition.
Interestingly, only 50Vo of the patients
who had sternotomy for sudden profound
hypotension had a documented cardiac
tamponade. All these patients ultimately
did well and were discharged from the
hospital. Most deaths occurred in group
1 patients in whom the low-output state
was due to causes other than cardiac tam
ponade.
Thus, if cardiac tamponade can be
excluded by a noninvasive means such as
echocardiography, exploratory ster
notomy can be avoided in patients who
will not benefit from it. Unfortunately,
the average systolic blood pressure in
these patients was 60 mm Hg and they
were being given inotropic agents (two
required intra-aortic balloon pump sup
port). It is unlikely that this situation
would lend itself to bedside echocardiog
raphy. Besides, in the interest of expe-

□ e a th s /M o rb id ity

G roup 1a

Group 1b

(n -

(n -

13)

5
1

A ft e r 4 8 h

2
1

3
1

In fe c tio n — p o s itiv e c u ltu re s fro m
sputum
urine
w ound

O th e r g ra m -n e g a tiv e bac illi

188

-

blood

<—

V4.

1

0

1

3

4
4

4

2
2

y

1
1

C h e s t tu b e

1
1

2
1

—
—

_

1
4
3
2
1
4

2
1

3

—

* 4

0

0

1

—

<

•

0

S te rn a l d e h isc en ce
M e d ia s tin itis
T ra c h e o s to m y

2
1

—

4

1

Pneum onia

M e d ia s tin u m

_

f ■'

M o rb id ity

Sputum

1

P 4

4*-

D e a th
W ith in 4 8 h

B lood

—

4.-

19)

S ite

Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus sp
Pseudomonas sp
Escherichia coli
Klebsiella sp
Haemophilus sp
Serratia sp
Enterobacter
Achromobacter sp

r

T a b le V - D e a t h s an d M o rb id ity o f G roup 1 P a tie n ts W h o U n d e rw e n t
S te rn o to m y in th e R e c o v e ry R oom (G roup 1 a ) or O p e ra tin g R oom (G roup 1b)

T a b le IV — B a c te ria C u ltu re d Fro m V a rio u s S ite s

O rg an ism

*><-

_
_
_

_

1

1

_
_

U rine

Groin
1
1

2
1
2

_

2
1

1

-

-

-

2

V O L U M E 29, N O . 3 , M A Y 19 8 6 / THE CANADIAN JOURNAL OF SURGERY

-

dience it might be safer to go ahead with
an urgent reopening in the recovery room
rather than lose valuable time obtaining
an echocardiogram. The highest death
rate (50%) was among the eight patients
who had a cardiac arrest and were
explored after unsuccessful attempts at
resuscitation. The overall survival of 83%
is commendable in view of the predicta
bly low survival rate that would have
resulted if these patients had not been
treated surgically. The 15% death rate in
the group of patients who were explored
for extensive bleeding was surprising, but
this can be explained by the fact that
bleeding is often associated with hypoten
sion and varying degrees of cardiac tam
ponade.6 Such a combination of situa
tions, especially in the presence of an
ischemic ventricle, is particularly
threatening.
Conclusions
Patients requiring urgent exploratory
sternotomy for life-threatening conditions
such as profound sudden hypotension or
postoperative bleeding experience sub
stantial morbidity in terms of infection
which results in prolonged hospital stay.
The morbidity is higher in those who have
profound hypotension than in those with
excessive bleeding. There is no apprecia

ble difference in morbidity between the
survivors of reopening in the recovery
room or the operating room. Consider
ing the life-threatening nature of the con
dition requiring an emergency ster
notomy, the overall survival rate of 83%
justifies its use. Consideration should be
given to this procedure even if it must be
done at the bedside.
We acknowledge the assistance of Dr. Rama
Nair, Associate Professor, Department of
Epidemiology, University of Ottawa, and of
Mrs. Evelyn Fry for help in preparing the
manuscript.
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W.B. Saunders Company Canada Limited,
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C o rre c tio n

In the March 1986 issue, the article
“ Aneurysmal bone cyst: a review of
26 cases” by K.S. Morton contains an
error. The illustrations for Figs. 7 and
9 have been reversed. We apologize to
Dr. Morton and to our readers for any
confusion generated by this error.
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Dalacin C Phosphate S.S.
(c lin d am yc in phosphate)

A.

Recommtnded Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and microaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when
the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride) has
not been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women.
i
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Khrnlngs: Some cases of severe and persistent diarrhea have been reported during or after therapy with
Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary,
continued only with close observation. Significant diarrhea occurring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration
or pseudomembrane formation, should be managed with fluid, electrolyte, and protein supplementa
tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis
should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 -1 0 or more days, there was a rapid observed
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea
Is should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Priciutions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the
clinical situation.
As w ith all antibiotics, perform culture and sensitivity studies in conjunction w ith drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not
effective means of removing the compound from the blood. Periodic serum levels should be determined
in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local.
(a) Intramuscular Injections: Of 404 patients treated w ith Dalacin C Phosphate (clindamycin phos
phate) intramuscularly (with a solution containing 150 m g /m l), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the
injection site and tw o developed sterile abscesses
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7,3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjunction w ith the use of indwelling I V. catheters and it is difficult to know how much
the drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as
follows:
Number o f Patients
R ash.................................................................................................................................................................. 7
U rtic a ria ........................................................................................................................................................... 1
Pruritus............................................................................................................................................................. 1
Fever, leucocytosis .................................................................................................................................. 1
Nausea, with or w ithout v o m itin g .............................................................................................................. 1
Diarrhea (See also under "W a rn ing s")..................................................................................................... 4
Hypotension ................................................................................................................................................... 1
Hypertension................................................................................................................................................... 1
Shortness of Breath .................................................................................................................................. 1
Superinfection” ............................................................................................................................................... 4
Cardiac arrest"” ............................................................................................................................................ 1
Bad and bitter taste in m o u th .................................................................................................................... 5
* Superinfection is a complication of antibiotic therapy in general and is not necessarily a true
side effect of clindamycin phosphate.
'” Due to underlying myocarditis in this patient.

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratorytests, including complete hematology,
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does not
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been clinical signs of drug-induced hepatic toxicity.
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Symptoms snd Trostmont of Overdosage: No cases of overdosage have been reported. No specific antidote
is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been
given without adverse effects.
DOSAGE AND ADMINISTRATION
Adults
4

Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 m g/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 ,3 or 4 equal doses. Intramuscular injections of more than
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to I V.
administration to a dilution of 300 mg in 50 ml of diluent (6 m g/ml) or more, and infused in not less
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended.
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
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Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each
infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over
20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip
or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution mil infusion rites:
Dose
300 mg
600 mg
900 mg
1200 mg
Alternatively, drug may be administered
by continuous I V. infusion as follows:
To maintain serum
clindamycin levels
Above 4 mcg/ml
10
Above 5 mcg/ml
15
Above 6 mcg/ml
20

Diluent
50 ml
100 ml
150 ml
200 ml

Time
10 min.
20 min.
30 min.
45 min.
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in the form of a single rapid infusion of the first dose followed
Rapid
infusion rate
mg/min. for 30 min.
mg/min. for 30 min.
mg/min. for 30 min.

Maintenance
infusion rate
0.75 mg/min.
1.00 mg/min.
1.25 mg/min.

i *

Children: (Over one month of age)
Intramuscular injection: 10 to 15 m g/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration:
Moderately severe infections: 15 to 25 m g/kg/day by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutes or longer. In severe infections, it is recommended that children begiven no less
than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in thesame
manner as for adults.)
Dilution and Compatibility:
4 ml (600 mg) Dalacin C Phosphate when diluted with 1000 ml of the following commonly used in
fusion solutions was found to be physically compatible and demonstrated no significant change in pH
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
Dextrose 5% in saline
Dextrose 5% in Ringer’s Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 2%% in Lactated Ringer’s Solution (Hartmann's Solution)
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is
not recommended that Dalacin C Phosphate be mixed w ith any infusion solution containing B vitamins.
Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.1C
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Excision of Abdominal Wall Tumours and
Reconstruction With Marlex Mesh
Because metastatic abdominal wall
tumours are rare and their biologic
activity is unpredictable, they must be
managed aggressively (a) for potential
cure of isolated recurrences and (b) to
obtain good palliation, as fetid exophytic
lesions alter the patient’s self-image and
life-style. An aggressive surgical approach
often leaves a large abdominal wall defect.
The authors describe 19 patients (10 men,
9 women) with these tumours who had their
abdominal wall reconstructed with Marlex
mesh. All patients received antibiotics
preoperatively, but 16 had either mechan
ically unprepared bowel due to obstruction
or abdominal contamination from the
intestine intraoperatively. The commonest
complication was wound abscess in 10 pa
tients; it was controlled without removing
the Marlex mesh. The majority of patients
had prolonged palliation with greatly re
duced symptoms, a reasonable quality
of life and acceptable cosmesis. Potentially
life-threatening intra-abdominal complica
tions were reduced. One patient was con
sidered cured. The authors believe that
there is a definite role for aggressive
surgical management of abdominal wall
metastases and that Marlex mesh may
be used for reconstruction even when
there has been peritoneal contamination.

Les tumeurs m§tastatiques de la paroi
abdominale sont rares et leur activite biologique est imprevisible. Elies doivent
done @tre traitees de fapon vigoureuse a)
pour tenter d'obtenir la gu6rison des recidives isolees et b) pour obtenir un bon
resultat palliatif puisque les lesions
exophytiques fetides affectent le respect
de soi et le mode de vie des patients.
Une technique chirurgicale agressive
laisse souvent une large brfeche dans la
paroi abdominale. Les auteurs decrivent
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les cas de 19 patients (10 hommes et 9
femmes) porteurs de telles tumeurs qui
ont eu une reconstruction de la paroi
abdominale 6 I'aide de la fibre Marlex.
Seize n'avaient pas eu de preparation
intestinale a cause d'une obstruction, ou
ils eurent une contamination abdominale
d'origine intestinale durant I'intervention.
Des abces de plaies survenant chez 10
patients repr6sentent la complication la
plus frequente; ils purent etre reduits
sans eniever la fibre Marlex. La majorite
des patients ben&ficia d'un effet palliatif
prolonge avec une diminution marquee
des symptomes, une qualite de vie satisfaisante et des resultats cosmetiques
acceptables. Les complications intraabdominales susceptibles de menacer le
pronostic vital ont £te reduites. Un
patient a ete consider^ gueri. Les auteurs
croient au role d'un traitement chirurgical
vigoureux dans les cas de cancers metastatiques de la paroi abdominale et conside
re d que la fibre Marlex peut etre utilisee
pour la reconstruction meme en presence
de contamination p£ritoneale.

Malignant tumours of the abdominal wall
are uncommon and usually arise as
metastases from primary colorectal
lesions. Soft-tissue tumours such as sar
comas may occasionally invade or arise
from the abdominal wall itself. When
present, abdominal wall tumours may
ulcerate, become infected or bleed, caus
ing unsightly painful lesions with a foul
smelling discharge, often having a
deleterious effect on the patient’s selfimage and life-style. Such lesions require
aggressive surgical treatment that often
leaves a large defect requiring reconstruc
tion o f the abdominal wall.
This report describes the results
obtained in 19 patients with abdominal
wall metastases or recurrences in whom
Marlex mesh was used to reconstruct the
abdominal wall.

bowel resection: right hemicolectomy in
3, left colon or sigmoid resection in 7 and
proctocolectomy in 5. Two rv>' _nts had
large retroperitoneal sarcomas extending
through the abdominal wall, and a third
had a colonic adenocarcinoma invading
abdominal wall at the time o f presenta
tion. The remaining patient had a breast
cancer metastasizing to an oophorectomy
incision.
After resection o f the primary tumour,
patients received adjuvant therapy, when
indicated, comprising a combination o f
chemotherapy, radiotherapy, immune
stimulation or radiofrequency hyperther
mia. All patients subsequently had evi
dence o f an abdominal wall mass. Most
complained o f discomfort or pain, three
having lesions that ulcerated or bled and
one an infected tumour. Concomitant
intra-abdominal disease included ureteric
obstruction (one patient), bleeding
through stoma or rectum (two) and bowel
obstruction (seven).
All patients received antibiotics and if
there was no obstruction mechanical
bowel preparation was given before they
underwent radical en-bloc resection o f the
abdominal wall lesion. Three had excision
T a b le
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Patients and Methods
The patients (10 men, 9 women) in this
study ranged in age from 39 to 78 years
(mean 52 years). All but four had under
gone laparotomy previously for adeno
carcinoma and 15 had had an associated
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of the abdominal wall lesion alone. The
abdominal wall was resected in combina
tion with small bowel in four patients,
with large bowel in one and with both
large and small bowel in three patients.
Six patients underwent resection of invol
ved bowel and bladder, kidney and ure
ter. Two patients required resection of a
segment of abdominal wall, kidney, ure
ter, head of the pancreas, large and small
bowel and a segment of liver. All proce
dures involved removing tumour with ad
jacent skin, subcutaneous tissue, fascia
and any associated intraperitoneal tumour
mass or involved organs. Marlex mesh
was used to reconstruct the abdominal
wall in all patients. A single layer of mesh
was sutured with nonabsorbable mono
filament nylon to fascial or bone edges.
Skin could be mobilized in all cases to
cover the abdominal wall defect.
Results
There was one early death, secondary
to a surgery-related coagulopathy.
Postoperative complications are listed in
Table I. Early complications associated
with the Marlex mesh included wound
infections in 10 patients, 3 of whom had
obstructed bowel at the time of surgery.
Nine o f the 10 had undergone bowel
resection just before the abdominal wall
defect was closed with Marlex. All
infected wounds were treated conserva
tively with debridement and packing. The

Marlex mesh was not removed. Other
septic complications included a sub
cutaneous seroma, a subphrenic abscess
that was drained through a flank incision
leaving the Marlex intact and a colonic
fistula that drained through the Marlex.
This last patient was reoperated on 2
months later to close the fistula, but the
Marlex was not removed. In one patient
who had a pelvic exenteration with
abdominal wall replacement, an ilealconduit cutaneous fistula developed
through the Marlex. The fistula was
managed locally for 6 months when
reoperation through the Marlex was per
formed, removing the conduit and replac
ing it with a wet colostomy. The only fur
ther complication in this patient was a
wound infection, managed by local meas
ures. Early systemic complications were
pulmonary embolism, deep vein throm
bosis and septicemia. The only late com
plication associated with the use of
Marlex was detachment of the mesh from
the symphysis pubis. Conservative
management resulted in healing by granu
lation without herniation or any other
problem. Thirteen of the 19 patients died
from 1 to 20 months after operation
(mean 12 months). Six patients are alive
1 to 20 months after surgery. Several were
able to return to their homes and jobs.
All reported a decrease in the amount of
pain and freedom from foul-smelling
lesions of the abdominal wall.

Discussion
Recurrent tumour in the abdominal
wall is unusual. Surgeons tend to avoid
operation in these patients because of the
questionable prognosis, the magnitude of
resection necessary and a concern about
closing the defect when there is contami
nation from infected tumour or ob
structed bowel. Several groups favouring
an aggressive surgical approach to such
tumours report a favourable 5-year rate
(up to 45% ),1 good tumour control and
prolonged palliation.2 However, a
limited resection of tumour predicates a
high rate of local recurrence,3 and
Ravitch has advocated en-bloc removal of
skin and underlying strictures taking a
wide margin of normal tissue, and ampu
tation of adherent organs.1 A major
problem is repair of the musculofascial
abdominal wall defect. Several methods
have been used in an attempt to recon
struct the normal anatomy. Fascial and
muscular flaps, musculocutaneous flaps,
free fascial grafts and free skin grafts
have all been tried.4 Subsequent hernia
tion or abdominal wall weakness is com
mon, as the nerve and vascular supply
may be damaged during dissection, and
tissues are less than optimal in these fre
quently malnourished or elderly patients.
If subsequent radiotherapy or surgery is
needed for local recurrence after tissue
replacement of the abdominal wall, fur-
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ther problems with strength and viability
arise and so foreign materials have been
used. Metallic meshes have been tried, but
they are heavy, prone to cause infection,
demonstrate a poor healing capacity and
tend to late fragmentation.
Mar lex, a knitted polypropylene mesh
exhibits many of the ideal characteristics
necessary for use in full-thickness
abdominal wall replacement.5,6 With a
uniform molecular structure it has a low
propensity for bacterial trapping and,
thus, a high resistance to infection. It
stimulates little foreign-body reaction.
Marlex has a high tensile strength in two
directions and does not degrade. In situ,
fibroblasts rapidly incorporate into the
mesh spaces and seal off the peritoneal
cavity. Within 6 weeks of insertion a 4to 5-mm layer of fibrous tissue through
the mesh has been measured.7 Healthy
granulation tissue overlying the mesh
allows skin grafting as necessary.
Ledesma and colleagues1 studied 22
patients with abdominal wall recurrences;
14 underwent radical en-bloc resection
of the tumour mass and abdominal
wall reconstruction with Marlex. As in
our group, Marlex was placed even when
the peritoneal cavity was contaminated.
There was no wound dehiscence, suture
line necrosis or small-bowel fistulas
related to the plastic mesh. One patient
had a chronic staphylococcal infection
associated with detachment of the mesh,

and a large hernia. Other groups8 found
no increase in the rate of wound infection
when Marlex was incorporated in the
closure. Antibiotics should be given
prophylactically if contamination is a
concern. When infection occurs, treat
ment with antibiotics and local wound
care usually suffice.
Summary and Conclusions
Our results with en-bloc resection of
abdominal wall tumours and reconstruc
tion of the full-thickness abdominal wall
defect with Marlex are encouraging. Six
of our 19 patients are alive 1 to 24 months
postoperatively (mean survival 12
months). Recently more patients have
undergone resection as we have been
encouraged by our early results. In the
m ajority of patients we achieved
prolonged palliation with freedom from
pain or pressure sensation and potential
intra-abdom inal catastrophes from
obstructed bowel or the urinary system.
Cosmesis was improved as patients no
longer had to deal with foul-smelling,
unsightly abdominal wall tumours. Even
when there was intestinal contamination
the use of Marlex did not lead to serious
septic complications. Local wound infec
tions were managed easily, at home, with
attentive local therapy. Marlex replace
ment did not interfere with subsequent
treatment with radiotherapy or hyperther

For prescribing information

mia and did not preclude reoperation for
intra-abdominal recurrence or bowel
obstruction. Finally, in isolated abdomi
nal wall recurrence major resection may
be curative. Thus, we believe that even in
the face of intestinal contamination, there
is a definite role for aggressive surgical
management of abdominal wall metastases using Marlex mesh for recon
struction.
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Host-Defence Mechanisms in Surgical Patients:
Case Report of Reduced Polymorphonuclear Neutrophil
and Antibody Functions Associated With Surgical Sepsis
The authors evaluated the host-defence
capability of a 33-year-old woman with a
history of poor wound healing, gastroin
testinal fistulas and bacterial and fungal
sepsis after abdominal operations. The
following tests gave normal results:
hemoglobin, blood neutrophil and mono
cyte counts, delayed hypersensitivity
skin test, serum albumin, immunoglobulin
and complement levels, blood T- and Bcell percentages, in-vitro immunoglobulin
synthesis and body cell mass.
The following tests gave abnormal
results: lymphocyte count, leukocyte
adherence, in-vivo and in-vitro polymor
phonuclear neutrophil chemotaxis, neu
trophil bacterial killing and antibody
response to tetanus toxoid. Decreased
polymorphonuclear neutrophil and
humoral immune functions could account
for the woman's history of repeated sur
gical sepsis. Evaluation of host-defence
mechanisms can illuminate the cause of
repeated episodes of sepsis.

Les auteurs ont evalue les defenses
immunitaires d'une femme de 33 ans
ayant des antecedents de cicatrisation de
plaie difficile, de fistules gastrointestinales et de sepsies bacteriennes et
fongiques apres operations abdominales.
Les epreuves suivantes se sont averees
normales: hemoglobine, decomptes des
polynucleaires neutrophiles et des
monocytes sanguins, test cutane
d'hypersensibilite retardee, albumine, taux
d'immunoglobulines et de complement,
pourcentages de lymphocytes B et T,
synthese in vitro des immunoglobulines
et masse cellulaire corporelle.
Des anomalies importantes des tests
suivants ont 6te observees: decompte
leucocytaire, adherence des leucocytes,
chimiotaxie in vivo et in vitro des polymorphonucleaires neutrophiles, bact£ricidie des neutrophiles et reponse anticorps
ci I'anatoxine tetanique. Une diminution
des polymorphonucleaires neutrophiles et
des fonctions immunitaires humorales
peuvent expliquer I'histoire de sepsies
chirurgicales repetees chez cette femme.
L'evaluation des mecanismes de defense
immunitaire peuvent gclairer la cause
d'episodes d'infections a repetition.

divided on the basis of effector cells.
Immune responses mediated by T lym
phocytes are classified as cell-mediated
functions, while those mediated by
specific antibody produced by B lympho
cytes are classed as humoral immune
functions. Antigen-nonspecific hostdefence mechanisms comprise phagocytic
activity, predominantly mediated by poly
morphonuclear neutrophils (PMN), and
complement functions. These distinctions
are arbitrary in that all body processes are
ultimately cellular in origin, and there is
substantial interaction between the vari
ous arms of host-defence mechanisms.
Methods

The following routine laboratory tests
were performed in the clinical labora
tory of the Royal Victoria Hospital in
Montreal: leukocyte count, including
differential counting, measurement of
hemoglobin, total serum protein, serum
albumin, alpha-, beta- and gamma
globulin levels, immunoglobulins G, A
and M, total hemolytic complement
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previously described.3 Mononuclear cells
were cultured under standard conditions,
either unstimulated or stimulated with
pokeweed mitogen (PWM) (a polyclonal
T-cell-dependent B-cell mitogen).
Delayed-type hypersensitivity (DTH)
skin testing was performed using a stan
dard method with five recall antigens:
Candida, mumps skin-test antigen, puri
fied protein derivative, Trichophyton and
streptokinase-streptodornase. The sum of
the mean greatest diameter of induration
at 24 or 48 hours after injection of the five
antigens was defined as the skin-test
score.4 Blood T-cell percentage was
determined using sheep erythrocyte
rosettes treated with 2-aminoethylisothiouronium bromide.5
Polymorphonuclear neutrophil adher
ence to nylon wool was tested by a
modification of the MacGregor tech
nique.6 The results are expressed as the
percentage of total leukocytes that adhere
to the nylon wool column. Polymor
phonuclear neutrophil chemotaxis was
measured in the Nucleopore assay sys
tem.7 The PMN chemotactic migration
is expressed as the number of cells per
high-power field using zymosan-activated
serum as the chemoattractant. The bac
terial killing ability of PMNs was meas
ured by a modification of the technique
of Quie and colleagues.8 Bactericidal
function was assessed at 10, 20 and 40
minutes after mixing of pre-opsonized
Staphylococcus aureus 502A and PMNs,
and expressed as a percentage of bacterial
inoculum killed by the PMNs at each
sampling time.
The body cell mass was determined by
the isotope dilution method.9
Case Report
A 33-year-old woman was referred to us
because she had a long history of surgical sep
sis, gastrointestinal fistulas and delayed wound
healing. On physical examination she was 170
cm tall and weighed 42.3 kg. There were mul
tiple healed abdominal incisions, but no evi
dence of active fistulas or inflammation. The
T a b le

remainder of physical examination gave nor
mal results.
An appendectomy performed when she was
16 years old had taken 6 months to heal. After
salpingo-oophorectomy and hysterectomy at
age 28, multiple skin-grafting procedures were
necessary to achieve wound closure. Three
years later she had similar wound-healing
problems after oophorectomy. No abnorm al
ities had been found except iron-deficiency ane
mia. Subsequently she had a low-output
enterocutaneous fistula. It was treated with
total parenteral nutrition and was complicated
by Candida septicemia. She then presented with
an intra-abdominal abscess requiring surgical
drainage. The postoperative course was com
plicated by several episodes of gram-negative
and Candida septicemia. At subsequent
laparotomy to resect the still-unhealed bowel
fistula, little inflammation and few peritoneal
adhesions were noted. The following year she
presented with peritonitis. Laparotomy demon
strated peritoneal rupture of a pelvic abscess.
The postoperative course was again compli
cated by prolonged wound healing and
abdominal pain. A repeat laparotomy during
the same hospital admission showed only a
small amount of fluid in the peritoneal cavity.
Two months later, a large pelvic mass contain
ing clear watery fluid was drained per rectum.
Coliforms were cultured from this fluid and
from all previous abscesses and fistulas.
Before referral to us she had again presented
with an enterocutaneous fistula and intra
abdominal abscess. Laparotomy was compli
cated by wound abscess and cecal fistula. Speci
mens of bowel obtained at various surgical
procedures consistently failed to show evidence
of inflammatory bowel disease.

T-Cell Function
Although a DTH skin test is usually
classified as a T-cell function test, the
skin-test score in surgical patients clearly
can be used as a global assessment of
antibacterial host-defence capability.4
The DTH skin-test score (45 mm) in our
patient was normal when compared with
those of 25 healthy control subjects (35.7
± 0.5 [mean ± SEM]). Using generally
accepted normal values from the litera
ture (60% to 80%) we found that the

— B -C e ll F u n c t io n
N o rm a l

S e r u m im m u n o g lo b u lin s , g /L *
Ig G

1 5 .6 9

8 .5 4

± 0 .3 8

Ig M

2 .5 3

1 .3 1

±

Ig A

2 .9 3

1 .4 1

± 0 .1 7

Serum IgG and IgA levels, although
higher than average normal data (Table
I), were within the normal clinical labora
tory range (IgG 2 to 12 g/L, IgA 0.50 to
3.50 g/L). The serum IgM level was
mildly elevated. The circulating blood Bcell percentage was within an accepted
normal range. Although the pre-immu
nization antitetanus toxoid antibody level
was normal, consistent with a history of
immunization by booster injection 5 years
previously, the increase in serum antibody
content after immunization was less than
twofold. In a previous study,10 71% of
healthy individuals showed a greater than
10-fold increase and 88% showed a
greater than 2-fold increase in antiteta
nus toxoid antibody content after immu
nization.
The pattern of in-vitro immoglobulin
synthesis was normal (Table I). In
unstimulated cultures, peripheral blood
mononuclear cells produced small
amounts of both IgG and IgM. In PWMstimulated cultures, less imunoglobulin
was produced than by the cells from the
normal donor on the same day, but the
quantity was within a normal range (100
to 2000 ng) and showed a satisfactory
response to PWM stimulation.

0 .1 0

While the circulating blood PMN count
was close to normal, percentage adher
ence to nylon wool was substantially
increased (Table II). In-vivo chemotaxis,
measured as cell delivery to a modified
Rebuck skin window chamber,11 was
depressed compared with'that in other
preoperative surgical patients. Similarly,
in-vitro chemotaxis was notably reduced.
Bactericidal function of PMNs against
the test organism Staphylococcus aureus
502A was reduced at all time intervals
compared with a simultaneously tested,
normal-cell donor.
Preincubation of PMNs with 10'6M
acetylsalicylic acid or 10'9M levamisole12
failed to correct in-vitro chemotaxis. The
possible existence of plasma inhibitors of
chemotaxis was investigated by prein
cubating normal PMNs in patient plasma.
No significant difference was found.

7 -1 7

9

B lo o d B c e lls , %
A n t it e t a n u s to x o id re s p o n s e

B-Cell Function

Polymorphonuclear Neutrophil Function

Results

P a t ie n t

Test

blood T-cell percentage was normal
(79%).

1 .9 fo ld

>

1 0 fo ld 9

Complement and Miscellaneous Tests

(r a tio in c re a s e )
In - v it r o im m u n o g lo b u lin s y n th e s is , n g t
S p o n ta n e o u s :
P W M s t im u la t e d :

Ig G

34

±

5

60

±

12

±

3

45

±

8

Ig M

43

Ig G

475

±

17

860

Ig M

313

±

38

1333

± 32
±

53

" N o r m a l v a lu e s a r e m e a n s ± S E M f r o m p re v io u s s t u d y 4 o f 2 5 h e a lt h y c o n t r o l s u b je c ts .
t N o r m a l v a lu e s a re m e a n s ± S E M f o r t r ip lic a te c u lt u r e w e lls f r o m s im u lta n e o u s ly c u lt u r e d m o n o n u c le a r
c e lls fr o m h e a lt h y c o n tr o l d o n o r.

Tests of complement levels gave nor
mal results (Table III). Moderately severe
lymphocyte depletion and normal cir
culating monocyte counts were obtained.
Despite a low serum albumin level, nutri
tional status, as assessed by determination
of body cell mass using an isotope dilu
tion method, was normal.
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Discussion
There are three determinants of infec
tion: the environment, bacteria and the
host. Despite advances in environmental
m anipulation, such as asepsis and
im proved surgical technique, and
developments in antimicrobial therapy,
postoperative sepsis remains a problem.
Attention has therefore been directed to
the evaluation of host-defence mechan
isms. A hierarchy of tests is now availa
ble for the immunobiologic evaluation of
patients, ranging from those commonly
available in specialized research facilities.
In the work-up of a patient with repeated
episodes of sepsis, these tests can be used
to answer the question, Are there iden
tifiable abnormalities of host-defence
mechanisms that could contribute to an
increased susceptibility to infection?
Immunologic deficiencies are usually
divided into those that are primary, or
congenital, and those that are acquired,
or secondary to another disease process.
The evaluation of the immunocompro
mised patient proceeds from history and
physical examination to laboratory inves
tigation of T and B lymphocyte, PMN
and complement functions.13
Delayed-type hypersensitivity, although
usually considered a test of T-cell func
tion, is clearly a means of globally assess
ing host defence.4 Indeed, a predictive
equation, including the skin-test score,
has recen tly been introduced by
C hristou14 as a means of calculating an
individual patient’s risk of septic-related
death. According to this formula, the risk
of death in our patient was 0.04. Despite

the recurrence of septic complications,
this low risk is in agreement with the con
tinued survival of this patient. Repeated
episodes of sepsis in this woman proba
bly occurred because of isolated defects
in immunity, rather than the global
acquired immunosuppression frequently
seen in surgical patients.
Additional tests of T-cell function are
available: analysis of T-helper and
suppressor-cell subsets with monoclonal
antibodies, dinitrochlorobenzene skin
testing, rejection of skin grafts, thymic
hormone assay and lymphocyte-transformation studies can add information
about the functional state of lympho
cytes. Assays for lymphokine activity are
on the horizon.
In the assessment of B-cell function,
the sine qua non is a normal antibody
response to immunization. Our patient
showed a reduced humoral immune
response to vaccination with tetanus tox
oid. Because the antibody response to
protein antigens, such as tetanus toxoid,
depends on normal T-helper-cell func
tio n , it is unknown whether this
represents T-cell failure or intrinsic B-cell
dysfunction.
The pattern of in-vitro immunoglobu
lin synthesis in this woman was normal.
The results of such mononuclear cell cul
tures reflect a complex set of interactions
between B cells and T-helper and suppres
sor cells. Mononuclear cells from surgi
cal patients with depressed skin-test reac
tivity and increased risk of septic
mortality produce increased amounts of
immunoglobulin spontaneously.3 They
frequently show an absent or reversed

Table II—Polymorphonuclear Neutrophil Function
Test
Blood PMN count, X 109/L
Adherence, %
In-vivo chemotaxis, X 106/mL
In-vitro chemotaxis
(cells/high-power field)!
Bacterial killing, %§
10 min
20 min
40 min

Patient
2.4
72.6
1.18 ± 0.04

3.6 + 0.2*
65.5 + 1.8*
2.04 + 0.46t

12.8 ± 1.5

37.0 + 2.5

Normal

-7
4
25
'Means ± SEM from previous study4 of 25 healthy control subjects.
tMean + SEM of previously collected data11 from surgical patients preoperatively.
4Arithmetic mean ± SEM of determinations on two separate occasions: normal data are
for simultaneously performed assays using normal donor cells.
§Normal data are from control cells run simultaneously with patient cells.
Table III—Complement and Miscellaneous Tests
Patient
Complement C3, g/L
1.04
Total hemolytic complement (CH50), U/mL
Normal
Hemoglobin, g/L
142
Lymphocytes, X 109/L
0.70
Monocytes, X 109/L
0.30
Total protein, g/L
64
Serum albumin, g/L
38
’ Means ± SEM taken from previous study4 of 25 healthy control subjects.
Test
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13
16
39

the average

Normal*
1.05 + 0.25
186 +13
143 + 3
2.06 + 0.13
0.35 + 0.03
74 + 1
44 ± 1

response to stimulation with PWM, a Tcell-dependent, B-cell mitogen, suggest
ing abnormalities in the balance of regula
tory T cells. The data in this subject indi
cate normal function of T-helper cells for
immunoglobulin synthesis and an absence
of PWM-inducible suppressor cells.
Additional tests that could be consi
dered in the evaluation of B-cell function
include bone-marrow exam ination,
lymph-node biopsy, antibody levels to
“ n a tu ra l” antigens and antibody
response to polysaccharide or other rela
tively T-cell-independent antigens.
The PMN is the principal cell in the
defence against bacteria. Alterations in
neutrophil function in surgical patients
have been described and are associated
with an increased risk of sepsis and
death.15 Adherence is a nonspecific test,
frequently increased in a variety of con
ditions. Chemotaxis, an essential PMN
function, is decreased after major
traum a16 and in patients with a reduced
DTH skin-test score.15 In these patients,
levamisole and acetylsalicyclic acid
restored the acquired defect in chemotaxis
to norm al.12 Failure to do so in our
patient suggests that the defect in neu
trophil motility was primary.
Cell delivery to skin abrasions can be
used to study in-vivo chemotaxis.11 The
decreased cell delivery in this patient
could result in failure to localize infection
during the early decisive period,17 with
subsequent tissue invasion. Reduced bac
terial killing, aggravated by low levels of
opsonins due to deficient humoral immu
nity, could account for the increased sus
ceptibility to recurrent sepsis.
Finally, the question of treatment
arises. It is known that malnutrition,
trauma, surgery, burns and malignant
disease13 variably alter host immunity.
Although intuitive, it is not clear at
present that the management of these
conditions restores host-defence mechan
isms. As a general principle, simple resto
ration of normal physiology is likely an
important positive immunomodulator.18
Beyond that, it is not yet clear what role
drugs and biologic agents will play in the
future management of the compromised
host.19 It is clear, however, that the first
step is to understand the problem both in
populations and in the individual patient.
We acknowledge the assistance of Dr. H.
Shizgal in performing the isotope dilution study
of body cell mass, the technical work of D.
Charrete, L. Chiasson and B. Kapadia and the
secretarial assistance of N. Theoret.
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Systemic Candidiasis in a Surgical
Intensive Care Unit
Treatment for syste m ic ca ndidiasis has
often been withheld b ecau se of the
nephrotoxicity of standard am photericin
B therapy, particularly in im m unodepressed patients. The a uthors describe
their experience betw een 1 9 8 1 and
1 9 8 3 w ith 2 9 su ch patients in the inten
sive care unit w h o w ere treated with
low -dose am photericin B. The diagnosis
w a s made w hen endophthalm itis or per
sistent fungem ia w a s present, or when
Candida w a s cultured from three or more
body sites. The daily d ose of am photeri
cin B w a s 0 .3 to 0 .5 mg/kg. Treatment
w a s accom panied by a m ean increase in
the serum creatinine value of 2 6 % in
patients w h o did not un dergo dialysis
before therapy, but this did not lead to
renal failure. The overall death rate w as
7 2 . 4 % . N on-survival appeared to be
associated with an inadequate total
d osage (less than 6 mg/kg); survivors
received a mean total d o se of 5 7 0 mg. A
retrospective analysis of positive
peritoneal cultures failed to support their
previously reported significance.
The authors conclude that, in som e
instances, low -d ose am photericin B will
effectively treat syste m ic candidiasis,
resulting in little renal impairment, and
that the criteria for su c h treatm ent
require re-evaluation.

nephrotoxicite de la therapie conventionnelle a I'am photericine B, particulierement chez le patient im m unodeprim e.
Les auteurs decrivent I'experience q u 'ils
ont conduite entre 1 9 8 1 et 1 9 8 3 chez
2 9 de ces patients aux s o in s intensifs,
utilisant de I'am photericine B a faible
dose. Le diagnostic a ete pose en pre
sen ce d ’une endophthalm ie ou d 'u n fongem ie persistante, ou quand du C an d id a
etait cultive de trois localisations anatom iques ou plus. La d ose quotidienne
d'am photericine B a varie de 0.3 a 0 .5
mg/kg. C hez les patients qui n'avaie nt
pas ete so u m is a une dialyse prealable,
ce traitement a ete accom pagn e d 'u n e
augm entation m oye nn e de la creatininemie de 2 6 % m ais n 'a pas provoque
d 'in su ffisa n ce renale. Le taux global de
mortalite a ete de 7 2 . 4 % . Le deces a
paru relie a une d o se cum ulative totale
insuffisante (de m o in s de 6 mg/kg); les
survivan ts ont recu une d o se totale
m oyenne de 5 7 0 mg. U ne analyse
retrospective des cultures peritoneales
positives n 'a pas reussi a dem ontrer
I'im portance q u 'o n leur a deja pretee.
Les auteurs concluent q u 'e n certaines
circonstances, I'am photericine B a faible
d ose est efficace contre la candidiase
generalisee et ca use peu d 'in su ffisa n ce
renale. Les criteres de traitement se doivent d'etre reevalues.

O n s'a b stie n t frequem m ent de traiter la
candidiase generalisee a c a u se de la
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Systemic candidal infections are now
more frequently recognized as contribut
ing to the death of patients after opera
tion, particularly those with multipleorgan-failure syndromes and systemic
bacterial sepsis.
In the past, treatment was often with
held or delayed because of the nephrotox

icity associated with standard amphoteri
cin B therapy, the dosage schedule for
which was taken from those used in the
treatment of other fungal infections, par
ticularly in immunodepressed patients.1,2
Recently Solomkin and associates3
recommended low-dose amphotericin B
therapy (a total dose of 6 to 8 m g/kg in
daily doses of 0.3 to 0.5 mg/kg) for sys
temic candidal infections, because it could
sterilize positive fungal cultures with lit
tle nephrotoxicity.
This study reviews our experience with
patients in the surgical intensive care unit
of the Toronto General Hospital who
were considered to have systemic candidi
asis and were treated with low-dose
amphotericin B, as recommended by
Solomkin and colleagues.
Patients and Methods
The charts of patients admitted to the
surgical intensive care unit at Toronto
General Hospital from 1981 to 1983 inclu
sive were reviewed to find patients who
had systemic candidiasis, according to
one of the following criteria: evidence of
endophthalmitis; fungemia 24 hours after
intravascular lines were removed; culture
of Candida from three or more body
sites. There were 34 patients of whom 29
received low-dose amphotericin B therapy
(group 1). This consisted of a test dose
of 1 mg followed by daily incremental
5-mg doses up to a maximum daily dose
of 0.3 to 0.5 mg/kg intravenously. All
patients were pre-treated with 50 mg of
Benadryl and 50 to 100 mg hydrocorti
sone intravenously. Sometimes they also
received 50 to 100 mg of Demerol
intramuscularly.
A second group of 27 patients in whom
Candida was cultured from abdominal
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abscesses, peritoneal drainage or from
swabs of the peritoneal cavity at
laparotomy were examined retrospec
tively. Eleven received amphotericin B
when, as noted above, the positive
peritoneal cultures formed a part of the
cri eria for systemic candidiasis. The 16
remaining patients were not given
amphotericin B and formed group 2.
Results
Group 1
Of the 29 patients in this group who
received amphotericin B there were 8 sur
vivors (death rate 72.4%). Comparisons
between survivors and nonsurvivors are
noted in Table I. Fungemia was present
in 45% of patients—50% of the survivors
and 43% of nonsurvivors. Endophthalmi
tis was present in 41% overall—38% of
survivors and 43% of nonsurvivors. Cul
ture of Candida from three or more body
sites (exclusive of stool, mouth, vagina
and blood) was positive in 75% of sur
vivors and in 48% of nonsurvivors.
Malignant disease was present more often
in survivors (25%) than nonsurvivors
(14%). The same was true for associated
bacteremia (63% versus 48%).
The mean time between diagnosing the
candidiasis and instituting therapy was
7.9 days in survivors versus 6.5 days in
nonsurvivors. F our survivors had
documented renal failure before therapy
was started. The other four showed a
mean increase in serum creatinine value
of 22% after completion of therapy. Of
the nonsurvivors, 12 (57%) had pre
treatment renal failure; the remaining 9
had a mean increase in serum creatinine
value of 28%.
All survivors received the recom
mended total dosage of amphotericin B
(more than 6 mg/kg), being given a mean
total dose of 570 mg, but only 38% of
nonsurvivors received the recommended
dosage, with a mean total dose of 356 mg.

Discussion
Diagnosis
The certain clinical diagnosis of sys
temic candidiasis is often difficult.
Besides the growth of Candida from
biopsy specimens, accepted criteria for
diagnosis include endophthalmitis, posi
tive blood cultures 24 hours after removal
of intravascular lines and culture of Can
dida from three or more separate body
sites.3,4 These three criteria formed the
basis for diagnosis of candidiasis and for
treatment with amphotericin B in our
series.
Because of autopsy findings of dissemi
nated candidiasis associated with negative
antemortem blood cultures,5-7 and of
negative optical findings in patients with
fungemia, recent reports3,4 have sup
ported the use of systemic antifungal ther
apy with low-dose amphotericin B based
solely on positive cultures from three
body sites. Although positive cultures
from multiple sites may reflect only mas
sive colonization rather than infection, it
was notable that of the 19 patients who
met this criterion, 11 (58%) also had fun
gemia or endophthalmitis. Moreover, the
death rate of the subgroup who had posi
tive cultures at three sites as the sole indi
cation for treatment was 57% (4 of 7) and
a number of patients with fungemia had
positive cultures at multiple sites before
documentation of Candida in the blood.
These data support contentions in the
recent literature3’4 that isolation of Can
dida from three separate body sites is
presumptive evidence of systemic can
didiasis.
It has been suggested4,8 that the cul
ture of Candida from the peritoneal
cavity should, by itself, be indicative of
systemic candidiasis. Review of our 16
patients who had positive cultures from
peritoneal abscesses, swabs and drainage

Renal Function
Only one patient required dialysis after
initiation of amphotericin B therapy. This
patient, like others, had many reasons for
deteriorating renal function (bacterial sep
sis, aminoglycoside therapy and multiple
episodes of hypotension).
The mean increase in the serum creati
nine value of 22% in survivors and 28%
in nonsurvivors was not considered
important in light of the multiplicity of
nephrotoxic factors present.
It seems clear that what little effect
there was on renal function should not
preclude the use of low-dose amphoteri
cin B therapy in these critically ill patients.
Dialysis is not a contraindication to the
use of amphotericin B; four of our eight
survivors required dialysis before systemic
antifungal therapy was begun and all had
return of adequate renal function. Deteri
oration in renal function is likely a result
of the septic state or other nephrotoxic
drugs and should not discourage the con
tinued use of amphotericin B in low
dosage.
Treatment
Of the factors considered in Table I,

T a b le 1— C o m p aris o n o f S u rv iv o rs and N o n s u rv iv o rs in th e G roup of

Group 2

P a tie n ts T re a te d W ith A m p h o te ric in B

Of the 16 patients with positive
peritoneal cultures who received no
specific antifungal treatment, 10 survived.
None of the 16 patients had evidence of
endophthalmitis or fungemia. Three of
the 10 survivors had cultures positive for
Candida from three different body sites.
On reviewing the case histories of these
patients, there was no evidence of sepsis
(prolonged fever, leukocytosis or a sep
tic hemodynamic profile) to alert the phy
sician to the possibility of systemic can
didiasis. In contrast all of the six
nonsurvivors exhibited a progressive
downhill septic course. Two of them had
cultures positive for Candida from three
body sites. The death rate in this group
was 37.5%.
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showed that the death rate was 37.5% (10
survived without treatment) which is
much lower than one would expect if
positive peritoneal cultures truly reflected
systemic candidiasis.
On the basis of this retrospective analy
sis, we would question culture of Candida
from peritoneal fluid alone is diagnostic
of systemic candidiasis. We contend,
however, that patients with sepsis whose
septic state continues after appropriate
surgical intervention and adequate anti
biotic therapy should be treated with lowdose amphotericin B if they have perito
neal cultures positive for Candida.

S u rv iv o rs
F e a tu re

(n -

M e a n age, y r ± SD

5 0 . 4 ± 1 3 .4

F requency o f m a lig n a n t d is e a s e , no. (% )
A s so ciate d b a c te re m ia , no. (% |
C rite ria fo r t r e a t m e n t, no. (% |
Blood c u ltu re
E n d o p h th a lm itis
P ositive c u ltu re fro m 3 site s
T im e in te rv a l, d ± S D
1 s t c u ltu re to th e ra p y

N onsu rv iv o rs
(n -

21)

5 4 .7 ± 1 6 .2

2 (2 5 )
5 (6 3 )

3 (1 4 )
1 0 (4 8 )

4 (5 0 )
3 (3 8 )
6 (7 5 )

9 (4 3 )
9143)
1 0 (4 8 )

1 2 .4 ± 1 2 .6

C rite ria m e t to th e ra p y
T h e ra p y to d e a th
P re -tre a tm e n t d ia ly s is , no. (% l
In c id en ce o f re n a l fa ilu r e , no (% )
M e a n in c re a s e in s eru m c re a tin in e v a lu e , %
M e a n to ta l dose o f a m p h o te ric in B, m g ± S D *
M e t re c o m m e n d e d dos a g e sch ed u le , no. (% )
'D if fe r e n c e is s ig n ific a n t a t p <

8)

7 .9 ±

8 .8

-

4 (5 0 )
0
22
570 ± 172
8 (1 0 0 )

1 1 .9 ± 1 0 .4
5 .5 ± 6 .5
2 8 .7
1 2 (5 7 )
1 1111
28
356 ± 349
8 (3 8 )

0 .0 5 (unpaired /- t e s t ) .
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age, frequency of malignant disease,
associated bacteremia and pre-treatment
renal failure did not seem to influence sur
vival. Similarly, the reasons for treatment
did not show a preponderance of any one
criterion.
To determine if there was a delay in
starting treatment in the nonsurvivors
(which might distort results), the interval
between meeting the diagnostic criteria
and the start of amphotericin B therapy
was determined. The mean was 7.9 days
in survivors and 5.5 days in the nonsur
vivors. One would expect a delay of 48
hours or more awaiting culture results,
and occasionally indecision in starting
amphotericin B therapy. It should be
remembered that all patients had systemic
bacterial sepsis, which frequently affected
the decision to start amphotericin B. In
both groups the start of treatment was
delayed in a few patients early in the ser
ies owing to reluctance in accepting a
diagnosis of systemic candidiasis on the
basis of three positive culture sites, until
fungemia or endophthalmitis was evident.
Later, initiation of therapy was more
prompt.
The major difference in the two sub
groups was the dosage of amphotericin
B given. Survivors received a mean dose
of 570 mg and all received the recom

->

- *

mended dose of 6 to 8 mg/kg.3'4 In the
group of nonsurvivors the mean dose was
only 356 mg because 13 of the 21 patients
received less than the recommended total
dose.
The clinical importance of inadequate
dosage in nonsurvivors is difficult to
ascertain. No definite cause and effect
relationship can be made as it may be that
patients who died were sicker from causes
other than candidiasis that resulted in
death before the recommended total
treatment dose was reached.
Since this is not a prospective study of
low-dose amphotericin B therapy versus
conventional antifungal regimens, it is
difficult to conclude that the former is as
effective. After analysing these patients
we are encouraged by the following find
ings. Low-dose therapy was effective in
removing Candida from cultures in all
patients who survived. Survival was
associated with a higher mean total dose
(570 versus 356 mg) and with a greater
percentage of patients who received the
recommended total dose (100% versus
38%). Renal function was not clinically
compromised in survivors or nonsur
vivors; the patient requiring dialysis fol
lowing treatment had many reasons for
suffering renal failure.
We recommend that critically ill

patients with systemic candidiasis who
meet the treatment criteria we have out
lined, receive low-dose amphotericin B
therapy. After a 1-mg test dose, daily
increments of 5 to 10 mg should be given,
depending on the severity of sepsis, to a
daily dose 0.5 m g/kg until a cumulative
dose of 6 to 8 m g/kg is reached.
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Chest-Tube Thoracostomy Causing
Homer’s Syndrome
Horner's syndrome developing early after
lung biopsy is reported in a 42-year-old
woman. At the end of the procedure a
thoracostomy tube was inserted with its
tip at the T 1 -2 posterior intercostal
space. The authors conclude that direct
injury to the second order preganglionic
neuron in the vicinity of the stellate gan
glion caused the Horner's syndrome.
They recommend placing the tip of the
thoracostomy tube below the level of the
second rib posteriorly to prevent this
complication.
On decrit le cas d'une femme de 42 ans
chez qui un syndrome de Horner est
apparu peu de temps apres une biopsie
pulmonaire. A la fin de I'intervention, un
tube de thoracostomie avait ete insere
dont le bout passait par I'espace inter
costal posterieur T 1 -2 . Les auteurs concluent qu'une blessure directe au neu
rone preganglionnaire de second ordre a
proximite du ganglion stellaire a cause le
syndrome de Homer. Ils recommandent
de placer le bout du tube de thoracosto
mie posterieurement sous le niveau de la
deuxieme cote, afin de prevenir cette
complication.

H orner’s syndrome of oculosympathetic
paresis (miosis, ptosis, hem ifacial
anhydrosis and apparent enophthalmos)
may result from any lesion that interrupts
the three-neuron sympathetic pathway
from the hypothalamus to the orbit.1 In
the largest series analysing its cause and
localization (216 cases in a general patient
population),2 the preganglionic secondorder neuron was involved in 90% of
cases, usually by malignant tumour.
However, the syndrome is also increasFrom the *Division o f Neurology and
t Division o f Surgery, Ottawa General
Hospital, University o f Ottawa, Ottawa,
Ont.

ingly recognized as a transient or perma
nent iatrogenic event. We report a case
of Horner’s syndrome secondary to
thoracostomy, in which the distal end of
the chest tube lay close to the pleural apex
posteriorly.
Case Report
A previously healthy 42-year-old white
woman was seen at another hospital because
of a sore throat, fever (body temperature 38.5°
C) and cervical lymphadenopathy, followed in
a few days by cough productive of yellow spu
tum and by increasing dyspnea. Broadspectrum antibiotics were prescribed but she
experienced progressive respiratory failure and
3 weeks later was referred to the intensive care
unit of the Ottawa General Hospital. Exami
nation of the chest revealed poor air entry at
both lung bases with scattered crepitations. A
chest film showed extensive alveolar infiltrates.
A lung biopsy was considered necessary
because of her continued deterioration, despite
the use of broad-spectrum antiobiotics.
Through an anterior thoracotomy, wedge
biopsies of the left lingula and lower lobe were
obtained. At the conclusion o f procedure, a
chest tube (32 French Argyle thoracic catheter)
was inserted through the left eighth intercostal
space in the midaxillary line. Twenty-four
hours later left-sided Horner’s syndrome was
noted: there was 3 mm ptosis in the primary
direction of gaze, 2 mm anisocoria and slight
hemifacial anhydrosis (Fig. 1). Instillations of
cocaine (10% solution) and epinephrine
(1/1000 solution) had no effect on the miotic
pupil.3 Visual fields, fundi and extraocular
movements were normal. Other neurologic
findings were normal; in particular, there was
no evidence of brachial plexopathy or
radiculopathy. An anteroposterior chest film
showed the tip of the thoracostomy tube lying
at the T l-2 intercostal space in the left paraver
tebral gutter (Fig. 2). The tube was promptly
repositioned and removed 48 hours later, but
the oculosympathetic paresis persisted. Other
wise the patient made an excellent recovery
from pneumonia due to Mycoplasma (serum
titre 1/640). Follow-up at 7 months revealed
a persisting but slightly improved Horner’s syn
drome.

FIG. 1—Patient’s eyes 7 days after lung
biopsy showing moderate left ptosis and
miosis.

FIG. 2—Anteroposterior chest film show
ing tip of chest tube at T l-2 intercostal space.

Discussion

A ccepted fo r publication Oct. 25, 1985.
Reprint requests to: Dr. Pierre Bourque,
Ottawa General Hospital, 501 Smyth Rd.,
Ottawa, Ont. KIH 8L6
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The list of surgical procedures linked
with the development of Horner’s syn
drome is growing. It includes: lower cer-

FIG. 3—Diagram showing three-neuron
ocular sympathetic pathway. Arrow points to
probable site of injury in our case.
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vical and upper dorsal sympathectomy,
stellate ganglion block, cordotomy,
tumour excision, thyroidectomy, phrenicotomy, percutaneous catheterization of
the carotid artery or internal jugular vein,
caudal anesthesia, obstetric extradural
block and interscalene brachial plexus
block.4 We could find only two previous
reports in the literature linking Horner’s
syndrome to placement of a thora
costomy tube. The first case followed a
left lower lobectomy for chest trauma and
persisted at follow-up 3 months later.4
The second followed a Sugiura procedure
and resolved completely in 3 weeks.5
The pathogenesis probably relates to
the close anatomic relation of the apical
pleura and ocular sympathetic pathway.
The second-order preganglionic neurons
are located in the ciliospinal centre of
Budge and their axons leave the spinal
cord in the C8 and T1 ventral roots (Fig.
3). The fibres then course through the
first thoracic and inferior cervical ganglia
and ascend to the superior cervical gan
glion where they synapse with the thirdorder neurons. Fleishman and col
leagues4 have demonstrated in histologic
sections that only a thin layer of connec
tive tissue, the endothoracic fascia,
separates the parietal pleura from the stel
late ganglion. In our case, one can read

ily envisage the tip of the chest tube
producing repeated, direct-pressure
trauma to the first thoracic ganglion dur
ing breathing movements. It is note
worthy that this complication occurred
within 1 day of tube insertion and per
sisted despite its prompt repositioning.
Unless specifically indicated by the clin
ical situation, we suggest that the chesttube tip should not be placed in close
proximity to the apical pleura. A location
inferior to the second rib posteriorly is the
one least likely to lead to the development
of iatrogenic Horner’s syndrome.

I think that this book should be available for
orthopedic residents and young orthopedists
who will find in it first-hand experience that
they can put to use in their daily practice.
The experienced orthopedist will find up-todate information that provides him with differ
ent management alternatives for those complex
cases in which the standard treatment cannot
easily be applied.
I recommend this text without reservation.
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SESAP V Critique
IT E M S 195-197

Opportunistic infection is a common complication among patients with multiple trauma, and severe debilitating illness
associated with an immunosuppressed state. Many of these patients have been treated with broad-spectrum antibiotics,
altering the natural body flora. Although once considered a skin contaminant, Staphylococcus epidermidis has become
an important pathogen among seriously ill patients and is a frequent cause of central venous catheter sepsis. S. epidermi
dis is resistant to most antistaphylococcal drugs, but is usually sentitive to vancomycin. Fungemia due to Candida albicans
is also observed among critically ill patients and as a central venous catheter contaminant. When invasive candidiasis is
present, the treatment of choice is amphotericin B.
195

C

196

197 [ a ]
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Surgical Treatment of Lung Cancer:
Promise and Problems of Early Diagnosis
Recent studies have shown that the sur
vival of patients with lung cancer is
improved if the tumour is resected
before it becomes larger than 3 cm in
diameter and before it spreads to lymph
nodes. While this suggests a positive
benefit from early detection, recent
mass-screening studies have claimed
that the benefit obtained from this proce
dure is illusory because it relates to a
lead-time bias. This study reports the
results of surgical resection of 143
primary lung cancers. The data con
firmed that the predicted 5-year survival
was greatest (74% ) following resection
of lesions that were less than 3 cm in
diameter without node involvement.
Analysis showed that the age of these
patients was 63 ± 8 years, the same as
in patients with larger tumours and more
extensive node involvement. This sug
gests that tumours progress rapidly from
a stage at which resection is beneficial
to stages at which it is not. Although it
is desirable that tests predict the
presence of small tumours, the high
requirements for sensitivity and specific
ity at current prevalence rates for lung
cancer make this goal impractical.

Des etudes recentes ont revele que la
survie des patients atteints de cancer
pulmonaire s'ameliore quand la tumeur
est resequee avant que son diamfetre
depasse 3 cm et avant qu'il envahisse
les ganglions lymphatiques. Alors que
ceci paraTt indiquer les effets positifs
d'une detection precoce, des etudes

From the Pulmonary Research Laboratory,
the Department o f Pathology, Department
o f Thoracic Surgery and Department of
Medicine, St. Paul’s Hospital, University
o f British Columbia, Vancouver, BC

recentes de depistage systematique ont
conclu que les avantages pretes a cette
intervention sont illusoires car ils decoulent d'un biais lie au delai de diagnostic.
Cette etude decrit les resultats de la
resection chirurgicale dans 143 cas de
cancer primitif du poumon. Les donnees
confirment que la survie h 5 ans est la
meilleure (74% ) apres resection de
tumeurs de moins de 3 cm de diametre
qui n'ont pas encore atteint les ganglions
lymphatiques. L'analyse revele que I'age
moyen de ces patients etait de 63 ± 8
ans, le meme que les porteurs de
tumeurs plus grosses ayant envahi les
ganglions. Ceci indique que les tumeurs
evoluent rapidement d'un stade ou la
resection est salutaire vers un stade ou
elle ne Test pas. Bien qu'il soit souhaitable de predire par des tests la presence
de petites tumeurs, les exigences elevees
en termes de sensibilite et de specificite
compte tenu de la prevalence actuelle du
cancer du poumon rendent ce but peu
realiste.

The purpose of this report is to discuss
the benefit of treating lung cancer when
the lesions are small and have not spread
to regional lymph nodes. The study was
carried out in British Columbia, a
province with a population of 2.6 million
people that reports approximately 1200
new lung carcinomas per year, giving a
crude prevalence rate of 200 per 100 000
people. During the past 5 years our insti
tution, which serves a wide cross-section
of this population, has attempted to
evaluate the benefits of resection. The
report concentrates on the value of resec
tion for lesions of a specific type and
stage. The relation of lung function to the
structure of the nontumorous lung is
reported elsewhere.
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Reprint requests to: Dr. J.L. Wright, Pul
monary Research Laboratory, St. Paul’s
Hospital, 1081 Burrard St., Vancouver, BC
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Patients and Methods

The study was based on 163 patients

who underwent resection for lung carci
noma at our institution between 1978 and
1983. Sixteen of these were lost to follow
up, and 4 more were excluded because
they were found to have small (oat) cell
carcinoma, so this report concerns 143
patients with non-oat-cell bronchogenic
carcinoma.
All patients were asked to answer a
detailed questionnaire that documented
smoking habits, occupational histories
and symptoms. All underwent specialized
pulmonary function testing. The tumour
in the resected specimen was measured
and histologically typed and the spread
to draining lymph nodes was systemati
cally examined.
Type o f Resection
There were 116 lobectomies, 23 pneu
monectomies and 4 wedge resections. A
lobectomy was performed on the right
lung 78 times (54 upper, 22 lower, 2 mid
dle) and on the left lung 38 times (22
upper, 16 lower). Pneumonectomy was
performed 6 times on the right and 17
times on the left.
Pathological Study
The surgeons sampled and labelled the
appropriate nodes in the mediastinum
using the American Thoracic Society
nomenclature.1 The lung specimen was
fixed by inflating with either formalde
hyde or glutaraldehyde through the bron
chial tree and then immersing the speci
men in this fixative, using a special tank
that held the pressure in the airways at 25
cm of fixative. The lungs were examined
after 24 hours of fixation, and the hilar
and intrapulmonary lymph nodes were
dissected, labelled and examined histolog
ically. The lungs were then sliced sagittally so that the tumour could be located,
measured and sampled for histologic
examination.
A histologic type was assigned to each
tumour using the World Health Organi
zation nomenclature.2 There were 75
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squamous cell cancers, 55 adeno- or bronchoalveolar carcinomas, 5 adenosqua
mous carcinomas and 8 large cell carci
nomas.

the predicted 3- and 5-year survivals were
both 62% in stage I cases, 34% and 23%
for stage II and 29% and 0% for stage
III.
The predicted survival for stage I dis
ease was further analysed (Fig. 3); it was
74% for tumours less than 3 cm in
diameter without node involvement.
Patients with larger tumours without
node involvement had a predicted survival
of 57% and the predicted survival in stage
I disease was lowest (43%) when nodes
were involved.
The predicted 5-year survival rates for
patients with squamous cell cancer and
adenocarcinoma in stage I disease were
similar (68% and 60% respectively).
Patients with stage I, large cell cancers
tended to have a lower survival (33% at
3 years) but the number was small.
Although relatively few of our patients
had stage II or stage III disease, the sur
vival rates of these patients were lower
than in those with stage I tumours.

Staging
The tum ours were staged using the
American Thoracic Society1 criteria; 105
tumours were stage I, 18 stage II and 20
stage III. Lymph-node involvement was
found in 7 cases of stage I disease (T1N1)
and 12 cases of stage III.
Statistical Analysis
Survival probabilities were estimated
using the method of Coldman and
El wood.3

Results
Table I shows the distribution of lung
cancer by stage with respect to age and
sex and predicted 5-year survival. Fiftyseven patients were in the 60- to 69-year
age range but 13 were younger than 50
years and 1 was younger than 40. The
overall male to female ratio was 2.8:1 and
varied from 2:1 in the fifth decade to
3.4:1 in the seventh decade.
Table II shows that the 75 squamous
cell carcinomas were divided between 64
men (85%) and 11 women (15%), while
the 55 cases o f adenocarcinoma were seen
in 32 men (58%) and 23 women (42%).
There were no statistically significant
differences in smoking history for
patients who had the major cell types,
although the patients with large cell
tumours may have smoked less.
The predicted survival curve for all 143
patients (Fig. 1) shows that the calculated
probability of survival was 54% at 3 years
and 49% at 5 years. The data for differ
ent stages of the disease (Fig. 2) show that

performed on the right lower lobe (22),
right middle lobe (2) and left lower lobe
(16). Pneumonectomies accounted for 23
(16%) cases (6 right, 17 left).
The overall operative death rate was
4.9%, 8.7% after pneumonectomy and
4.3% after lobectomy. These rates com
pare favourably with those in other
reports where the overall operative death
rate ranged from 2% to 8%,5-10-13 and
pneumonectomy carried an operative risk
of 6% to 12%.10-12
Tumour Types
There were 75 cases of squamous cell
cancer and 55 cases of adenocarcinoma
for a ratio of 1.4:1—not statistically
different (Table II). Women had a greater

Discussion
Several studies4-5 have shown an
increase in the survival of patients with
lung cancer if the tumour is resected when
it is smaller than 3 cm in diameter and
before the disease has spread to the lymph
nodes. However, recent screening
studies6-8 contradicted this, claiming that
the benefit is illusory because it relates to
a lead-time bias.
The results of the present study are con
sistent with those of other reports6-9
showing that lung cancer occurs slightly
more often in the right lung, with the
upper lobes accounting for a high percen
tage of all resections. Our results show
that lobectomy was the predominant
operative procedure (in 116 [81 %] of 143
cases) with 76 lobectomies being per
formed on the upper lobes (54 right, 22
left). The remaining 40 lobectomies were

FIG. 1—Overall survival probabilities for all
143 patients.

Table 1 -S ta g e of Cancer in Relation to P atient Age, Smoking History
and Survival (M ean ± S tandard Error]
No. of
patients

S tage
I-T 1 N 0
T2N 0
T1N 1
II
III

Age, yr

38
60
7
18
20

6 2 .7
6 2 .7
6 3 .3
6 0 .6
6 2 .8

± 8 .3
± 9 .0
± 4 .9
± 1 2 .0
± 9 .5

Smoking history,
cigarette-yr
1087
1412
1277
940
16 81

Predicted 5-yr
survival, %

± 679
+ 1729
± 513
± 574
± 2078

FIG. 2—Influence of stage on survival.

74
57
43
23
0

Table II —M ale to Female Ratio of Histologic Types of Lung Cancer
Tum our ty p e
Squam ous
B ro nchoalveolar
adenocarcinom a
Adenosquam ous
Large cell

M ale,
no. (%)

Fem ale,
no. (%)

Smoking history,
cig arette-yr*

6 4 (8 5)

11 (15)

1204 ± 699

3 2 (58)
4 (8 0 )
3 (3 7 )

2 3 (4 2)
1 (2 0)
5 (6 3 )

947 + 658
1264 + 603
4 3 7 ± 105

'F ig u re s are means ± standard error.
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FIG. 3—Survival curves for subtypes of
stage 1. T1N1 lesions have worst prognosis,
again showing influence of node involvement.
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ratio of adenocarcinoma and large cell
cancer to squamous cell carcinomas than
did men. Belcher,13 the first to recognize
the increasing incidence of adenocarci
nomas, found that the ratio of squamous
carcinoma to adenocarcinoma declined
steadily from 1962 to 1975 but the per
centage of large and small carcinomas
remained fairly constant. An increased
number of adenocarcinomas has also
been reported,4-s’9’12’14,15 although two
studies11,15 have shown a predominance
of squamous cell carcinoma. Vincent and
colleagues16 suggested that the increase
in adenocarcinoma might result from
changing histopathologic criteria, occupa
tional and environmental factors, and an
increasing incidence of carcinoma in
women. This suggestion is supported by
our study in which adenocarcinoma
accounted for 23 of the 40 tumours found
in women (Table II).

FIG. 4—Influence of node involvement on
survival.

Tumour Staging and Survival
Stage I carcinomas comprise three
groups: tumours less than 3 cm in
diameter with no node involvement
(T1N0), tumours greater than 3 cm and
no node involvement (T2N0) and small
tumours with local node involvement
(T1N1). Our data show that the predicted
5-year survival was 74% for T1N0, 57%
for T2N0, and 43% for T1N1 lesions,
with an overall survival of 62% (Figs. 1
and 3). This is consistent with several
other reports,1’11’12'17 showing that the
T1N0 lesions had the best 5-year survival
at 55% to 80%, while for T1N1 lesions
survival ranged from 25% to 50%, and
T2N0 tumours had an intermediate sur
vival ranging from 40% to 60%.
Patients with stage II or III disease
have a much worse prognosis. The
present study shows that the 3-year sur
vival probability of patients with stage II
disease was 34%, which was only slightly
better than the 29% survival of stage III
patients (Fig. 2). These rates are compara
ble to those of other reports of a 3-year
survival of 40%9’17 and a 5-year survival
of approximately 20% to 40% .1,9 Stage
III disease accounted for approximately
30% of resections in one study1 and car
ried a 5-year survival of only 25%.
A major question in assessing these
findings is whether the predicted 5-year
survivals are a result of a lead-time bias
in detecting the tumour. If this were so,
one might expect the T1N0 lesions to be
found in substantially younger people
than the more advanced tumours. The

fact that our data showed no difference
in age between the groups suggests that
the tumour progresses from stage I to
stage III rapidly, so there should be value
in detecting the tumour as early as possi
ble in the T1N0 stage.
The Value o f Early Detection
The bracketed numbers in Table III
show the sensitivity and specificity
requirements for predictive values of
50%, 60%, 70%, 80% and 90% in a
population with a prevalence of lung
cancer of 200 cases per 100 000 people
(i.e., 1200 cases in a population of 2.5
million). W hile these requirem ents
become less as the prevalence goes up they
remain high even in the very highest risk
groups. For example, even with a preva
lence of 4000 per 100 000 (20 times that
for lung cancer in our province), a speci
ficity of 97% is required for a predictive
value of only 50%. This means that mass
screening to detect lung cancer with tests
that lack this level of specificity and sen
sitivity are unlikely to be of value. In
several large mass-screening studies,3-5
cytologic evaluation, a highly specific test,
did not add significantly to radiologic
interpretations in diagnosing lung cancer,
and even in the additional detected cases,
the staging and survival were the same as
in the cases detected by roentgenography
alone. The fact that several centres,
including our own, are now showing
improved survival when tumours are
found and resected at the T1N0 stage
should serve as a spur to find tumours at

Table III—Specificity and Sensitivity Required for Predictive Values of
50% to 90% in Population with Prevalance of Lung Cancer of 2001100 000
„ ...
Sensitivity, %
Specificity, ----------------------------------------------------------------------------------------------------------- - —
50
60
70
80
90
91
92
94
%
85
93
95
50.0
0
0
0
0
0
0
0
0
0
0
0
60.0
0
0
0
0
0
0
0
0
0
0
0
70.0
0
0
0
1
1
1
1
1
1
1
1
80.0
1
1
0
1
1
1
1
1
1
1
1
90.0
1
1
2
2
2
2
2
2
2
2
2
1
1
91.0
2
2
2
2
2
2
2
2
2
1
2
2
93.0
2
2
3
3
3
3
3
3
2
2
4
95.0
3
3
3
3
4
4
4
4
4
97.0
3
4
5
6
5
6
6
6
6
6
11
12
14
99.0
9
15
15
15
16
16
16
16
99.1
10
12
13
15
16
17
17
17
17
17
17
99.3
13
15
17
19
20
21
21
21
21
20
21
99.5
17
19
22
24
27
27
25
27
27
27
27
99.7
29
32
25
35
36
38
38
38
38
39
39
62
64
99.90
55
58
63
65
65
65
65
66
[50]
64
99.91
53
57
61
65
67
67
67
67
68
68
64
70
99.92
56
[60]
67
68
69
70
70
70
70
72
99.93
59
63
67
70
71
72
72
73
73
73
99.94
67
63
73
74
75
75
75
76
76
76
[70]
74
79
79
79
99.95
67
71
76
77
78
78
79
99.96
71
75
78
82
82
82
82
82
81
83
[80]
99.97
77
82
84
80
86
86
86
86
86
85
86
99.98
83
86
86
89
90
90
90
90
89
90
[90]
94
99.99
91
92
93
94
95
95
95
95
95
95
100
100
100
100
100
100
100
100
100
100
100
100
Reproduced in part from: Galen RS, Gambino SR: Beyond Normality: the Predictive Value and Efficiency o f Medical Diagnosis, Wiley, New York, 1975.
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this stage. However, it is clear that these
tests will be useful only if they have high
sensitivity and specificity and are concen
trated on the groups with the highest
prevalence o f the disease.
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Coffee Consumption and Fibrocystic Breasts:
an Unlikely Association
Caffeine and other methylxanthines have
recently come under scrutiny as sub
stances that may cause breast tissue to
undergo fibrocystic changes. The authors
present a retrospective 5-year study of
358 women with fibrocystic breast dis
ease and a 6-month prospective study of
72 women with this condition. Although
methylxanthine consumption was cons
tant, the clinical findings in semiannual
or monthly examinations in both studies
were inconsistent. On the basis of their
results and a review of available studies,
the authors believe there is no scientific
basis for an association between the
consumption of methylxanthines and the
development of fibrocystic breast
disease.
La cafeine et autres methylxanthines ont
recemment fait I'objet d'un examen
minutieux afin de determiner si ces subs
tances pouvaient provoquer des changements fibrokystiques du tissu mammaire.
Les auteurs presentent une etude retros-
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pective sur une periode de 5 ans de 358
femmes souffrant de maladie fibrokystique du sein, ainsi qu'une etude prospec
tive de 6 mois chez 72 femmes atteintes
de cette affection. Bien que la consommation de methylxanthine soit demeuree
constante les examens cliniques biannuels ou mensuels ont revele dans les
deux etudes des resultats contradictoires. A partir de leurs resultats et a la
revue des etudes disponibles, les auteurs
croient qu'il n'existe pas de fondement
scientifique a I'existence d'une associa
tion entre la consommation de
methylxanthines et le developpement de
la maladie fibrokystique du sein.

In the past 20 years, no health warning
has had a more measurable impact on the
coffee-consuming public than the anec
dotal report1 that linked methylxanthine
intake with a condition commonly called
“ fibrocystic breast disease” . Over the last
2 years clinicians have exhibited a grow
ing appreciation of a widespread and
essentially harmless condition,2,3 prevail
ing in a clinically recognizable form in
50% of American women and in a histo
logically detectable form in 90%.2
Previous reports linking coffee con
sumption with myocardial infarcation,4
bladder cancer5 and pancreatic cancer,6
found instant outlet in the lay press, but
they were not followed by a decrease in
coffee consumption. Nevertheless, many
physicians have been surprised at the
readiness with which women have
accepted advice, mainly from ladies’ jour
nals, to reduce caffeine intake from var
ious sources: soft drinks, chocolate and
cookies, certain drugs, tea and coffee.
The results of voluntary abstention from

these sources of methylxanthine have
been equivocal: some women have tem
porarily been free of breast discomfort or
experienced spontaneous disappearance
of nodules, but others have noticed no
changes. The purpose of this report is to
analyse the natural history of fibrocystic
disease in women whose intake of
methylxanthine is constant. The first part
reviews the evolution of changes among
358 women who were considered to have
fibrocystic breasts and were followed-up
every 6 months for 5 years. This study
was completed in 1979, the year Minton’s
report1 on caffeine and benign breast
disease was published. No previous arti
cle had ever suggested an association
between coffee and diseases of the breast.
The second part is a prospective study
carried out in 1982 of 72 women with pal
pable breast cysts. Their caffeine intake
was recorded on a monthly basis and pur
posely kept constant.

Patients and Methods
Study 1
This was a retrospective chart analysis
of 358 patients, examined at a time when
there was no concern about a potential
association between coffee consumption
and breast disease.
From 1974 to 1979, women between 35
and 74 years of age were examined for
benign and malignant breast disease. In
all, 10 000 women, whose physicians had
attested to absence of palpable lesions,
were recruited into the Breast Cancer
Demonstration Project at Duke Medical
Center. The chosen patients were re
examined every 6 months until surgery
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was performed when the diagnosis of
fibrocystic breast disease was confirmed
histologically.
The clinical findings and menstrual sta
tus were abstracted from the charts at
each recorded visit; in some women as
few as 3 and in others as many as 10
follow-up visits were made over the 5-year
period. The records of women with men
strual activity were separated from those
of menopausal women. The average age
at the end of the study of the first group
was 49 years and the second was 59 years.
Findings were classified as follows:
• Always positive: clinical examination
revealed the same or a similar description
of findings in the same quadrant of one
or both breasts throughout the observa
tion period.
• Unidirectional change: patients were
described as having undergone a single or
unidirectional change, that is, from nor
mal to abnormal in the same breast or
vice versa, or from a single lesion to mul
tiple lesions, or from a single node to
diffuse nodularity or vice versa. The
essential criterion was that once these
changes had occurred, they remained
unchanged until surgery.
• Fluctuations: findings changed back

and forth from one examination to the
next, for example, from negative first to
positive and then back to negative, or
from a single mass to multiple masses and
back to a single one or from diffuse
nodularity to a single nodule and then
again back to diffuse nodularity.
The clinicians had an opportunity to
read the reports of the previous exami
nations, confirming or updating earlier
results. Study forms required uniform
reporting on location, size, mobility and
texture of lesions. The women were
instructed not to come for their clinic
visits if they were premenstrual, so it was
unnecessary to relate clinical findings to
the individual’s menstrual cycle.
Study 2
The purpose of the second study was
to evaluate the clinical course of fibrocys
tic breast disease over a 6-month period,
recording the women’s usual methylxanthine intake in an employed population.
In 72 women, fibrocystic breasts were
diagnosed by clinical examination during
a cancer screening program at Cannon
Mills in Kannapolis, NC; the women
agreed to return for monthly follow-up
examination. Mean age was 48 years

Table 1--Study 1. Clinical Findings Over 5 Years in 153 Premenopausal
and 205 Menopausal Women With Fibrocystic Breasts
Findings
Always positive
Unidirectional change
Fluctuations

Premenopausal,
no. (%)

Menopausal,
no. (%)

44 (29)
46 (30)
63 (41)

3 6 (1 8 )
64 (31)
105 (51)

Table II—Study 2. Clinical Findings Over 6 Months in 72 Women With
Fibrocystic Breasts*

Findings
Cysts
Cysts
Cysts
Cysts
Cysts

present at baseline
disappeared
disappeared then reappeared
changed in number only
changed in position and number

Left breast,
no. (%)

Right breast,
no. (%)

50 (69)
9 (1 3 )
20 (28)
32 (44)
65 (90)

58 (81)
12(17 )
28 (39)
19(26)
60 (83)

Both
breasts,
no. (%)
108
21
48
51
125

(75)
(15)
(33)
(35)
(87)

'Reprinted, in part, by permission from Heyden S, Muhlbarer LH: Prospective study of "fibrocystic
breast disease" and caffeine consumption. Surgery 1984; 96: 4 7 9 -4 8 3 .
Table Ill-S tu d y 2. Daily Methylxanthine Consumption (mg) in 72
Women With Fibrocystic Breasts* t
Source

First month,
mean ± SE
± 18.77
± 8.56
± 4.31
± 1.68
± 0.07
± 0.13

Coffee
Tea
Soft drinks
Drugs
Candies
Food

121.35
64.48
29.02
3.84
0.23
0.08

Totals!

230.06 ± 19.51

Last month,
mean ± SE

Maximum

± 19.73
± 6.88
± 4.73
± 1.34
± 0.05
± 0.05

915.0
36.0
157.7
64.0
3.3
7.3

225.80 ± 22.25

960.0

145.17
44.96
28.48
2.91
0.20
0.18

‘ Reprinted, in part, by permission from Heyden S, Muhlbarer LH: Prospective study of "fibrocystic
breast disease" and caffeine consumption. Surgery 1984; 96: 4 7 9 -4 8 3 .
tThe result of self-reported intake of methylxanthines.
tAverage individual methylxanthine consumption (total from all sources). Overall methylxanthine con
sumption decreased by only 4.3 mg/d between the first and the last examination (NS).

(range from 24 to 65 years). The examiner
who performed the breast examination
was unaware of previous findings. For
each nodule, the position, size, texture
and mobility were recorded. A question
naire on methylxanthine consumption
from beverages (15 questions), foods (9
questions) and caffeine-containing drugs
(6 questions) was completed at each visit.
Data collected included method of prepa
ration, serving size and frequency of con
sumption. Methylxanthine content was
obtained from several sources.7,8
The number of nodules that disap
peared was considered separately from
those that disappeared but recurred over
the 6 months. Cysts were counted and the
numerical change during the observation
period was recorded. With the clock-face
image as a guide and division of the breast
into 12 sections (hours), “ no change” in
the position of a given nodule was
assumed when its location was recorded
either in the same position or ± 1 hour
from the location previously noted.

Results
Study 1
The most important observation was
that 41% of the premenopausal women
and 51% of the menopausal women
showed fluctuations (Table I). When
unidirectional changes are combined with
these fluctuations, a clear picture of the
“ waxing and waning” condition emerges.
Only 29% of women in the premeno
pausal and 18% in the menopausal group
had findings similar from one examina
tion to the next during the study.
Overall, 31% had changes recorded as
“ unidirectional” either improving or
worsening over the 5-year period, and
47% had fluctuating changes. These find
ings suggest that more than 70% of
women w ith histologically proven
fibrocystic breast disease show change
with breast examinations 6 to 12 months
apart. Stable clinical findings in fibrocys
tic breasts over a long period appear to
be the exception rather than the rule, at
least in this retrospective study. It is
highly unlikely that these women made
any major change in methylxanthine
intake during the study period.
Study 2
This study attempted to achieve more
precise measurements of change than
those recorded retrospectively, by using
the clock-face diagram to locate breast
nodules.
During the study period, 90% of left
breasts and 83% of right breasts showed
changes in position or number of nodules
(Table II). All nodules disappeared from
13% of the right breasts and from 17%
of the left. In 28% of left breasts and
39% of right breasts, the nodules disap-
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peared only to reappear during the 6
months. The total methylxanthine intake
did not change significantly, although
caffeine consum ption from coffee
increased by 24 m g/d between the first
and last examination (Table III).
Discussion
The results of these two studies offer
no support for the claim that caffeine is
associated with benign breast disease.
Clinically, the important point in the
prospective study was the spontaneous
disappearance of breast nodules without
any relation to the methylxanthine con
sumption. Equally relevant was the obser
vation that breasts examined did not
undergo nodular changes over the 6
months. Another indicator is the number
of cysts counted from one examination
to the next and changes in their position.
All these measurements demonstrate a
high degree of unreliability of clinical
findings over such a brief observation
period.
For the purpose of the second study it
was important that the methylxanthine
intake of the study population did not
change. The change in total consumption
between the first and last examination was
a decrease of only 4.3 mg/d.
Thus, for a condition in which stabil
ity of clinical findings is the exception, it
would be difficult to associate certain
habits (i.e., methylxanthine consumption
or abstention from it) with the presence
or absence of benign breast disease. A
number of women might, by chance, have
b reast lesions while consum ing
methylxanthines or no lesions while
abstaining from them.
Review o f Literature

dition, precludes any conclusion that
there is a causal association between giv
ing up the Ijabit and becoming asympto
matic.
Following these publications,1'9 five
studies10-14 were reported, by other inves
tigators, on the same subject.
One10 reported on 72 women with
fibrocystic breast disease on a
methylxanthine-free diet and 68 patients
who did not change their dietary habits.
Among a subsample from whom breast
fluid specimens were obtained, no rela
tion was found between changes in breastfluid caffeine levels and improvement of
fibrocystic breast disease. “ Absolute
changes in clinically palpable breast find
ings in the abstaining group were minor.”
In addition, “ comparison of before-after
mammograms offered little support for
the methylxanthine hypothesis” .
The second study11 was of 323 women
with palpable benign lesions of the breast
and 1458 women free of palpable nod
ules. No difference in coffee and tea con
sumption between the two groups was
noted. “These findings do not support the
recent suggestion of Minton et al that
methylxanthine ingestion is causally
related to benign breast disease or breast
cancer.”
Methylxanthine consumption among
210 women with fibrocystic breast lesions
and 241 breast cancer patients was the
object of a third investigation.12 In com
paring the patients’ daily intake with that
of controls, the authors found no signifi
cant differences in the consumption of
coffee or tea. For both benign and malig
nant breast disease, the risk was slightly
higher for those who drank one to three
cups per day than for those who drank
seven or more.
In a case-control study13 o f 854
women in whom benign breast disease
was diagnosed histologically, 755
matched surgical controls and 723
matched neighbourhood controls, no
association was noted between coffee
consumption and benign breast disease.
The estimated mean intake of methylxan
thines was similar: 302, 312 and 313 mg
for cases, surgical controls and neigh
bourhood controls, respectively. No evi
dence of a dose response was noted.
In contrast, only one hospital-based
case-control study14 showed a positive
association with coffee consumption. In
634 women with fibrocystic breast disease
and 1066 control women, the authors
reported as unclear why an association
between symptoms and caffeine con
sumption was found only among the con
trols; “ we, of course do not know which
controls may have undiagnosed fibrocys
tic disease” .
Because of the uncertainty expressed by
the authors concerning the status of the
control women, their results are of doubt
ful value, especially in view of the

widespread prevalence of fibrocystic
breast changes which, according to
autopsy reports, involve 90% of women
in our society. On the basis of the reports
mentioned, the Council on Scientific
Affairs of the American Medical Associ
ation concluded: “ There is currently no
scientific basis for associating methylxan
thine consumption with fibrocystic dis
ease of the breast. Indeed, it has been sug
gested that lumpy, fibrous breast tissue
in women is normal and represents a
response to physiological hormonal var
iation.” 15
Minton has taken his hypothesis one
step further on the assumption that
“ breast cancer occurs in patients with
fibrocystic breast disease four to six times
more often than in women with normal
breasts” . In an animal experiment, he and
his colleagues16 showed that caffeine and
a fat diet enhanced the development of
mammary tumours in the DMBA-treated
rats. Indirect support for this new
hypothesis is claimed from epidemiologic
studies supposed to have shown indepen
dently a correlation with breast cancer in
countries where there is documented high
caffeine and high fat consumption. “ Our
analyses of their independent reports
show that the countries reporting the
highest incidence of breast and other
cancers are countries where both high fat
diets and high caffeine consumption have
occurred simultaneously.” 16
One must separate the issues addressed
in this statement on coffee consumption.
The basic premise that the risk of breast
cancer is increased four to six times in
women with fibrocystic breasts is no
longer tenable. A recent editorial3 found
it high time to empty the “ fibrocystic dis
ease” waste basket and thereby mitigate
the anxiety of a large number of women
who no longer need to be concerned
about the risk of breast cancer. After sur
gical excision of noncancerous breast tis
sue, approximately 70% of women with
fibrocystic breasts could not be consi
dered at high risk. Only about 4% would
be identified as high-risk persons. But, as
H utter3 reminds us, histopathologic
findings do not tell the whole story. A
more meaningful picture is revealed by
combining histologic findings with age
and family history of breast cancer.
Women over 55 years of age with non
proliferative lesions have a reduced risk
(0.3 times), while those with proliferative
lesions have a higher risk (2.2 times).
Women with cysts are not at increased
risk unless they have a positive family his
tory of breast cancer, in which case their
risk rises threefold.
Before one can associate the develop
ment of breast cancer with “ high coffee
and high fat” consumption, one has to
account for the missing link, the nonex
isting causal association between coffee
intake and benign breast conditions. Is it

Patients with fibrocystic breast disease
are advised to abstain from coffee, cola
drinks, tea and chocolate.1 This recom
mendation is based on a preliminary
study of 47 women with fibrocystic
breasts: 13 of 20 who stopped consum
ing beverages containing methylxanthines
experienced complete disappearance of all
palpable breast nodules within 1 to 6
months. No long-term follow-up of this
group has been reported.
Later, the same group9 found that in
37 women with fibrocystic breast disease,
the condition resolved when they stopped
using
m ethylxanthine-containing
products.
From our findings in the retrospective
study, it could be expected that 70% of
prem enopausal or even 80% of
menopausal women would show “ wax
ing and waning” of their condition and,
of these, a considerable number by
chance might have negative clinical find
ings after initial positive ones. The nature
of “ waxing and waning” , which is the
predominant feature of this chronic con210
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reasonable to associate a very common
habit (coffee drinking) with such a
widespread disorder when there is no bio
logically plausible connection between the
two and when experimental evidence is
lacking?
A dietary case-control study17 o f 818
breast-cancer patients com pared
methylxanthine intake from all sources
with matched surgical and neighbour
hood controls. In addition, analysis was
done in relation to fat consumption.
Neither methylxanthine consumption nor
the amount or quality of fat showed any
association with breast cancer.
A study18 o f 2651 women with newly
diagnosed breast cancer failed to disclose
any association between breast cancer and
coffee consumption when data were com
pared with those from noncancerous con
trol women.
As others have previously disproved in
pancreatic cancer,19 bladder cancer20 and
renal cancer,21 we conclude that in breast
cancer coffee is not a carcinogen.
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Contraindications
Known hypersensitivity to trimethoprim or sulfonamides;
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nylurea hypoglycemics, phenylbutazone, oxyphenbutazone,
indomethacln, sulfinpyrazone and salicylates.
Adverse Reactions
Hematological: primarily, neutropenia and throm bo
cytopenia; less frequently, leukopenia, aplastic or hemolytic
anemia, purpura, agranulocytosis, and bone marrow depres
sion. Occur particularly in the elderly and are m ostly asymp
tomatic and reversible on withdrawal.
Most frequent: nausea, vomiting, gastric intolerance, rash.
Less frequent: diarrhea, constipation, flatulence, anorexia,
pyrosis, gastritis, gastroenteritis, urticaria, headache, and
elevated alkaline phosphatase and serum transaminase.
Occasional: erythema, edema, pruritis, toxicoderma, photo
sensitivity, glossitis, stomatitis, dyspepsia, dry mouth,
dysuria, oliguria, anuria, hematuria, urgency, dyspnea, tremour, vertigo, tiredness, jaundice, vision troubles, drug fever,
alopecia, epistaxis, black tongue, elevated BUN, NPN, serum
creatinine or urinary protein and anaphylactoid reactions.
Rare: goiter, diuresis and hypoglycemia have occurred with
sulfonamides.
Dosage and Administration
INTRAVENOUS
Parenteral therapy is indicated if patient cannot take oral
medication or if high serum concentrations are required
rapidly.
PARENTERAL TREATMENT SHOULD BE TERMINATED AND
ORAL TREATMENT INSTITUTED AS SOON AS POSSIBLE.
CAUTION - 'BACTRIM' FOR INFUSION MUST BE DILUTED IN
STERILE D5W, RINGER'S OR NaCI 0.9% SOLUTION PRIOR
TO ADMINISTRATION. DIRECT INTRAVENOUS INJECTION
NOT RECOMMENDED. DO NOT MIX WITH OTHER DRUGS OR
SOLUTIONS. For method of dilution and infusion administra
tion, see Package Insert.
Pneumocystis carinii pneumonitis:
Children and adults: 5 mg trim ethoprim/kg + 20 mg
sulfamethoxazole/kg q.i.d. until oral therapy can be
instituted.
Serious systemic infections:
Adults: 16 0to240 m g trim e th oprim + 800to 1200 mg sulfa
methoxazole (10-15ml ‘Bactrim 1for Infusion)every 6 , 8 o r 12
hours, depending on severity of infection.
Children: 5 to 10 mg trim ethoprim /kg/day + 25 to 50 mg
sulfamethoxazole/kg/day in 2-4 equally divided doses.

BOOK REVIEWS
continued fro m page 203

devoted to surgery of the alimentary tract, the
major part of the general surgeon’s practice.
Other sections include the urogenital tract and
transplantation (80 pages); heart, lungs and
blood vessels (88 pages) and the endocrine sys
tem (43 pages). Interestingly, breast, head and
neck diseases are discussed in the section on
tumours of those areas (26 pages) and trauma
and surgical technique are addressed in a com
bined section (107 pages), almost reminiscent
of a “ miscellaneous” section. The book ends
with a 71-page section on patient care, which
1 would have preferred at the beginning.
As a practising general surgeon with a spe
cial interest in emergency surgery, I identified
particularly with the sections covering the
alimentary tract, trauma and patient care. In
the first, two very complete chapters are
devoted to the acute abdomen, offering many
useful approaches and recommendations, and
another deals exclusively with incisions and
drains. The rest of the alimentary tract section
is covered in an anatomical order. A chapter
on pediatric and neonatal surgery is included.
1 found a section on surgery in tropical coun
tries most helpful in view of the recent influx
of immigrants from Central America and the
Far East.
The section on trauma avoided an inventory
of organ injuries and instead concentrated,
appropriately, on the assessment of the criti
cally injured patient. It provides excellent
guidelines on how to organize emergency
department action and assess and treat head
continued on page 217
PATIENTS WITH IMPAIRED RENAL FUNCTION
Not recommended if creabnine clearance (CICr) less than
15 m l/m in . A t CICr 15-30m l/m in : 1/2 usual regimen. At CICr
above 30 m l/m in : usual regimen.
Supply
Adult tablets: 80 mg trim ethoprim and 400 mg sulfa
methoxazole. Bottles of 100 and 500. Unit dose: boxes of 100.
DS tablets: 160 mg trim ethoprim and 800 mg sulfam ethox
azole. Bottles of 100 and 250. Pediatric tablets: 20 mg
trim ethoprim and 100 mg sulfamethoxazole. Bottles of 100.
Suspension: Cherry-flavoured, 40 mg trim ethoprim and
200 mg sulfamethoxazole, per 5 m l. Bottles of 2 0 ,1 0 0 and
400 m l. Solution for Infusion: Each ml contains 80 mg
sulfamethoxazole and 16 mg trim ethoprim, for infusion with
D5W, Ringer's or NaCI 0.9% solution. Packs o f 10 x 5 m l
vials, single 30 m l vials and 10 x 5 ml ampoules.
Product Monograph available on request.
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novantrone
Mitoxantrone Hydrochloride Injection
For Intravenous Infusion Only
ANTINEOPLASTIC
CAUTION
NOVANTRONE' IS A POTENT DRUG AND SHOULD BE USED ONLY BY PHYSI
CIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE
WARNINGS AND PRECAUTIONS). BLOOD COUNTS SHOULD BE TAKEN AT FRE
QUENT INTERVALS PRIOR, DURING AND POST THERAPY. CARDIAC MONITOR
ING IS ADVISED IN THOSE PATIENTS WHO HAVE RECEIVED PRIOR ANTHRACYCLINES, PRIOR MEDIASTINAL RADIOTHERAPY OR WITH PRE-EXISTING
CARDIAC DISEASE.
PHARMACOLOGICAL ACTION
Although its mechanism of action has not been determined, mitoxantrone is a DNAreactive agent. It induces nuclear aberrations with chromosome scattering in cell
cultures (human colon carcinoma line) and is a potent inhibitor of RNA and DNA
synthesis. Compared on an equimolar basis, mitoxantrone is seven times more
potent than doxorubicin in inhibiting the uptake of 3H-uridine and four times more
potent in inhibiting the uptake of 3H-thymidine by mouse lymphoma L5178Y cells in
vitro.
INDICATIONS
NOVANTRONE' is indicated for chemotherapy in patients with carcinoma of the
breast, including locally advanced and metastic disease. Also for relapsed adult
leukemia and lymphoma patients with hepatoma.
CONTRAINDICATIONS
NOVANTRONE* is contraindicated in patients who have demonstrated prior hyper
sensitivity to anthracyclines.
WARNINGS
Since NOVANTRONE* produces myelosuppression [see ADVERSE EFFECTS], it
should be used with caution in patients in poor general condition or with pre-existing
myelosuppression.
Cases of functional cardiac changes, including congestive heart failure and
decreases in left ventricular ejection fraction have been reported. These cardiac
events have occurred almost exclusively in patients who have had prior treatment
with anthracyclines, prior mediastinal radiotherapy or with pre-existing heart disease.
Cardiac monitoring is advisable in such patients. It is suggested that cardiac monitor
ing also be performed in other patients during therapy exceeding 160 mg/m2
(approximately 12 courses) of NOVANTRONE*, as experience during prolonged
treatment is limited.
NOVANTRONE* may impart a blue-green colouration to the urine for 24 hours
after administration, and patients should be advised to expect this during active
therapy. A reversible blue coloration in the sclerae has been reported in two cases.
Safe use of NOVANTRONE* in pregnancy has not been established. No information
is available concerning the presence of NOVANTRONE* in the milk of nursing
mothers. Safety for intrathecal use of NOVANTRONE* has not yet been established
PRECAUTIONS
Full blood counts should be undertaken serially during a course of treatment. Dosage
adjustments may be necessary based on these counts [see DOSAGE section].
It is recommended that NOVANTRONE’ not be mixed in the same infusion with
other drugs. [See DRUG COMPATIBILITY section],
ADVERSE EFFECTS
NOVANTRONE * is clinically well tolerated, demonstrating a low overall incidence of
adverse events, particularly those of a severe, irreversible or life-threatening nature.
Some degree of leucopenia is to be expected following recommended doses of
NOVANTRONE*. With dosing every 21 days, suppression of WBC counts below
1000/mm3 is infrequent; leucopenia is usually transient, reaching its nadir at about 10
days after dosing, with recovery usually occurring by the 21st day. Thrombocytope
nia can occur, and anaemia occurs less frequently. Myelosuppression may be more
severe and prolonged in patients having had extensive prior chemotherapy or radio
therapy or in debilitated patients.
The most commonly encountered side effects are nausea and vomiting, although
in the majority of cases these are mild (WHO Grade 1) and transient. Alopecia may
occur, but is most frequently of minimal severity and reversible on cessation of
therapy.
Other side effects which have occasionally been reported include allergic reactions
(one with anaphylaxis), abdominal pain, amenorrhoea, anorexia, constipation,
diarrhoea, dyspnoea, fatigue, weakness, fever, gastrointestinal bleeding, stomatitis/
mucositis, and non-specific neurological side effects. Tissue necrosis following
extravasation has been reported rarely.
Changes in laboratory test values have been observed infrequently e g
increased liver enzyme levels, elevated serum creatinine and blood urea nitrogen
levels (with occasional reports of severe impairment of hepatic function in patients
with leukemia).
Cardiovascular effects, which have only occasionally been of clinical significance,
include decreased left ventricular ejection fraction (determined by ECHO or MUGA
scan), EKG changes and acute arrhythmia. Congestive heart failure has been
reported. Such cases generally responded well to treatment with digitalis and/or
diuretics. In patients with leukemia there is an increase in the frequency of cardiac
events, the direct role of NOVANTRONE* in these cases is difficult to assess, since
most patients had received prior therapy with anthracyclines and since their course is
frequently complicated by anemia, fever, sepsis, and intravenous fluid therapy.
In leukemia patients treated with a single course of 12 mg/m2 1.V. daily x 5 days, the
following drug-related toxicities occured: moderate or severe jaundice or hepatitis in
8% , moderate nausea or vomitting in 8%, moderate or severe stomatitis/mucositis in
9-29%, diarrhea in 9-13%, and moderate or severe alopecia in 11%,
CLINICAL RESULTS
Introduction
Clinical trials experience has established the dosage range, efficacy and safety pro
file of NOVANTRONE.
A single dose can be given intermittently every three or four weeks. The recom
mended initial treatment dose in good risk patients is 14 mg/m2.
Efficacy
Breast
Efficacy data are available on 349 patients with locally advanced or metastatic breast
carcinoma. Results are dependent on many predisposing factors including prior
chemotherapy and/or radiotherapy, the health of the patients, sites of metastases,

and dose of the agent employed. In a European multi-centre first-line single-agent trial
using an initial dose of 14 mg/m2, the overall response rate was 39% which com
pared favourably to doxorubicin therapy at a dose of 60-75 mg/m2 when given to
patients with similar stage disease. In an ongoing study of a direct comparison with
doxorubicin, given as second-line therapy to breast cancer patients who failed a
standard first-line combination, response rates are 27 % for NOVANTRONE and 23%
for doxorubicin. The mean duration of response observed after NOVANTRONE was
greater than those reported after doxorubicin. Responses have been seen in all major
sites of metastases including lymph nodes, lung, bone, skin and viscera, in patients
both with and without prior hormonal therapy. Available data suggest that
NOVANTRONE is comparable in efficacy with doxorubicin in the treatment of
advanced breast cancer. Myelosuppression with 21-day treatment intervals is com
parable with that observed with doxorubicin. Multiple courses of single-agent
NOVANTRONE therapy, in some cases for longer than twelve cycles have been
administered with excellent tolerance and a good response. NOVANTRONE showed
incomplete cross-resistance with doxorubicin since responses have been observed
in patients in whom doxorubicin had failed or who relapsed after response to that
drug. A continuing large-scale clinical trials program with combination therapy also
demonstrated early positive results for efficacy and safety. In seven studies over 100
cycles of combination therapy have been given to 77 patients.
Additional Indications
A total of 966 patients have been treated with NOVANTRONE * for three other indica
tions of which 259 patients had non-Hodgkin's lymphona (NHL). 546 had leukemia,
and 161 had hepatocellular carninoma (HOC). The following summarizes the accrual
of these 966 patients:

Indication
NHL
Leukemia
(including pediatric cases)
HOC

Lederle-Sponsored
Studies
(No. Treated)
186
282

Independent Studies
Reported in the
Literature
(No. Treated)
73
264

75
JS 6
543
423
N O N -H O D G K IN ’S LYMPHOMA. Three key studies evaluated single agent
NOVANTRONE * in 148 patients with relapsed or refractory advanced NHL at a dose
of 14 mg/m2, IV, every 3 weeks. Of 127 patients evaluable for response in two trials,
there were 10 complete responses (CR) and 42 partial responses (PR) producing an
overall therapeutic response rate of 41%. The median duration of responses in the
multicenter study (122 evaluable patients) was 195 days. Many patients’ responses
lasted in excess of one year. Responses were seen in all histological subtypes of
NHL. Response to NOVANTRONE* was independent of prior chemotherapy and
independent of whether the patient received prior doxorubicin. This demonstrated a
lack of complete cross-resistance between NOVANTRONE * and other drugs includ
ing anthracyclines.
NOVANTRONE* was evaluated in combination with other agents for the treatment
of NHL. A total of 28 patients were treated with different regimens. A first-line compar
ative trial of the combination of intermediate dose METHOTREXATE with LEUCOVORIN rescue + bleomycin + doxorubicin + cyclophosphamide + vincristine +
dexam ethasone (m-BACOD) versus the same com bination with 10 m g/m 2
NOVANTRONE* replacing doxorubicin (m-BNCOD) has shown activity: 4 PRs in 6
evaluable patients with m-BNCOD and 3 PRs in 6 with m-BACOD. The combination
of NOVANTRONE* at 10 mg/m2, daily for 3 days, + vincristine + dexamethasone
(NOD) produced 3 PRs in 5 evaluable patients. A first-line comparative trial of the
combination of cyclophosphamide + vincristine + prednisone + doxorubicin
(CHOP) versus the same combinations with 10 mg/m2 NOVANTRONE* replacing
doxorubicin (CNOP) has only recently begun.
NOVANTRONE* at 5 mg/m2, daily for 3 days every 3 weeks produced oneCR and
2 PRs in 8 evaluable patients with NHL; ten patients were enrolled. Several other
studies reported in the literature and not sponsored by Lederle support the activity of
NOVANTRONE* in the treatment of NHL.
LEUKEMIA. Four key studies sponsored by Lederle evaluated single agent
NOVANTRONE* in 181 adult patients with refractory or relapsed acute nonlymphocytic leukemia (ANLL) or chronic myelogenous leukemia in blast crisis (BCML) at doses ranging from 8 to 12 mg/m2, IV, daily for 5 days, every 3 weeks. A dose
response effect was evident. Optimal activity was seen at a dose of 12 mg/m2, daily for
5 days. At this dose level, there were 19 CRs in 49 evaluable adult patients with ANLL
in relapse producing an overall response rate of 39%. The median duration of com
plete response in the largest (121 patients) single agent study was 98 days. Several
patients had remissions lasting in excess of one year. There were four studies com
prising 63 patients in which NOVANTRONE* was evaluated in combination with
other agents in the treatment of leukemia. The highest complete remission rate of
49 % (11 CRs in 23 eva lu a b le pa tients w ith A N L L ) was o b ta in e d when
NOVANTRONE* at 10 to 12 mg/m2, daily for 3 days, was combined with cytosine
arabinoside at 100 mg/m2 daily for 7 days. When NOVANTRONE * at 10 mg/m2, daily
for 5 days was combined with the same dose of cytosine arabinoside, it produced 2
CRs in 8 evaluable patients. Treatment of patients with acute lymphoblastic leukemia
using 10 mg/m2 NOVANTRONE*, daily for 3 days, + vincristine + prednisone
produced 10 responses in 16 evaluable patients, for a response rate of 62.5%.
Activity was also seen in B-CML. Since no standard therapy exists for this disease
and bone marrow is never truly normal in this disorder, both CRs and PRs were
considered evidence of efficacity. The optimal dose of NOVANTRONE* was 12
mg/m2, daily for 5 days, producing 6 responses in 17 evaluable patients.
Experience in pediatric leukemia patients is limited. Twenty-four patients were
treated with 6 to 8 mg/m2 NOVANTRONE *, daily for 5 days. There were 3 responses
in 24 evaluable children.
Fourteen adult leukemia patients received 20 to 37 mg/m2 NOVANTRONE* once
every two weeks. No therapeutic responses were observed using this schedule.
Several other studies reported in the literature and not sponsored by Lederle
support the activity of NOVANTRONE* in the treatment of ANLL and B-CML.
HEPATOCELLULAR CARCINOMA. Three clinical trials sponsored by Lederle have
been conducted using NOVANTRONE* in the therapy of HCC. NOVANTRONE*
was administered to 65 patients intravenously at 12 mg/m2 every 3 weeks in two
studies, and in one study with 10 patients at 6 to 10 mg/m2/day by continuous hepatic
artery infusion for three consecutive days, every 3 weeks. Considering the short life
span of patients presenting with HCC, a response of stable disease was included
along with PRs and CRs in assessing efficacy. In these three studies, the overall
therapeutic response rate was 46.7% (11 CRs and PRs + 10 stable disease in 45
evaluable patients). Activity was confirmed in other studies not sponsored by Lederle
Durations of response were variable among these studies and ranged between 3 and
52 weeks.

Safety
Data on the overall safety profile of NOVANTRONE (based on 989 patients) demon
strated advantages of NOVANTRONE compared to the anthracyclines with respect
to both the quality of life and the long-term safety of patients. The majority of side
effects with NOVANTRONE are m ild in nature. Rem oval of patients from
NOVANTRONE treatment for reasons of toxicity has been rare in clinical studies. A
number of patients have reported no side effects at all. In addition, the relatively low
risk of serious side effects has permitted treatment of patients on an out-patient basis.
The most common acute effects were nausea and/or vomiting (only 3.5% severe or
very severe with NOVANTRONE, compared to 10-15% reported with doxorubicin),
stomatitis/mucositis (only 0.3% severe or very severe with NOVANTRONE) and
alopecia (only 0.9% severe or very severe, and 15% overall with NOVANTRONE
compared with 85% severe or very severe and 100% overall reported with doxoru
bicin), Serious local reactions have been reported rarely following extravasation of
NOVANTRONE at the infusion site.
With respect to myelosuppression, initial NOVANTRONE doses of 14 mg/m2 every
three weeks are well tolerated in good-risk patients. Severe degrees of myelosup
pression have been rare. The median white cell nadir in a European second-line
study was 2.5x103; in a European first-line study only 4.8% (2/42) of patients experi
enced a nadir of less than 1,000. The nadir usually occurs around day 10 or 11 and
returns to normal baseline value by day 21, in time for the next course of treatment.
After multiple courses of NOVANTRONE, white blood cell and platelet nadirs show no
further decrease beyond those observed in the first few cycles, indicating no cumula
tive or permanent effects of NOVANTRONE on marrow reserves.
NOVANTRONE* had an exceptional safety profile and was well-tolerated by
patients treated for NHL, leukemia and hepatoma, as well as for breast cancer.
However, due to the pathophysiology of leukemia and the higher doses of
NOVANTRONE* employed, the safety profile differed from that seen in NHL and in
hepatoma (see ADVERSE EFFECTS). The most severe and life-threatening events,
i.e. bleeding and infection, are well described morbid complications of acute
leukemia. Many of the episodes of hepatic dysfunction were probably related to the
increased bilirubin load and increased exposure to hepatitis viruses as a result of the
multiple transfusions of blood products necessary in the proper treatment of this
disorder.
Cardiotoxicity
Adverse cardiac experiences have been infrequent. In contrast, doxorubicin has
been reported to produce chronic cardiomyopathy and irreversible congestive heart
failure in up to 11% of patients given nine or more courses of that drug at the usual
dose schedule (60 m g/m 2 every three weeks). W hether or not related to
NOVANTRONE, only 119 cardiac-related episodes have been reported from a total
data-base of more than 3,200 treated patients, including only 29 (0.9%) reports of
clinical congestive heart failure, of which only one had no other known predisposing
factors. The risk of cardiotoxicity is increased with prior anti-neoplastic drug or radia
tion therapy. In patients without predisposing factors, development of congestive
heart failure with NOVANTRONE therapy is rare.
Clinical experience suggests there is no need to lower the dose for patients with
existing renal or hepatic disease.
In summary, NOVANTRONE" is well tolerated and provides a better quality of life
for patients compared with doxorubicin and yet shows comparable efficacy.
NOVANTRONE has been used alone or in combination in patients with or without
prior chemotherapy, as well as in those who have received prior adjuvant therapy. It is
less cardiotoxic than anthracyclines such as doxorubicin and thus represents a clear
therapeutic advance over currently available compounds.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no known specific antidote for NOVANTRONE. As would be expected from
the pharmacological actions of the drug, haematopoietic, gastrointestinal, hepatic
and renal toxicity may be seen, depending on the dosage given and the physical
condition of the patient. The management of overdosage is symptomatic and sup
portive and patients should be monitored closely. (See also the sections ‘ WARN
INGS", “ PRECAUTIONS” and "ADVERSE REACTIONS").
DOSAGE
Breast Cancer, Lymphoma, Hepatoma
The recommended initial dosage for use as a single agent is 14 mg/m2 of body
surface area, given as a single intravenous dose, which may be repeated at 21-day
intervals. A lower initial dose (12 mg/m2 or less) is recommended in patients with
inadequate marrow reserves due to prior therapy or poor general condition.
Dosage modification and timing of subsequent dosing should be determined by
clinical judgement depending on the degree and duration of myelosuppression. If
21-day white blood cell and platelet counts have returned to adequate levels, prior
doses can usually be repeated. The following Table indicates a guide to dosing based
on myelosuppression.
TIME TO
WBC AND
SUBSEQUENT DOSING
RECOVERY
PLATELET NADIR
REPEAT PRIOR DOSE OR
IF WBC NADIR > 1 500
RECOVERY
INCREASE BY 2 mg/m2 IF
AND
< 21 DAYS
MYELOSUPPRESSION NOT
PLATELET NADIR > 50 000
CONSIDERED ADEQUATE
WITHHOLD UNTIL RECOVERY
IF WBC NADIR > 1 500
RECOVERY
THEN REPEAT PRIOR DOSE
AND
> 2 1 DAYS
PLATELET NADIR > 5 0 000
DECREASE BY 2 mg/m2 FROM
IF WBC NADIR < 1 500
ANY DURATION
PRIOR DOSE AFTER RECOVERY
OR
PLATELET NADIR < 5 0 000
DECREASE BY 4 mg/m2 FROM
IF WBC NADIR <1 000
ANY DURATION
PRIOR DOSE AFTER RECOVERY
OR
PLATELET NADIR < 2 5 000_______________
Combination Therapy for Breast Cancer, Lymphoma
NOVANTRONE * has been given in various combination regimens with the following
cytotoxic agents for the treatment of breast cancer and lymphomas: cyclophos
phamide, fluorouracil, vincristine, vinblastine, bleomycin, METHOTREXATE (stan
dard dose or 200 mg/m2 with LEUCOVORIN rescue) and glucocorticoids.
As a guide, when used in combination chemotherapy with another myelosuppressive agent, the initial dose of NOVANTRONE* should be reduced by 2-4 mg/m2
below the doses recommended above for single agent usage; subsequent dosing,
as outlined above, depends on the degree and duration of myelosuppression.
Dosage for Patients with Acute Leukemia in Relapse
The recommended dosage for induction is 12 mg/m2of body surface area, given as a
single intraveneous dose daily for five consecutive days (total of 60 mg/m2).
In clinical studies, with a dosage of 12 mg/m2 daily for 5 days, patients who
achieved a complete remission did so as a result of the first induction course.

Re-induction upon relapse may be attempted with NOVANTRONE * and again the
recommended dosage is 12 mg/m2 daily x 5.
Combination Therapy for Leukemia
NOVANTRONE *, together with cytosine arabinoside, has been used successfully for
the treatment of both first line and second line patients with acute non-lymphocytic
leukemia
For induction, the recommended dosage is 10-12 mg/m2 of NOVANTRONE* for 3
days and 100 mg/m2 of cytosine arabinoside for 7 days (the latter given as a continu
ous 24 hour infusion).
If a second course is indicated, then the second course is recommended with the
same combination at the same daily dosage levels but with NOVANTRONE * give for
only 2 days and cytosine arabinoside for only 5 days.
If severe or life-threatening non-hematological toxicity is observed during the first
induction course, the second induction course should be withheld until the toxicity
clears.
Note regarding pediatric usage: Experience in pediatric patients is limited; how
ever, complete remissions have been observed with NOVANTRONE * as single agent
therapy at a dosage of 8 mg/m2 daily for 5 days.
ADMINISTRATION OF SOLUTION
NOVANTRONE* solution should be diluted to at least 50 mL with either Sodium
Chloride for Injection (USP) or 5% Dextrose for Injection (USP). This solution should
be introduced slowly into the tubing of a freely-running intravenous infusion of
Sodium Chloride for Injection (USP) or 5% Dextrose for Injection (USP) administered
over not less than three to five minutes intravenously. If extravasation occurs, the
administration should be stopped immediately and restarted in another vein. The
nonvesicant properties of NOVANTRONE minimize the possibility of severe reactions
following extravasation, however, tissue necrosis has been reported rarely.
NOVANTRONE should be administered by individuals experienced in the use of
anti neoplastic therapy.
Caution in the handling and preparation of NOVANTRONE solutions must be
exercised and the use of protective eyeglasses, gloves and other protective clothing
is recommended. (See “ GUIDELINES FOR SAFE USE BY HOSPITAL PERSON
NEL” section.)
STORAGE DIRECTIONS
NOVANTRONE should be stored at room tem perature-D O NOT FREEZE. With
recommended storage, NOVANTRONE remains stable for two (2) years.
Following preparation of the infusion, the diluted solution should be stored at room
temperature and used within 24 hours. Any original solution which remains in the vial
should be discarded. NOTE: LIKE THE ORIGINAL SOLUTIONS, THE DILUTIONS
SHOULD ALSO NOT BE FROZEN.
DRUG COMPATIBILITY
NOVANTRONE* should not be administered concommitantly with heparin since a
precipitate may form. Until specific compatibility data are available, it is recom
mended that NOVANTRONE* not be mixed in the same infusion with other drugs.
GUIDELINES FOR SAFE USE BY HOSPITAL PERSONNEL-CONSULT THE
PACKAGE INSERT.
CHEMISTRY
Composition
NOVANTRONE* mitoxantrone hydrochloride, a synthetic anthracenedione, is a
potent antineoplastic agent. Its molecular formula is C222H28N40 62HCI and its molec
ular weight is 517.4. It is a hygroscopic dark blue solid supplied as a sterile, aqueous
solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone
free base, with sodium chloride, sodium acetate, and acetic acid as inactive ingredi
ents. The product does not contain antibacterial preservatives. Its structural formula
appears below.
H
H
HO
O
NCH2CH2NCH2CH2OH

Molecular Formula: C22H28N40 6.2 HCi
Molecular Weight: 517 4
Chemical Name: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)aminol-ethyl]amino]9,10-anthracenedione dihydrochloride
AVAILABILITY
NOVANTRONE mitoxantrone hydrochloride injection is supplied as a sterile aqueous
solution at a concentration equivalent to 2 mg mitoxantrone free base per mL, and is
available in the following vial sizes:
10 mL/vial (20 mg) Product C o d e .....................................................................9393-34
12.5 mL/vial (25 mg) Product Code...................................................................9393-72
Identification
Glass vials containing 10 and 12.5 mL of a clear, dark blue solution.
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Life Salvage With Fibrin Glue in Three Cases of
Exsanguinating Hemorrhage
Fibrin glue, although widely used in
Europe for a decade, has not been com
mercially available in North America
because its fibrinogen component is
obtained from multiple, pooled, human
blood donors with the subsequent
increased risk of blood transmissible dis
eases. Techniques developed recently to
isolate fibrinogen from single-donor
plasma will circumvent these potential
hazards. In Canada the use of fibrin glue
has not been widespread even though
biologic fibrin glue can be made from
components readily available within most
hospitals.
Equal amounts of cryoprecipitate from
fresh frozen plasma and bovine thrombin
will combine within 2 minutes to form
the fibrin glue. Simultaneous injections
of each component at bleeding sites
form a film of the glue that will effec
tively control even small arterial bleed
ing. The authors present three case
reports to illustrate how use of the glue
can save lives in cases of exsanguinating
hemorrhage. They discuss the multiple
applications of the fibrin glue which they
believe will soon be part of the arma
mentarium of all Canadian surgeons.
Bien que son usage soit largement repandue en Europe depuis une decennie, la
code de fibrine n'est pas offerte commercialement en Amerique du Nord parce
que son contenu en fibrinogene provient
de pools de plasmas obtenus de multi
ples donneurs; il en decoule un risque
accru de maladie transmise par voie san
guine. Des techniques recentes ont permis d'isoler le fibrinogene du plasma
d'un donneur unique reduisant d'autant
les risques potentiels. Au Canada, la
colie de fibrine n'a pas ete largement utilisee meme si une colle de fibrine biologi-

que peut etre fabriquee a partir de composantes facilement obtenues dans la
plupart des hopitaux.
Des quantites etales de cryoprecipite
de plasmas frais congeles et de thrombine bovine reagissent en 2 minutes pour
former la code de fibrine. Des injections
simultanees de chacune des composantes sur un foyer hemorragique forment
un film de code capable meme d'arreter
le saignement de petites arteres. Les
auteurs decrivent trois cas pour illustrer
comment I'emploi de cette code peut
sauver des vies dans les cas d'exsanguination hemorragique. lls commentent les
multiples applications de la code de
fibrine qu'ils croient devoir venir s'ajouter bientot a I'arsenal therapeutique des
chirurgiens canadiens.

Fibrin glue has been used in a variety o f
surgical specialties. Plastic surgeons, over
40 years ago, found fibrin glue helpful in
reanastom osing n erves.1 A lthough
microsurgical techniques have supplanted
this function, it is still used in skin graft
ing and as an adjunct to microvascular
surgery.2 Orthopedic surgeons have used
the glue in hip surgery, cartilage and bone
grafting and tendon repairs.3 General
surgeons have stopped bleeding from
spleen and liver lacerations4 and used it
to seal intestinal anastomoses.5 Perhaps
the widest applications are in cardiovas
cular and thoracic surgery. Fibrin glue has
been used as a sealant in persistent pneu

mothoraces,5-6 postoperative thoracic
duct leaks,7 tracheal8 and esophageal
anastomoses and transbronchial plugging
o f bronchopleural cutaneous fistulas.5
Vascular grafts and anastomoses have
been sealed with a thin coating o f fibrin
glue.6’911 This agent, of course, does not
replace meticulous surgical techniques,
but it can be used in novel ways and, as
will be discussed, in catastrophic bleeding.

Materials and Methods
The fibrin glue technique mimics the
final common pathway in coagulation
(Fig. 1). Fibrinogen is converted by
thrombin into fibrin monomers that are
strengthened by the action o f Factor XIII
into a cross-linked fibrin polymer mesh
which, with interwoven blood compo
nents, results in a hemostatic plug.12 The
fibrin mesh acts to promote wound heal
ing by attracting migrating fibroblasts
and stimulating the formation o f granu
lation tissue.13 In vivo, enzymes o f cellu
lar origin such as leukocyte elastase
(thought to be important in prolonged
bleeding following cardiopulmonary
bypass) activate plasminogen to a proteo
lytic enzyme plasmin that will degrade the
fibrin scaffolding. For this reason some
European centres add fibrinolytic inhibi
tors such as aprotinin (Trasylol) to the
preglue.1214 We have not found this
necessary and have never had problems
with delayed bleeding secondary to
fibrinolysis.

From the Division o f Cardiovascular and
Thoracic Surgery, McGill University and
the Montreal General Hospital, Montreal,
PQ
Accepted fo r publication Jan. 20, 1986
Reprint requests to: Dr. Lee Errett, Rm.
9849, The Montreal General Hospital, 1650
Cedar Ave., Montreal, PQ H3G 1A4

214

FIG. 1—Coagulation cascade demonstrating sites of glue interaction.
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The technique used by the Canadian
Red Cross Society to produce cryoprecipitate from fresh frozen plasma will con
centrate fibrinogen as well as the other
coagulation factors including Factor XIII
(which is important as a pre-glue compo
nent), Factor VIII, von Willebrand’s dis
ease factor and fibronectin.15 This tech
nique is normally used to treat the specific
coagulation disorders of hemophilia, von
Willebrand’s disease and hypofibrinogenemia, but we have capitalized on its
fibrinogen and Factor XIII components
to produce a glue to control bleeding at
local sites in patients with exsanguinating
hemorrhage. The fibrinogen concentra
tion of fresh frozen plasma is approxi
mately 2.6 g/L and this will be doubled
to quadrupled by the cryoprecipitant tech
nique.16 Bovine thrombin (Thrombinar,
USV Canada Inc., Mississauga, Ont.)
with one ampoule of calcium chloride
constitutes the second component of the
epoxy (Fig. 2).
The two components, if drawn up in
separate plastic syringes, can be injected
simultaneously at the bleeding site. Excess
thrombin and cryoprecipitate are kept
separately in sterile stainless-steel bowls.
Equal amounts of each component are
injected simultaneously at bleeding sites
or suture lines. We used 100 mL of each
component on adult patients bleeding
from multiple needle holes in aortic
anastomoses.
Some European investigators have
devised an elaborate pressurized dual
nozzle system, analogous to a paint
sprayer, to produce a thin fibrin film.17
Initially a transparent gel (fibrin
monomer) forms that, with the action of
Factor XIII and calcium chloride, will
polymerize into an opaque glue. The reac
tion begins immediately and is complete
in approximately 2 minutes. The rapid
ity of clotting can be varied by adjusting
the concentration of throm bin.3 With
the highly concentrated European fibrino
gen and the recently described North
American technique of Dresdale and col-

leagues,16 1 to 2 mL of pre-glue fibrino
gen and 1 to 2 mL of thrombin can be
directed at specific bleeding sites, leaks or
fistulas. Calcium chloride, which we used,
may not be necessary as calcium is part
of the commercial bovine thrombin.
The following case reports illustrate our
experience with fibrin glue in saving the
lives of three patients who had exsan
guinating hemorrhage.

Case Reports
Case 1
A previously healthy 71-year-old man
presented with a type A (ascending aorta only)
aortic dissection and severe aortic insufficiency,
confirmed by angiography. He had no history
of bleeding disorders and he was not taking any
medications. Femorofemoral bypass was
initiated after median sternotomy. A large col
lection of blood was found within the
pericardium. The patient was heparinized,
attaining an activated clotting time of more
than 600 seconds. Cardiopulmonary bypass
was instituted and the patient cooled to 28°C.
After the aortic dissection and true lumen had
been opened and inspected, it was decided to
repair the valve with pledgeted sutures at each
commissure.
A tubular graft stent was inset in the true
lumen. This was fixed in place and the aorta
repaired over it with pledgeted sutures. The
patient was rewarmed and the cross-clamp
released after 72 minutes. The heart resumed
normal sinus rhythm with a competent aortic
valve. Bleeding from every suture hole was sub
stantial. Attempts at repair created even more
bleeding through the friable aortic tissue.
Cardiopulmonary bypass was discontinued and
lines were removed. Heparin was reversed to
the point of a normal activated clotting time.
Total bypass time was 134 minutes. Bleeding
persisted at more than 200 m L/m in so
cryoprecipitate and thrombin were prepared
and injected simultaneously on to various
bleeding sites. Approximately 100 mL of each
component was needed, but the bleeding
ceased, the patient was stabilized and the oper
ation was completed without further compli
cations.

Case 2
A 67-year-old hypertensive man presented
with a type A aortic dissection similar to that
in case 1. A composite graft was used to replace
the aortic valve, and the coronary arteries were
reimplanted into the Dacron-velour graft.
Bleeding persisted at the coronary and distal
aortic graft anastomoses. After bypass was dis
continued and the heparinized state reversed,
bleeding persisted. He received 18 units of
blood and 15 units o f plasma, which depleted
all sources. Fibrin glue was applied with suc
cess, arresting the hemorrhage promptly. The
patient’s recovery was smooth.

Fig. 2—Components of fibrin glue: (1)
Cryoprecipitate contains fibrinogen and Fac
tor XIII; 20 units are diluted with normal saline
to total volume of 200 mL. (2) Two vials (5000
units/vial) of thrombin are mixed with one
ampoule of calcium chloride giving total
volume of 50 mL. Cryoprecipitate and
thrombin-calcium mixture are injected simul
taneously. Fibrin glue is formed within 2 minu
tes of ingredients coming into contact.

Case 3
A 4-year-old child underwent repair of a pul
monary stenosis with an intact ventricular sep
tum. A subclavian-to-pulmonary artery shunt
had been performed previously. A Dacronvelour conduit was fashioned from the right
ventricle to the pulmonary artery. Despite

preclotting, the graft leaked, most profusely
around suture lines. Fibrin glue was used suc
cessfully after all blood-bank stores were
depleted of packed cells. The child did well
postoperatively.

All three patients recovered with no
further complications. There was no
hypersensitivity,
fib rin o ly sis
or
coagulopathy following the use of fibrin
glue and no infection. A t 9 months
follow-up after the last patient’s opera
tion, all were alive and well.

Discussion
Fibrin gluing offers new solutions to
old problems not necessarily in accor
dance with traditional surgical concepts.
As a natural extension of this glue’s
hemostatic properties, its greatest use has
been in the field of cardiovascular sur
gery. In this context it was introduced in
1976 by Spangler18 and used by Akrami
and associates in 197819 for sealing
prosthetic vascular grafts. Both woven
and highly porous knitted grafts can be
reliably pre-sealed, and this is now the
preferred method of sealing grafts in
many European centres.6 The technique
is effective in systemically anticoagulated
patients or in those who have known
coagulopathies,6 and it does not require
a completely dry surgical field. Follow
ing the death of a patient from exsanguination through the pores of a left
ventricular-aortic conduit in 1979, two
Toronto investigators17 developed a
preclotting technique using thrombin and
cryoprecipitate, but it was not widely used
because of the high cost. With the advent
of fibrin presealing, knitted grafts that
currently have limited application because
of their excessive porosity will replace the
low-porosity woven grafts because of
their superior handling, suturing and
healing capabilites.14,16,20
Glues have been used to approximate
aortic dissections,13 to fix kinked coro
nary grafts6,10 for prophylactic sealing of
vascular anastomoses and needle punc
ture sites before clamp removal,6,13 and
for the control of various forms of bleed
ing in the operative field when conven
tional suturing techniques fail (i.e., with
poor tissues that will not hold sutures) or
would be dangerous.2’9’13 The glue works
well on venous bleeding, low-pressure,
diffuse oozing and even small arterial
bleeding can be reliably stopped.6 It can
be used in conjunction with collagen
fleeces (Avitene, Gelfoam) in a moist
field.3’6-810,13-14
With the dissemination of knowledge,
the gluing process and the availability of
fibrinogen economically prepared from
single-donor, fresh frozen plasma, fibrin
glue will soon be part of the arm am en
tarium of all Canadian surgeons and will
save lives as we have demonstrated.
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(^Mefoxin
(sterile cefoxitin sodium, Frosst Std.)

ANTIBIOTIC
ACTION
In v itro s tu d ie s d e m o n stra te th a t the
bactericidal action of cefoxitin, a cephamycin
derived from cephamycin C, results from the
inh ib itio n of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
the 7a p o s itio n is re s p o n s ib le fo r the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia m arcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
s h o u ld be perform ed to d e term ine the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rg a n is m s p a rtic u la rly a p p ro p ria te fo r
therapy with MEFOXIN* are:
Gram positive
Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)
E. coli
K l e b s i e l l a s p e c ie s ( in c lu d in g K.
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
w h o a re a ls o re c e iv in g c a r b e n ic illin ,
gentam icin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION)
Intravenous Administration
The intravenous route is preferable fo r
p a t ie n t s w ith b a c te re m ia , b a c te r ia l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
fro m s u c h d e b ilita tin g c o n d itio n s as
m alnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE
MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
p o sto p e ra tive ly) to patients undergoing
vaginal o r abdom inal hysterectom y and
abdominal surgery when there is a significant
risk of postoperative infection or where the
o ccu rre n ce of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
a d m in is tra tio n of any a n tib io tic beyond
*®T rademark

24 hours fo llo w in g surgery increases the
possibility of adverse reactions but, in the
m ajority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens fo r culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
s e n s it iv it y r e a c tio n s to M E F O X IN *,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c r o s s -a lle rg e n ic ity between
cepham ycins and the other beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta -la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is im portant to consider a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. While studies indicate that a toxin
produced by C lostridium d iffic ile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in is tra tio n o f th e drug sh o u ld be
d is c o n tin u e d . Serious h y p e rs e n s itiv ity
re a c tio n s m ay re q u ire tre a tm e n t w ith
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
w ith transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
h ig h and p ro lo n g e d serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling’s solutions
but not w ith the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
va lues in serum may o c c u r if serum
concentrations of cefoxitin exceed 100 Arg/mL.
Serum samples from patients treated with
MEFOXIN* should not be analyzed fo r
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
fo llo w in g concom itant adm inistration of
c e p h a lo s p o r in s and a m in o g ly c o s id e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tra tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100m g/kg/day and
above) have been a sso cia ted w ith an
increased incidence of eosinophilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a c tio n s ra re ly req u ire d ce ssa tio n of
treatment and usually have been mild and
transient.
Local Reactions
T h r o m b o p h le b itis has o c c u rre d w ith
intravenous administration. Some degree of
pain and tenderness is usually experienced
after intramuscular injections using water.
Induration has occasionally been reported.
Allergic
M acu lo p a p u la r rash, u rtica ria , p ru ritu s,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood
T ra n s ie n t e o s in o p h ilia , le u k o p e n ia ,
neutropenia, hemolytic anemia, and thrombo
c y to p e n ia have been re p o rte d . Som e
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been rep o rte d rare ly. The role of
MEFOXIN* in changes in renal function tests
is d i f f ic u lt to a ssess, s in c e fa c to rs
predisposing to prerenal azotemia or to
im paired renal function have often been
present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
M EFOXIN* may be adm inistered in tra 
venously or intramuscularly when required.
(See complete monograph for full details on
ADMINISTRATION and RECONSTITUTION.)
TREATMENT DOSAGE
Adults
The usual adult dosage is 1 g or 2g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
o f in fe c tio n

D a ily
Dosage

F re q u e n c y
a n d R o u te

U n c o m p lic a te d
fo rm s * o f in 
fe c tio n s s u c h as
p n e u m o n ia ,
u r in a r y tr a c t
in f e c t io n , s o ft
tis s u e in fe c tio n

3 -4 g

1 g e v e ry 6 -8 h
I.V . o r I.M .

M o d e r a te ly
s e v e re o r s e v e re
in fe c tio n s

6 -8 g

1 g e v e ry 4 h
or
2 g e v e r y 6 - 8 h I.V .

In fe c tio n s
c o m m o n ly
n e e d in g a n t i
b i o t i c s in h i g h e r
d o s a g e (e .g . g a s
g a n g re n e )
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’ In c lu d in g

in

p a tie n ts

2 g e v e ry 4 h
or
3 g e v e r y 6 h I.V .

w h o rri

b a c te r e m ia

is

a b s e n t o r u n lik e ly

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infectionsshould be maintained
for at least 10 days to guard against the risk of
rheumatic fever or glom erulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage

should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
A fte r a lo a d in g do se , th e fo llo w in g
recommendations for maintenance dosage
may be used as a guide:
RENAL
F U N C T IO N

M ild
im pairm ent
Moderate
im pairm ent
Severe
im pairm ent
Essentially
no fu n ctio n

C R E A T IN IN E
CLEARANCE
m L /m in

DOSE

FREQ UENCY

50-30

1-2 9

every 8-12 h

29-10

1-2 9

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

In the patient undergoing hemodialysis, the
loading dose of 1 -2 g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
Above 1500 g
Neonates

2 0 -4 0 m g /k g e v e ry 12 h I.V.

1 w e e k o f 20-40
age m g / kg ev e ry 12 h I.V.
4 w e e ks o 20-40
f age m g /k g ev e ry 8 h I.V.

01-

Infants
1 m o n th to 2 years
o f age

20-40 m g /k g e v e ry 6 h or
every 8 h I.M. o r I.V.

Children

20-40 m g /k g e v e ry 6 h or
every 8 h I.M. o r I.V.

In severe infections, the total daily dosage in
in fa n ts and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recommended for the ther
apy of meningitis. If meningitis is suspected,
an appropriate antibiotic should be used.
A t present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function. However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g a d m in is te re d in tra m u s c u la rly or
in tr a v e n o u s ly ju s t p r io r to s u rg e ry
[approximately one-half to one hour before
initial incision).
The second and third 2 g doses should be
administered at 2-6hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* (sterile cefoxitin sodium, Frosst
Std.) is supplied as sterile powder in boxes of
10 vials:
No. 3356 1 g cefoxitin as sodium salt
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.
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BOOK REVIEWS
continued from page 211
injuries, and it offers an interesting review of
missile injuries.
The section on surgical technique offers an
overview of microsurgery, surgery of the hand
and a chapter on hernia repairs that I found
very detailed. In the section on patient care,
excellent descriptions of fluid, electrolyte and
nutritional support, blood replacement,
hemostasis and infections in surgery are all
included.
To test the value of this book in daily surgi
cal practice, I reviewed questions 1 encountered
in my office during the previous month. These
included problems in the handling of biliary
tree calculi, treatment of thrombosed hemor
rhoids, perianal abscesses and chronic pan
creatic pain. I was pleasantly surprised to find
all of them addressed in this book. I was,
however, disappointed at the dogmatic
approach followed in most cases, outlining the
authors’ approach without discussion or anal
ysis of alternative methods or justification of
the approach taken and almost never listing
references on the subject. In my estimation,
this is the major flaw in an otherwise excellent
book.
In summary, 1 was pleased with the
approach taken in this book. Lengthy physio
logical explanations, better left to physiology
treatises, were avoided, and specific, everyday,
practical surgical problems were addressed.
The editors also felt the need to review more
specialized subjects on the grounds that general
surgeons are often involved, directly or
indirectly, in such situations. The reviews are
concise yet contain a wealth of information.
The book is well written and easy to read. The
style, very uniform despite the 50 contributors,
is a credit to the editors. 1 recommend the
book.

TRANSPLANTATION OF LYOPHILIZED
CARTILAGE IN MAXILLO-FACIAL
SURGERY. Experimental Foundations
and Clinical Success. Hermann F. Sailer.
138 pp. Illust. S. Karger AG, Basel, 1983.
$69. (US). ISBN 3-8055-3570-8.

Luis O ppenheimer , md , frcsc

K. C o n r a d ,

Associate Professor of Surgery,
Department of Surgery,
Health Sciences Centre,
700 William Ave.,
Winnipeg, Man.,
R3E 0Z3

Cosmetic Facial Surgery Service,
Department of Otolaryngology,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont.,
M5G 1X5

The use of allogeneic or xenogeneic cartilage
grafts for mechanical support or as tissue fillers
has become increasingly popular in maxillofa
cial surgery over the last 40 years. Many
methods of preservation, storage and sterili
zation of the grafting material exist. Few pub
lications are available on the clinical or
experimental use of lyophilized cartilage and
these have mostly originated from Eastern
Europe. The author has been involved in the
use of lyophilized cartilage at the Department
of Maxillo-Facial Surgery, University Clinic of
Zurich, where such material has been used for
over 20 years.
Sailer’s monograph is well written, elegantly
organized and will prove equally useful to cli
nicians and researchers working in this field.
He provides a good review of existing litera
ture. Proper histologic documentation illus
trated by good-quality microphotographs
forms the basis for clinical applications of
lyophilized cartilage grafts.
With such an impressive scientific introduc
tion, one would expect more voluminous clin
ical descriptions and presentations, with long
term follow-up, to gain greater acceptance for
the material under investigation.
It is a study designed and conducted by a
clinician with direct applications in mind and
with a thorough knowledge o f the principles
of scientific experimentation. This particular
combination makes the book not only educat
ing but also easy and pleasant to read.
md
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A Fatal Pulmonary Embolus Composed
of Gross Liver Tissue
A snowmobile accident caused a pulp
injury to the liver and tear of the vena
cava of a 21-year-old man. Improvement
after fluid resuscitation, right hepatic
lobectomy and caval repair was followed
by sudden hemodynamic collapse and
death. Autopsy revealed pulmonary
embolism caused by liver tissue.
Presumably the pieces of liver entered
the vena cava through the tear and
travelled to the lung when blood flow
improved. The authors believe that this
is the first report of fatal pulmonary
embolism caused by macroscopic liver
tissue.

Un accident de motoneige est a I'origine
de lesions de la pulpe hepatique et d'une
dechirure de la veine cave chez un
homme de 21 ans. Une amelioration con
secutive au retablissement des volumes
liquidiens, a la resection du lobe hepati
que droit et & la reparation de la veine
cave, a ete suivi d'un collapsus hemodynamique brutal puis de la mort du
patient. L'autopsie a revele une embolie
pulmonaire causee par du tissu hepati
que. On presume que des pieces du foie
ont penetre dans la veine cave par la
dechirure et ont voyage jusqu'au foie
lorsque le debit a ete ameliord. Les
auteurs croient qu'il s'agit de la premiere
description connue d'un cas d'embolie
pulmonaire fatale causee par du tissu
macroscopique hepatique.

The commonest autogenous material
causing pulmonary embolism is clot from
a venous thrombus. Fat, marrow,
amniotic fluid and tumour cells are other

From the *Department o f Surgery and the
t D epartment o f Pathology, Orillia Soldiers’
M emorial Hospital, Orillia, Ont.
A ccepted fo r publication Sept. 17, 1985
Reprint requests to: Dr. R.C. Munkittrick,
D epartment o f Pathology, Orillia Soldiers’
M em orial Hospital, Orillia, Ont. L3 V 2Z3
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known autogenous embolic materials.
Bacteria, air, cannulas, and even bullets
are among recognized exogenous emboli.
This report describes a patient who died
o f pulmonary embolism from autogenous
liver fragments and explains the mechan
ism o f embolization. Although Camps1
stated that liver cells may occasionally be
found in the lungs o f patients with severe
crush injury, we have not found a previ
ous report of multiple, fatal macroscopic
emboli composed o f liver tissue.

Case Report
A 21-year-old man was thrown off a snow
mobile, striking a fence post with his right side.
Fie lay in the snow for about 30 minutes before
transportation to the emergency department.
On arrival, he was conscious and complained
of severe right-sided abdominal pain. His blood
pressure was 70 mm Hg systolic and the pulse
rate 84 beats/min. The abdomen was dis
tended, guarded and silent. Roentgenograms
showed no thoracic or spinal injury. Frank
blood was recovered on peritoneal tap. His
hemoglobin level was 119 g/L. He was known
to drink alcohol liberally, although he denied
drinking before his accident and his breath did
not smell of alcohol at the time of admission.
Massive fluid replacement was begun using
colloid and crystalloid solutions (12 units of
packed cells, 400 mL plasma and 3000 mL crys
talloid). On his arrival in the operating room,
his systolic blood pressure became unobtaina
ble and remained so for about 50 minutes, dur
ing which time bleeding sites were controlled.
With volume replacement, the pressure slowly
rose.
Laparotomy 30 minutes after admission rev
ealed several litres of free blood in the
peritoneal cavity. A pulp injury of the right
hepatic lobe resulted in multiple liver fragments
of various sizes floating in the intraperitoneal
blood. The right hepatic vein was avulsed from
the vena cava, causing a longitudinal tear in
the latter (Fig. 1). The right adrenal gland was
torn, leaving the adrenal vein to bleed freely.
No other injuries were evident.
The portal pedicle was clamped, and the
blood and hepatic debris were removed. The
vena caval tear was isolated by a Satinsky aortic
clamp and repaired (Fig. 2). The adrenal vein
was ligated and a partial hepatectomy done at
the site of liver damage. Hemostasis was con
firmed after release of the portal pedicle clamp.
Measured blood loss was 6000 mL.

When the patient was transferred to the
intensive care unit he had good colour, evi
dence of urine output, a systolic blood pres
sure of 95 mm Hg and a pulse rate of 90
beats/min. He was put on a respirator. Thirty
minutes later he became cyanotic, hypotensive
(blood pressure 40 mm Hg systolic) and
tachycardiac (pulse rate 148 beats/min). The
endotracheal tube was still in place, air entry
was good bilaterally and there was no pneu
mothorax. Absence of an obvious cause for
this sudden moribund state in a previously sta
ble patient suggested recurrent hemorrhage. He
was returned to the operating room for re
exploration, but because the vital signs were
absent, there was no electrical activity of the
heart and the pupils were fixed and dilated, the
proposed laparotomy was cancelled. Cardi
opulmonary resuscitation was initiated, but
was unsuccessful.

Autopsy Findings
At autopsy the peritoneal cavity was
found to contain 150 mL blood with some
liver fragments. The parenchyma o f the
2200-g liver was pale, soft and yellow,
compatible with severe fatty metamor
phosis. The right adrenal gland was frag
mented. The repair of the inferior vena
cava was intact. A striking finding was
the presence o f a large fragment o f liver
(2 cm in diameter) lodged in the main
right pulmonary artery (Fig. 3). In addi
tion, there were smaller fragments in the

L o M C -lT U D lld ^ L . T E A R
IM V E N A C A V A

FIG. 1—Schematic representation of inju
ries to liver and inferior vena cava as seen from
right anterolateral aspect.
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Discussion

secondary branches. Sectioning of the
lung revealed yellow liver tissue impacted
in the lumina of the small pulmonary
artery radicles. There was no evidence of
head injury.
Microscopic examination revealed
severe fatty metamorphosis of the liver.
Lung sections showed intra-alveolar
hemorrhage and plugs of liver occluding
the lumina of many arteries (Fig. 4).

tort-cRucSRl/sic,

To our knowledge, this is the first
reported case o f fatal pulm onary
embolism by liver tissue. Liver cells found
in the lungs after crush injury get there
by an intrahepatic route; presumably dis
ruption of intrahepatic venules allows
crushed cells to enter the bloodstream and
lodge in the lungs, where they may be dis
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covered as incidental findings during
autopsy after death caused by associated
injury. In our patient, the particles of liver
probably entered the circulation extrahepatically. Avulsion of the hepatic vein left
a large rent in the vena cava through
which free liver particles could have
entered and presumably remained within
its lumen during the low flow state. At
surgery, the tear in the vena cava was iso
lated from the lumen, leaving undetected
the bits of liver tissue within the vessel
(Fig. 2). Once hemostasis was achieved
and blood loss restored, the patient’s
hemodynamic status improved. The much
better flow now carried these liver pieces
through the right heart into the pulmo
nary vascular bed, where they lodged as
a fatal shower of large pulmonary emboli.
This explains the sudden and unexpected
irreversible collapse and death after
apparently successful resuscitation and
stabilization.
Reference

) D IM F E R lo R \JEbiaJ
C-AVA

£ > lR E C T Io /N

1. CAMPS FE: Gradwohl’s Legal Medicine, Wright, Bristol,
1968: 459-461

OF

o N iM P E D e is Pl.d W

LLLLLLLULLi
o n j DE.Te c .t e _D P a r t i c l e s
L is /e e . t i s s u e , i n t h e

NOTICES

o f

8YPAS5ED l u m e n
FIG. 2—Vascular clamp in place, controlling blood loss and isolating tear for convenient
repair, yet leaving adequate lumen for unimpeded continuous flow during repair. Liver tissue
within lumen is undetected. When flow improves, these particles will be carried by bloodstream
to become pulmonary emboli.

Innovative Cancer Therapy
for Tomorrow
This Chemotherapy Foundation Sympo
sium will be held at the Sheraton Centre
Hotel in New York, Nov. 12-14, 1986.
Session topics will include p o s t
menopausal breast cancer, polychemotherapy, differentiation chemotherapy,
chemoimmunotherapy and new Phase II
drugs.
For further information write the
Director, the Page and William Black
Post-Graduate School of Medicine, One
Gustave L. Levy Place, New York, NY
10029 or call (212) 650-6772.

FIG. 3—(a) Photograph and (b) line drawing of gross specimen of right lung with embolus
in situ. Large fragment of liver tissue (arrow) is impacted in right pulmonary artery.

Fig. 4b
FIG. 4—(a) Photomicrograph of embolus in situ. LU = lung parenchyma, RPA = right
main pulmonary artery, LE = liver embolus which completely occludes lumen of artery (origi
nal magnification x 40) (b) Embolus (LE) at higher magnification is identified as liver tissue
with marked fatty metamorphosis ( x 100) original magnification.

50th Anniversary
Surgery Course
The Department of Surgery, University
of Minnesota Medical School is sponsor
ing “ Trauma and Critical Care Surgery”
as its 50th-anniversary surgery course,
which will be held June 18-21, 1986, on
campus.
Fees are $400 ($200 for medical resi
dents), and the course is accredited for
25 'h hours in Category 1 by the Ameri
can Medical Association.
For more information contact: Office
of CME, University of Minnesota, Box
202, 420 Delaware St. SE, Minneapolis,
MN 55455; (612) 373-8012.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1 month before issue
date. Regular classified rates (for each insertion): $38.00 for the first 40 words or less, additional words 45C each (additional $15.00 for frame). Special Display
under 75 words, 2 V " X V $95.00. $5.00 charge (first insertion only) for CJS box numbers. Display rates available on request.
________________ ________ Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
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GENERAL SURGEON: ON
Required for surgical group.
F u ll-tim e

e m p lo y m e n t

(T o ro n to

area)

Ideal w orking conditions.
A ll replies w ill be treated in co n 
fidence.

Reply:
________________________________________ - S 8 6 - 1 1

CLINICAL DAY IN COLOPROCTOLOGY: - at the
Toronto General Hospital, Toronto, Canada, Fri
day, June 13th, 1986. Guest speakers include:
Robert Beart, Mayo Clinic: John Goligher, Leeds
England; Richard Hunt, McM aster University: Ber
nard Cummings, Ontario Cancer Institute, Prin
cess M argaret H ospital. The fee is $100
(Canadian). For more information and registration
please contact: Dr. Zane Cohen, Toronto General
Hospital, 9-242 Eaton North, 200 Elizabeth St.,
Toronto, ON M5G 2C4. Tel.: (416) 595-3556.
-S 8 6 -1 8
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GENERAL SURGEON: PQ — required to join an ac
tive department o f surgery, which includes several
surgical subspecialties in a 140-bed acute care
university affiliated bilingual teaching hospital.
Candidate w ith appropriate training w ill have op
portunity to do surgical endoscopy, thoracic and
peripheral vascular surgery. A pply to: The Direc
tor of Professional Services, Dr. Zoltan Ferenczi,
37 5 Argyle St., Sherbrooke, (Quebec), J1J 3H5.
(819) 569-3661.
-S 8 6 - 1 7

ICU RESEARCH FELLOW: — Ewart Angus Inten
sive Care Unit, The Wellesley Hospital. Available
July 1, 19 8 6 for a one year period in an academic
Medical-Surgical Unit. Research areas include clin
ical epidemiology o f ICU care, nutrition and
respiratory muscle physiology. Reply to: Dr. I.M.
Fraser, Director EAICU, 247 The Jones Bldg., 160
Wellesley St. E., Toronto, ON M 4Y 1J3 (416)
926-77 47.
-S 8 6 -0 4

GENERAL SURGEON: ON — Lakeshore to w n of
85 000 near Toronto requires fifth general sur
geon. 340-bed hospital. General surgery practice
does not include ortho, gyne, plastic, vascular or
thoracic surgery. Position available now. Send cv
and three reference to: Box S 113 CJS.
-S 8 6 -1 4

Box S112 CJS

Persantine/Asasantine

THORACIC SURGEON: — Fully certified, tho
racic and general surgeon wishes to relocate.
Wide experience in all aspects of noncardiac
thoracic surgery. Experience in surgical education
at all levels both clinical and organizational. Aca
demic affiliation desired. Please reply to: Box
S 1 14 CJS.
-S 8 6 -1 9

OBSTETRICIAN/GYNECOLOGIST: YK - Yukon
Territory requires a certified FRCSC obstetrician/gynecologist w ith LMCC. Whitehorse (popu
lation 25 000) is a vibrant com m unity linked w ith
daily je t service to Vancouver and Edmonton. A
consulting practice only, there is no shortage of
hospital beds or operating room tim e . A
knowledge o f colposcopy, ultrasound and infer
tility w orkups w ould be an asset. Routine ob
stetrics are handled by the fam ily physicians and
weekend call is provided by the general surgeon
and therefore is optional. Whitehorse in the
southern Yukon is located on the Yukon River. It
is close to mountains and lakes and within 160
km of the w orld fam ous Kluane Park. There is ex
cellent climbing, kayaking, canoeing, ski touring,
hunting and fishing. The fee schedule is generous,
(BC plus 30% ), w ith a minimal expected income
o f $250 0 0 0 gross. This is certainly the best
OBS/GYN job in Canada and we invite you to ap
ply to the follow ing address: Dr. Roger S. Mitch
ell, Whitehorse Medical Service Ltd., 406 Lambert
St., Whitehorse, YK Y1A 1Z7 or telephone collect:
(4 0 3 )6 6 7 -4 4 2 1 .
-S 8 6 -1 6

PLASTIC SURGEON: ON — FRCS, required for
very active m etropolitan Toronto community
hospital. General plastic surgery practice with
emergency responsibilities especially in regards to
hand injuries. Please send curriculum vitae to:
Department of Plastic Surgery, Northwestern
General Hospital, 21 75 Keele St., Toronto, ON
M6M 3Z4.
-S 8 6 - 1 5
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The General H ospital, St. J o h n 's , N ew foundland is
seeking an experienced individual to chair its D epart
m ent o f Intensive Care. The unit is located in a modern
health sciences centre w hich also houses The Mem ori
al U n iversity Faculty o f M edicine. It accom m odates
b o th medical and surgical patients.

Dr. David Hawkins
Health Sciences Centre
St. John's, Newfoundland
A1B 3V 6
(709) 737-6551
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Now indicated for the
prevention o f occlusion of the saphenous vein
in coronary bypass procedures.
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No hang ups!
Staples are now
immediately, automatically
and completely released
regardless of direction of
stapler movement.

''..from the b + G wound closure system

THE SMOOTH ONE

Davis + Geek Introduces

S iT O T
Something
you’re used to
without
the problems
you’re used to
You told us that you liked using catgut but you didn't like its
problems. So we took catgut and made it •
• soft and supple
. easy to tie
. less likely to curt, ‘pigtail" and tangle
• easy to handle and control

DEXON* PLUS

In fact we made it

S FTGUT
Better than catgut — but still catgut

